INDEX TO VOLUME 58—1990

AUTHOR INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

Abalos, R. M., (O) 1, (A) 161, 193, 420
Abbot, N. C., (A) 627
Abel, L., (A) 431
Abou-Zeid, C., (A) 159, 628
Abraham, A., (O) 466
Acharekar, M. Y., (A) 759
Adala, H. S., (A) 150
Adallah, S. O., (A) 150
Adams, E., (A) 605, 747
Adiga, R. B., (O) 319
Aditi, B., (A) 770
Agarawal, J. S., (A) 736
Agarwal, J. K., (A) 601
Agrawal, J. K., (A) 743
Agrewala, J. N., (A) 156
Agzamova, R. A., (A) 767
Aisen, P., (A) 168
Ajello, L., (A) 150
Al Attiyah, R., (A) 425
Al-Mohaya, S., (A) 602
Al Quabati, Y., (A) 741
Al Saffar, M., (A) 156
Al Shimali, B., (A) 156
Al Sogair, S. M., (A) 432
Albuquerque, M. de F. P. M., (A) 619
Alburquerque, E. C., (A) 596
Alle, N., (A) 151
Almeida, J., (A) 622
Almeida, R. G., (A) 170
Almeida, S. M. R., (A) 596
Alvarenga, A. E., (A) 408
Alvarez, S., (A) 742
Ambrus, G., (A) 441
Amerio, N., (A) 157
Amezcua, M. E., (O) 651
Amezcua-Chavarria, M. E., (C) 723
Anand, V. K., (A) 447
Anandan, D., (A) 158
Anandi, V., (A) 150
Anarygyros, P., (A) 760
Andersen, A. B., (A) 175, 763
Andersen, B. R., (O) 342, 534
Anderson, D. C., (A) 422, 612
Anderson, R., (A) 146
Andreoli, A., (A) 159
Antia, N. H., (A) 169, 170, 624
Antonov, B. I., (A) 769
Aparicio Gomez, J., (A) 612, 746
Appelberg, R., (A) 627
Apt, A. S., (A) 176
Arantharaman, D. S., (A) 758
Argentieri, R., (A) 445
Arienzo, F., (A) 440
Arora, S. K., (A) 625
Arpinelli, F., (A) 73, 739
Ashmalla, L., (A) 410, 624
Aspinall, G. O., (A) 636
Astbury, L., (O) 25
Astill, D. S. J., (A) 760
Avdienko, V. G., (A) 632
Averbakh, M. H., (A) 176
Axcar, S. R., (A) 150
Ayed, K., (A) 604
Azulay, R. D., (Ob) 134, (A) 424

Baas, J. G., (A) 417
Bach, M.-A., (C) 387, (A) 609
Backstrom, B. T., (A) 419
Bacon, P. A., (A) 606
Badukshanova, N. M., (A) 438
Bagshawe, A. F., (O) 25, (A) 414
Bahna, S. L., (A) 752
Bahr, G. M., (A) 156, 448
Bailey, L. C., (A) 606
Bajpai, H. S., (A) 601, 743
Baker, R. J., (E) 78
Balachandran, C., (C) 115
Balakrishnan, A., (O) 273
Baldwin, B. E., (A) 171
Balguzhinov, D. B., (A) 767
Balistreri, F. J., (A) 597
Balkrishna, (A) 741
Banavalikar, J. N., (A) 447
Banda, H. M., (A) 630
Bandres Sanchez, M. P., (A) 598
Banerjee, D. K., (O) 690, (A) 756
Bansal, S. K., (E) 717
Baquillon, G., (A) 432, 611, 739
Barba-Rubio, J., (O) 651
Barbancon, O., (A) 741
Barbaro, D. J., (A) 438
Barbolini, G., (A) 438
Bardin, C. W., (A) 152
Barik, B. K., (A) 153
Barnes, P. F., (A) 200, 628
Barrow, W. W., (A) 449
Bartow, R. A., (A) 443
Basappa, K., (A) 414
Baskin, G. B., (O) 358, (A) 431
Basset, A., (Ob) 394

Basten, A., (A) 424, 605, 747
Battacharya, C. P., (A) 168
Baumgart, K., (O) 25
Bazurov, G. I., (A) 147
Bechelli, L. M., (A) 620
Beck, J. S., (A) 176, 177, (O) 347, (A) 424, 428, 627, 747
Becx-Bleumink, M., (A) 624
Bedsole, G., (A) 449
Behbehani, K., (A) 156, 448
Belda, W., (A) 170
Bell-Krotoski, J., (A) 625, 625
Belskaya, O. B., (A) 601
Benedetti, M., (A) 73, 739
Bercovier, H., (A) 446, (O) 681
Bergsteinsdottir, K., (A) 162
Berhe, D., (A) 624
Berlin, O. G. W., (A) 177
Bermudez, L. E. M., (A) 628, 629, 761
Bernardes, M. F., (A) 178
Bernheimer, H., (A) 426
Berry, G., (A) 414
Bertoya, L., (A) 418
Bertrand, F., (A) 410
Besra, G. S., (A) 614, 762
Beuerman, R. W., (O) 554
Beyers, A. D., (A) 146
Bhainagar, P., (A) 146
Bharadwaj, V. P., (A) 169, 600, 604
Bhatia, A. S., (O) 31
Bhatia, M. S., (A) 741
Bhatia, V. N., (A) 158, 614, 743, 751
Bhatki, W. S., (O) 334
Bhattacharya S. N., (C) 116, 118
Bhoopat, L., (O) 469
Biglino, A., (A) 73
Bik, E. M., (A) 765
Billingham, M. E. J., (A) 604
Biryukov, A. V., (A) 601
Bisetti, A., (A) 438
Biswal, S. K., (A) 153
Biswas, S. K., (A) 754
Bix, L. P., (A) 150
Blake, D., (A) 768
Blake, J. M., (A) 408
Blom-Potar, M.-C., (A) 445
Bloom, B. R., (A) 157, 165, 168, 186, 191, 196, 200, 201, (E) 365, (A) 415, 430, 605, 747
Bocart, D., (A) 429
Boddingius, J., (A) 415, 415
Bodey, G. P., (A) 634
Bogaert, H., (A) 741
Bolton, R. C., (A) 768
Bonner, F. J., (A) 408
Bonney, G. E., (A) 431
Booth, R. J., (A) 192, 419
Born, W. K., (A) 607
Borremans, M, (A) 629
Bosecker, B., (A) 189
Bothamley, G., (A) 420, 445
Bothamley, G. H., (A) 428
Bottasso, O., (A) 157, 416
Bottone, E. J., (A) 441
Boucher, P., (A) 626
Boudghene-Stambouli, O., (A) 620
Bouree, P., (A) 434
Bourland, J., (A) 147
Bourrel, P., (A) 174
Boutin, J.-P., (A) 157, (O) 512
Bowe, E. T., (A) 155
Brander, E., (A) 442, 635
Brandsma, J. W., (A) 625
Brandt, F., (A) 741, 756
Brandwein, M., (A) 761
Breckenridge, A. M., (A) 406, 737, 737
Breger-Lee, D., (A) 625
Brennan, P. J., (A) 168, 190, 200, 415, 605, 606, 628, 636, 766
Brenner, M. B., (A) 165, 191
Brett, S. J., (A) 416
Bridbord, K., (A) 636
Brisson-Noel, A., (A) 630
Britton, W. J., (O) 319, 480
Brooks, B. W., (A) 763
Brooks, B. J., Jr., (A) 742
Brouet, J. C., (A) 597
Brown, B. A., (A) 449
Brown, L., (A) 765
Brown, M. A., (A) 761
Brown, R. A., (A) 176, 177
Bruckner, D. A., (A) 177
Bruins, J., (A) 637
Brusina, L. L., (A) 438
Buchanan, D., (A) 765
Buford, W. L., Jr., (A) 437
Bulmer, K., (A) 617
Burkhardt, R. A., (A) 161
Buschman, E., (A) 176, 419
Bussel, A., (A) 597
Busso, M., (A) 73
Butler, R., (A) 604
Butlin, R., (O) 334
Byrne, C., (A) 762

Cabello-Inchausti, B., (A) 413
Cambiaso, C. L., (A) 762
Cao, G., (A) 179
Caplin, M., (A) 177
Carayon, A., (A) 436
Carmichael, A. J., (A) 595
Carney, S., (A) 604
Carnochan, F. M. T., (A) 627
Carrazar › Hernandez, G. B., (A) 757
Carrazana Hernandez, G. E., (A) 757
Carrillo, M. P., (O) 1
Cartel, J.-L., (A) 157, (O) 512
Carter, A. O., (A) 759
Castells, E. G.-A., (A) 145
Castes, M., (A) 415
Castro, E., (C) 723

Cazares, J. V., (O) 651
Cellona, R. V., (O) 1, (A) 161, 193, 420
Cen, Y.-H., *et al.*, (A) 757
Cervera, I., (A) 631
Cestari, T. F., (A) 406, 432
Chacko, J., (C) 573
Chae, G.-T., (A) 186
Chakkalath, H. R., (A) 164
Chakrabarty, A. N., (A) 168, 168, 620, 754
Chan, J., (A) 157, 168
Chan, R., (A) 615
Chanteau, S., (A) 157, (O) 512
Chatterjee, B. R., (C) 376, (A) 615
Chatterjee, D., (A) 636
Chattopadhya, D., (O) 660
Chaturvedi, R. M., (A) 621, 759
Chaudhary, S. D., (A) 596, 602, 742
Chaudhury, S., (A) 146, 410
Chaudhury, S. N., (A) 146, 600
Chavez-Nunez, M., (O) 651
Chehl, S. K., (C) 726
Chen, J.-K., (A) 406
Chen, M.-Y., (A) 753
Cheng, C.-S., (A) 613, 753
Cherian, S., (E) 719
Chiang, T. J., (A) 167
Child, R. P., (A) 761
Chin A Lien, R. A. M., (A) 744, 749
Chiplunkar, S. V., (O) 334
Chiron, J. P., (A) 603
Cho, S. N., (A) 162
Choi, H.-S., (A) 761
Choi, I. H., (A) 162
Chopra, J. S., (E) 717
Chopra, N. K., (O) 526, (A) 736
Chopra, S. P., (A) 608
Choudhury, A., (A) 169
Christian, M., (O) 273
Chuang, C.-Y., (A) 613, 753
Chugh, T. D., (A) 156
Chujor, C. S. N., (A) 426
Chukanov, V. I., (A) 766
Chulawalla, R. G., (O) 334
Clague, R. B., (A) 600
Clancy, L. J., (A) 762
Clark, C. E., (A) 600
Clark-Curtiss, J. E., (A) 189, 190, 429, 751
Clements, B. H., (A) 752
Closs, O., (A) 163
Coghill, G., (A) 747
Cohen, I. R., (A) 637
Cohn, Z. A., (A) 160, 161, 195, 198, 420, 610
Coldiron, B. M., (A) 438
Cole, S. T., (A) 617
Coleblunders, R. L., (A) 630
Coleman, M. D., (A) 406, 737, 737
Colizzi, V., (A) 438, 440
Collazo Caballero, S., (A) 425
Collins, D. M., (A) 438
Collins, F. M., (A) 439
Collins, T., (A) 630
Cologlu, A. S., (A) 605
Colston, M. J., (O) 73, (A) 162, 431, 604, (O) 641, (A) 755
Condez, A., (A) 423
Conn, D. L., (A) 762
Content, J., (A) 629
Converse, P. J., (A) 166
Conville, P. S., (A) 439
Convit, J., (A) 415, 605
Cook, G. C., (B) 592
Cooper, C. L., (A) 157, 196
Cooper, G. L., (A) 177
Corrigan, O. I., (A) 740
Corsico, B, (A) 426
Cossermelli, W., (A) 425
Costello, E., (A) 762
Coulon, C. P., (A) 630
Coursaget, P., (A) 603
Courtright, P., (O) 39, (A) 601
Cowley, S. A., (O) 560
Cox, J. H., (A) 416
Crain, E., (A) 440
Cree, I. A., (O) 347, (A) 747
Crisci, C., (A) 418
Cristofolini, L., (A) 150
Croce, M. V., (A) 426
Croft, S. L., (A) 632
Crowle, A. J., (A) 165
Cruaud, P., (A) 615
Csajagi, E., (A) 441
Cummings, E., (A) 738
Curtis, J., (O) 560, 674
Cynamon, M. H., (A) 440

D'Souza, D., (O) 666, (A) 742
da Costa Rocha, A. L., (A) 406
Daffe, M., (A) 169
Damasco, M. H. S., (A) 596
Damiani, G., (A) 438
Damsker, B., (A) 441
Das, B. C., (O) 666
Das, B. R., (A) 742
Das, P. K., (A) 417
Das, S., (A) 146, 168, 168
Das, S. K., (A) 409
Dash, K., (O) 660
Dastidar, S. G., (A) 168, 168, 620, 754
Dautzenberg, B., (A) 448
Davey, R. W., (A) 633
David, H. L., (A) 445, 615, 769
David, M., (A) 611
Davidson, W. R., (A) 758
Davis, E. O., (A) 431
Dayal, R., (A) 600
de Almeida, F. A., (A) 745
de Almeida, R. G., (A) 626
de Bruyn, J., (A) 179, 629
de la Barrera, S., (A) 611
de la Cruz, F., (A) 427

de la Maza, L. M., (A) 444
de Lima, F. D., (A) 626
De Lisle, G. W., (A) 438
de Melo, F. S. F., (A) 423
de Melo Marques, M. A., (A) 423
de Paula, S. R., (A) 626
de Rojas, V., (A) 594, 742, 757
de Soldenhoff, R., (A) 167
de Vries, R. R. P., (A) 158, 612, 748
de Wit, L., (A) 629
de Wit, M. Y. L., (A) 420, 429, 753
DeBruyn, J., (A) 421
Dechandt, H. S., (A) 615
Dechandt, I. T., (A) 615
Declercq, E. E., (O) 296, (A) 410
Deguerry, M., (A) 410
Dehertogh, D., (A) 738
DeJoy, S. Q., (A) 631
Del Gallo, F., (A) 440
Del Porto, P., (A) 440
del Rincon, K., (A) 594
dela Cruz, E. C., (O) 1, (A) 193, 420
Delgado Rodriguez, M., (A) 621
Demchuk, B., (A) 446
Demenais, F., (A) 431
Deming, A. T., (C) 392
Deng, Y., *et al.*, (A) 417
Denis, F., (A) 603
Denis, M., (A) 417
Denning, D. W., (A) 444
Deo, M. G., (O) 334, (A) 418, (E) 566, (A) 621
Dersimonian, H., (A) 158
Desai, R. G., (O) 462
Desfontaine, M., (A) 432
Deshmukh, M. V., (O) 334
Deshpande, S. S., (A) 173
Dettrairat, S., (O) 302
Deverchin, J., (A) 148
Dey, S. K., (A) 410
Dhanapaul, S., (A) 146
Dhand, U. K., (E) 717
Dhandayuthapani, S., (A) 158
Dhawan, S., (A) 155
Dhawan, V., (A) 742
Dhople, A. M., (A) 737, 740, 755, 756
Diaz de la Rocha Quevedo, A., (A) 425
Dieye, A., (A) 609
Dijkman, H. P., (A) 415, 415
Diop Mar, I., (A) 603
Dixit, V. B., (A) 596, 742
Dobson, G., (A) 762
Dockrell, H. M., (A) 159, 163, 491
Dos Santos, L., (O) 518
Douglas, J. T., (A) 420
Douglas-Jones, A. G., (A) 631
Drachman, D. B., (A) 440
Drain, V., (C) 392
Dudani, A. K., (A) 418
Duddridge, L. R., (A) 631
Duerksen, F., (A) 437
Dukes, T W., (A) 763
Duncan, J. R., (A) 763
Dupont, M.-A., (A) 763
Dutta, J., (A) 598
Dutta, P. K., (A) 414
Duvanchelle, D., (A) 411
Dwek, R., (A) 159

Edinborough, N. B., (A) 409
Edstein, M. D., (A) 737
Ehrenberg, J. P., (A) 166
Elferink, D. G., (A) 612, 748
Ellahbadi, S. L., (A) 432
Ellard, G. A., (A) 177, (E) 704
Emmel, T., (A) 615
Emru, M., (A) 175
Engleman, E. G., (A) 606, 610
Escobar-Gutierrez, A., (O) 651, (C) 723
Espita, C., (A) 631, 631
Esser, R. E., (A) 751
Esterre, V. P., (C) 387
Evans, A. T., (A) 632
Evans, M., (A) 766
Evers, R., (A) 178
Extremera Castillo, F., (A) 621
Eze, L. C., (A) 738

Facs, C. B., (A) 171
Fadeeva, N. L., (A) 438
Fafutis-Morris, M., (C) 126
Fahelelbom, K. M. S., (A) 740
Failbus, S. S., (O) 319, 480
Fajardo, T. T., (A) 161, 193, 420
Fajardo, T. T., Jr., (O) 1
Fandinho, F. C. O., (C) 389
Farber, C. M., (A) 179, 762
Farber, W. E., (A) 749
Farrell, C., (A) 761
Fassin, D., (E) 111
Feige, U., (A) 771
Ferguson, K. M., (A) 631
Ferlini, A., (A) 739
Fermand, J. P., (A) 597
Fernandez Bussy, R., (A) 418
Ferra Torres, T. M., (A) 757, 757
Ferreira, J., (A) 432
Ferreira, M. L., (A) 153
Ferreira, P., (A) 627
Festenstein, H., (A) 167
ffytche, T., (A) 600, 743
Figueiredo, M. S., (A) 406
Filley, E., (A) 159, 159
Fine, P. E. M., (A) 171, 419, 757
Firdausi, F., (A) 491
Firenza, G., (A) 418
Fischeder, R., (A) 446
Flesch, I. E. A., (A) 161, 608
Flores, O., (C) 723
Flory, M. A., (A) 764
Floyd, C., (A) 444

Foley, N., (A) 425
Fondaminskaya, L. D., (A) 441, 632
Fong, S.-J., (A) 628
Font, R. L., (A) 151
Fontoura Heidrich, R., (A) 406
Ford, E. G., (A) 441
Forget, A., (A) 417, 425
Forno, B., (A) 73
Foster, F. N., (A) 171
Foster, R. L., (A) 171, 618
Fournie, J. J., (A) 170
Fournie, J.-J., (A) 605, 763
Fowler, J. W., Jr., (A) 409
Francisco, W., (A) 170
Franzblau, S. G., (A) 187, 406, 596, 738
Freerksen, E., (A) 147
Freitas, J. A. de S., (A) 151
Friedly, G., (A) 444
Fu, T. H., (A) 427
Fujiwara, T., (A) 168, 171, 607
Fukutomi, Y., (A) 196
Furuta, M., (O) 697
Furuyama, J., (A) 197
Fusco, F., (O) 503

Gabric, D. M., (A) 438
Gabriel, M., (A) 156
Gabriel, S. E., (A) 762
Gadi, S., (A) 751
Gallagher, A., (A) 424
Gallo, M. E. N., (A) 596
Galvao, E. C., (A) 171
Galvez Vargas, R., (A) 621
Ganapati, R., (A) 148, 173, 412
Ganesan, J., (A) 606
Gangadharam, P. R. J., (A) 632
Gangal, S. G., (O) 334
Ganguly, N. K., (A) 599, 742
Ganguly, S. S., (A) 414
Gans, L. P., (A) 595
Gao, X.-L., *et al.*, (A) 748
Garcia, B., (A) 741
Garcia, M. M., (A) 763
Garcia, M. R. de A., (A) 622
Garcia da Veiga, R. R., (A) 406
Garcia Lima, E., (C) 726
Gardner, G. D., (A) 737
Garg, B. R., (A) 155
Garg, R., (A) 601, 743
Garg, S. P, (A) 743
Garsia, R. J., (O) 25, (A) 747
Gas, N., (A) 763
Gasser, J., (A) 771
Gaston, J. S. H., (A) 606
Gaudernack, G., (A) 610
Gawkrodger, D., (A) 596
Gaylor, H., (A) 636
Gebro, N., (A) 166
Geiter, L. J., (A) 768
Gelber, R. H., (O) 39, (A) 187, 606, 610
Gennene, M., (A) 750
George, J., (A) 743
George, K., (A) 621
George, N. D., (C) 382
Georgiev, G. D., (A) 405, 411, 598
Gerber, M. A., (C) 392
Gergert, V. Y., (A) 766
Gertman, M. I., (A) 769
Gervais, F., (A) 417
Gharpuray, M. D., (A) 601
Ghei, S. K., (A) 156
Gheorghiu, M., (A) 421
Ghidella, C. C., (A) 172
Ghosh, A., (A) 598
Ghys, P., (A) 147, 148, (O) 641
Giardina-Becket, M.-A., (O) 503
Gibbs, J. H., (A) 176, 627
Gibson, J. A., (A) 177
Gibson, S. J., (A) 756
Gicquel, B., (A) 429, 630
Gigli, I., (A) 160
Gilardini Montani, M. S., (A) 440
Gilburd, B. S., (A) 441, 632
Gilis, H., (A) 178
Gill, H. K., (A) 606
Gill, N. S., (A) 153
Gilleron, M., (A) 763
Gillis, T. P., (A) 192, 422, 752, 753
Gimenez, M. F., (A) 160
Ginsberg, R. S., (A) 440
Girdhar, A., (A) 153
Girdhar, B. K., (O) 31, (A) 153, 156, 600, 608, 609, 611
Girdhar, M., (A) 625
Giurintano, D. J., (A) 178, 437
Gobel, M., (A) 172
Gobel, M. B. B., (A) 172
Godal, T., (A) 606, 750
Godbole, P. M., (A) 759
Goh, K. S., (A) 769
Goldstein, N., (A) 411
Goloshchapov, N. M., (A) 147
Goloshchapova, E. N., (A) 147, 596
Goncalves, A., (A) 437
Goncalves, N. N. S., (A) 172
Gonzalez, A. B., (A) 748
Gonzalez, A. H., (A) 177
Gonzalez, R., (A) 631
Gonzalez-Abeu, E., (A) 612, 748
Gonzalez-Abreu Castells, E., (A) 607
Gonzalez-Mendoza, A., (C) 126
Gonzalez Segredo, A., (A) 607
Good, R. C., (A) 771
Goodman, D. D., (B) 591
Gordon, G., (A) 440
Goren, M. B., (A) 165
Gormus, B. J., (O) 65, (A) 193, (O) 358, (A) 431
Goto, Y., (A) 198, 419
Goyal, N., (A) 173

Graham, D. R., (A) 449
Grandchamp, B., (A) 429
Grange, J. M., (A) 176, 177, 177, 428, 633
Grant, K. A., (A) 159, 163
Grayston, J. T., (A) 767
Gregory, D. R., (A) 145
Grillone, S., (A) 147
Groenen, G., (A) 147, 148, (O) 641
Groothuis, D. G., (A) 178, 417, 637
Grosset, J.-H., (O) 12, 281, (C) 378, (A) 421, 448, (O) 512, (A) 634
Gruer, P. J. K., (A) 419
Grugni, A., (O) 19
Gruner, J., (A) 770
Gschmeissner, S. E., (O) 560, 674
Gu, C., *et al.*, (A) 407
Guelpa-Lauras, C.-C., (O) 12, 281
Guido, L. S., (A) 161, 193
Guimaraes Proença, N., (A) 601
Guinn, B., (A) 759
Gunzler, V., (A) 441
Guo, Y.-P., (A) 744
Gupta, A. K., (A) 153
Gupta, B. K., (A) 409
Gupta, J. K., (A) 598
Gupta, M. D., (A) 758
Gupta, M. M., (O) 660
Gupta, R. S., (A) 418
Gupta, S., (A) 761
Gupta, S. K., (A) 423, 608, 611
Gupta, V., (A) 173
Gurav, V. J., (A) 148
Guthertz, L. S., (A) 441

Haaijman, J. J., (A) 426
Haas, M., (A) 407
Hadley, W. K., (A) 638
Hah, Y.-M., (O) 1
Hall, J. E., (A) 441
Halperin, M., (A) 417
Hance, A. J., (A) 429, 630
Hancock, G. E., (A) 160, 195
Handzel, Z. T., (A) 163
Hansen, E. B., (A) 175
Hansson, M., (A) 750
Happ, M. P., (A) 607
Harada, K., (A) 160
Harada, N., (O) 697
Harboe, M., (A) 161, 763
Harding, D. R., (A) 419
Harris, D. P., (A) 419
Harris, E. B., (A) 430
Harrison, J. H., Jr., (A) 407
Harshan, K. V., (O) 526
Hartskeerl, R. A., (A) 429, 753
Hasan, R., (A) 159, 491
Hasan, R. S., (A) 167
Haslov, K., (A) 763
Hass, H., (A) 769
Hastings, R. C., (E) 98, (C) 117, 392, (A) 618, (C) 726, (A) 748
Haubitz, I., (A) 408
Hay, F. C., (A) 448
Hayashi, Y., (A) 442
Hayat, S., (A) 634
Hazra, S., (A) 146
Hazra, S. K., (A) 410, 600
He, Y., (A) 744
Heifets, L. B., (A) 633, 764, 764
Helbert, M., (A) 765
Hellqvist, L., (A) 747
Hellyer, T., (A) 765
Henry, P., (A) 626
Hensen, E. J., (A) 637
Hermans, P. W. M., (A) 765
Hetzer, R., (A) 444
High, A. S., (A) 151
Hirata, T., (A) 192
Hirsch, D. S., (A) 420
Hirschfield, G. R., (A) 628
Hirunpetcharat, C., (O) 311
Hiu, I.-J., (A) 765
Hoeppner, V., (A) 177
Hoffner, S. E., (A) 633, 766
Hofman, R. M., (A) 165
Hogervorst, E. J. M., (A) 637
Holcombe, D. J., (A) 151
Holt, P., (A) 747
Holzer, T. J., (O) 342
Hon, Y.-H., (A) 406
Honig, P. J., (A) 412
Horibe, S., (A) 625
Horwitz, M. A., (A) 200, 751
Howerth, E. W., (A) 758
Hsieh, R.-P., (A) 613
Huang, L., *et al.*, (A) 411
Hui, F., (A) 636
Humphres, R. C., (A) 619
Hunter, S. W., (A) 190, 200, 606, 628
Husain, S., (A) 153, 436, 436
Hussain, R., (A) 159, 163, 491
Hussein, N., (O) 39
Husser, J. A., (A) 739
Huygen, K., (A) 629

Ibrahim, M. A., (O) 73
Ikeda, M., (A) 191, 607
Ilkoy, E., (A) 441
Inderlied, C. B., (A) 633
Inui, S., (A) 196
Iredale, J. P., (A) 407
Irgens, L. M., (O) 353, (A) 621
Isenberg, D. A., (A) 448
Ishaque, M., (A) 152
Ishida, Y., (O) 697
Islas-Rodriguez, A., (C) 126
Ito, T., (O) 1
Ivanyi, J., (A) 416, 420
Iyere, B. B., (A) 760

Izumi, S., (A) 191, 607

Jackett, P., (A) 420
Jackson, M., (A) 159, 615
Jackson, R. K., (A) 441
Jacob, A. J. W., (A) 409
Jacobs, W. R., Jr., (A) 201, 430, 605, 747
Jacobson, R. R., (C) 117
Jagannathan, R., (A) 740
Jagidar, J., (A) 761
Jain, S., (C) 118
Jain, S. K., (A) 746
Jain, V. K., (A) 596, 742
Jairam, B. T., (A) 632
James, G. D., (A) 771
Jamet, P., (A) 739
Jamil, S., (A) 491
Janda, J. M., (A) 441
Jansons, V. K., (A) 738
Janssens, L., (A) 148
Jayalakshim, P., (A) 152
Jayapal, N., (A) 607
Jayaraman, K. S., (N) 137
Jeevan, A., (A) 634
Jekkel, A., (A) 441
Jenkins, P. A., (A) 631
Jenner, P. J., (A) 177
Jessen, K. R., (A) 162
Jha "Amar," A. K., (A) 744
Jha, P. K., (A) 739
Ji, B.-H., (O) 281, (C) 378
Jiang, C., (A) 594
Jimenez, J., (A) 430
Job, C. K., (C) 117, 392, (A) 420, 618, (C) 726, (A) 748
Joginder, (A) 413, 602
John, K. R., (A) 621
Johnson, Z. T., (A) 446
Joseph, A., (A) 621
Jouy, N. E., (A) 159
Junqueira, T. B., (A) 622
Juras, R. A., (A) 441

Kaada, B., (A) 175
Kaben, H., (A) 156
Kadochkin, A. M., (A) 769
Kagame, K., (A) 150
Kakaiya, R. M., (A) 738
Kallenius, G., (A) 633, 766
Kalra, V. K., (A) 743
Kamat, R. S., (O) 44, 50, 58
Kaminski, D. A., (A) 770
Kanda, P., (A) 432
Kannan, S., (A) 758
Kaplan, G., (A) 152, 157, 160, 161, 195, 198, 420, 610
Kapoor, K. K., (A) 153
Kapur, J., (A) 608
Kar, H. K., (A) 752
Kar, P. K., (A) 597, 739
Kar, S., (A) 756
Karanth, S. S., (A) 756
Kardjito, T., (A) 176, 177, 428
Karjivkar, V. G., (A) 148
Karr, R. W., (A) 635
Kartikeyan, S., (A) 621, 759
Kasinrerk, W., (A) 163, (O) 302, 311
Kasirskaya, N. G., (A) 438
Katila, M.-L., (A) 442
Kato, H., (A) 605
Katoch, K., (O) 31, (A) 165, 169, 604
Katoch, V. M., (A) 169
Katz, P., (A) 766
Kaufmann, S. H. E., (A) 161, 420, 421, (E) 566, (A) 608, 635, 768
Kaur, I., (A) 146, 739
Kaur, S., (A) 146, (O) 466, (A) 599, 739, 742
Kawatsu, K., (A) 191, 607
Kazantseva, I. A., (A) 601
Kazda, J., (C) 130, (O) 353, (A) 756
Kehrer, D., (A) 608
Keiser, J. F., (A) 439
Kelly, P., (A) 762
Kemeny, D. M., (A) 428
Kemp, M., (A) 177
Kennedy, C., (A) 744
Kenny, M. T., (A) 597
Kerwar, S. S., (A) 631
Khamidulina, K. K., (A) 438
Khandelwal, N., (E) 717
Khardori, N., (A) 634
Kharkar, R. K., (C) 573
Khomenko, I. S., (A) 766
Khromova, E. B., (A) 147
Khuller, G. K., (A) 444
Kielstrup, R. W., (A) 148
Kiessling, R., (A) 166, 750
Kifayet, A., (A) 491
Kikuchi, S., (A) 429
Kim, D.-I., (O) 1
Kim, J. D., (A) 162
Kim, S. H., (A) 162
Kim, S. J., (A) 162
Kingston, A. E., (A) 162
Kini, M. S., (O) 19
Kislaitis, L., (O) 342
Klatser, P. R., (A) 420, 429, 753
Kochetkova, E. Y., (A) 442
Koga, T., (A) 421, 608
Kohsaka, K., (A) 192
Kolattukudy, P. E., (A) 429
Kolk, A. H. J., (A) 178, (O) 353, (A) 636, 637, 749, 753, 756, 765
Kolonoski, P., (A) 628
Konishi, T., (A) 442
Kosenko, V. I., (A) 769
Koshi, G., (A) 150
Kostina, Z. I., (A) 442
Kothari, A., (A) 746
Krahenbuhl, J. L., (A) 186
Kratz, M., (A) 633

Kripke, M. L., (A) 634
Krishnamurthy, K. V., (A) 760
Krishnan, M. M., (A) 155
Krishnan, S., (A) 597
Kubo, R. T., (A) 607
Kuijper, S., (A) 178, 637, 749
Kulkarni, D. S., (A) 601
Kulkarni, V., (A) 601
Kumar, A., (A) 153
Kumar, B., (A) 146, 599, 739, 742
Kumar, R., (A) 163
Kumar, V., (A) 609
Kuo, C.-C., (A) 767
Kurmanbayev, K. K., (A) 767
Kurz, X. M., (C) 380
Kuykens, L., (O) 641
Kuze, F., (A) 442
Kysaka, T., (A) 429

LaBrecque, J. F., (A) 632
Lacave, C., (A) 767
Lacerda, M. H., (A) 153
Lachmann, P. J., (A) 442
Lagrange, P. H., (A) 421
Lakhotia, M., (A) 746
Lakshmi, R., (A) 770
Lamb, F. I., (O) 73, (A) 431, 755
Lamb, J. R., (A) 416
Lamba, P. A., (A) 175
Lancero, M. G., (A) 633
Lanéelle, G., (A) 767
Lanéelle, M.-A., (A) 169, 767
Lange, F. W., (A) 193
Languillon, J., (A) 603
Lansley, C. V., (A) 151
Lanza, A. P., (A) 152
Larsson, L., (A) 430
Lastra, R. A., (A) 742
Lau, B. H. S., (A) 171
Launois, P., (A) 609
Laura, C. J., (C) 726
Laxman, R., (C) 571
Lazovskaya, A. L., (A) 769
Le Kinh Due, (A) 622
Lebughe, I., (A) 630
Lechat, M. F., (O) 296, (A) 621
Lecoeur, H. F., (A) 421, 448, 634
Lecossier, D., (A) 429, 630
Lee, H.-S., (A) 601
Lee, S. P., (A) 159, 163
Legros, F., (A) 179
Leguisamon, O., (A) 408
Lemieux, S., (A) 167
Lesage, G., (A) 603
Levenstein, S., (A) 445
Levett, P. N., (A) 630
Levi, V., (A) 408
Levis, W. R., (O) 65, (A) 152, 422, 426, (O) 503, (A) 610
Levy, L., (A) 446, (O) 681
Levy-Frebault, V., (A) 429, 630
Lewallen, S., (O) 39, (A) 601
Li, H.-Y., *et al.*, (A) 597
Li, M., *et al.*, (A) 421
Li, S. G., (A) 748
Li, X.-Y., (O) 328, (A) 428
Liang, Z., *et al.*, (A) 749
Life, P. F., (A) 606
Lim, I. S. L., (A) 760
Lim, K. J., (A) 152
Limbassa, J., (A) 432
Lin, C., (A) 408
Lin, D., *et al.*, (A) 411
Lin, G., (A) 433
Lin, M.-F., (A) 613
Lin, T.-P., (A) 753
Lindholm-Levy, P. J., (A) 633, 764, 764
Lindner, B., (A) 170
Liu, J.-H., (A) 618
Liu, M.-F., (A) 753
Liu, Q., (O) 328, (A) 428
Liu, Z., *et al.*, (A) 422
Ljungqvist, L., (A) 763
Locniskar, M., (A) 167
Lombardi, C., (A) 433, 440, 622
Looi, L. M., (A) 152
Looker, D., (A) 192
Lopes dos Santos, M. A., (A) 406
Lorand-Metze, I. G. H., (C) 384
Loretti, A., (A) 411
Lounatmaa, K., (A) 635
Loureiro, R., (A) 432
Love, S. G., (A) 419
Lovik, M., (A) 163
Lowe, J. G., (A) 176, 627
Lu, B.-X., *et al.*, (A) 745
Lu, R., (A) 444
Lu, X.-H., *et al.*, (A) 635
Lucas, S., (A) 491
Lucas, S. B., (A) 159, 422
Ludwig, H., (O) 319
Lugosi, L., (A) 430
Lugozi, L., (A) 605
Lundin, K. E. A., (A) 750
Luo, N. P., (A) 630
Luthra, H., (A) 762
Lydyard, P., (A) 755
Lydyard, P. M., (A) 448
Lyle, M. A., (A) 768

Ma, H., (A) 594
Ma, Z.-X., (A) 428
Machado, A. de M., (A) 161
Mackworth-Young, C., (A) 158, 609
Madarang, M. G., (A) 420
Magnusson, M., (A) 762, 768
Mahadevan, P. R., (A) 166, (O) 540, 548 (A) 610, 740
Mahajan, V. M., (A) 743
Mahakul, K. C., (A) 153
Mahapatra, B. N., (A) 153
Mahmood, K. H., (A) 447

Maiga, M., (A) 739
Maillere, B., (A) 609
Maine, N., (A) 419
Majumdar, V., (A) 600
Majumder, V., (A) 146
Makonkawkeyoon, S., (A) 163, (O) 302, 311
Malarkannan, S., (A) 164
Malatre, X., (A) 173
Malaty, R., (O) 554
Malaviya, G. N., (A) 153, 436, 436, 608
Malhotra, Y. K., (A) 746
Mallet, A., (A) 431
Mallet, A. I., (A) 762
Manchester, K., (A) 736
Mancilla, R., (A) 631, 631
Mangiarotti, R., (A) 445
Manjunath, N., (A) 770
Marcombe, D., (A) 736
Mariette, X., (A) 597
Marino Albernas, J., (A) 607
Markov, A. N., (A) 441, 632
Markusse, H. M., (A) 602
Marolia, J., (A) 610
Martin, L. N., (O) 358, (A) 431
Martinez Granja, R., (A) 425
Masaki, S., (A) 442
Masalov, A. K., (A) 164
Masatomi, T., (A) 625
Mastoba, A., (A) 151
Mathias, T., (A) 436
Mathur, N. K., (A) 420
Mathur, P. P., (A) 600
Matoba, A. Y., (A) 615
Matsuo, E., (A) 194
Mattila, J., (A) 442
Maury, L., (A) 448
Mavroudakis, N., (A) 179
Max, E., (A) 594
Mayen, E., (O) 651
Mayr, A. C., (A) 444
Mbengeranwa, O. L., (A) 178
Mboup, S., (A) 603
McAdam, K. P. W. J., (A) 158, 159, 163, 167
McCarthy, M., (A) 765
McCloskey, D. J., (A) 167
McCormick, G. M., (A) 748
McDermott-Lancaster, R. D., (O) 690
McDonald, J. C., (A) 623
McDougall, A. C., (C) 121, (A) 405, 411, 598
McFadden, J. J., (A) 177
McGregor, J. A., (A) 177
McIntosh, K. R., (A) 440
McLean, L., (A) 768
McLeod, D. T., (A) 178
McMurray, D. N., (A) 443
McNeil, M., (A) 168
Meeker, H. C., (O) 65, (A) 152, 422, 426, (O) 503
Mehlert, A., (A) 416, 448
Mehra, V., (A) 200, 415, 628, 749
Mehta, J., (N) 583
Mehta, J. M., (A) 412, 602
Mehta, S., (A) 746
Mehta, V. R., (O) 19
Mejia-Arreguin, S., (C) 126
Melancon-Kaplan, J., (A) 415
Melo Caeiro, F., (A) 621
Meng, M.-B., *et al.*, (A) 598
Merad-Boudia, A., (A) 620
Merali, S., (A) 768
Merianos, A., (A) 414
Meshnick, S., (A) 768
Metral, S., (A) 626
Meyers, W. M., (O) 65, (A) 193, (O) 358, (A) 431, (Ob) 575
Michalany, N. S., (A) 745
Michel, M., (A) 410
Midura, T. F., (A) 441
Migaldi, M., (A) 438
Miko, T. L., (C) 722
Millan, J., (A) 603, 626
Millan, J. P., (A) 147
Miller, E. S., (A) 443
Minnikin, D. E., (A) 614, 762, 768
Mintzer, C. L., (A) 443
Miranda, R. N., (A) 615
Miranda, R. P. G., (A) 615
Mirsky, R., (A) 162
Mishra, B., (A) 153
Mishra, R., (A) 749
Mishra, R. S., (A) 164, 423
Misra, H., (A) 600
Misra, R. S., (A) 172, (O) 526, (A) 635, 745, 752
Misson, C. B., (O) 296. (A) 410
Mistry, N. F., (A) 169
Mistry, Y., (A) 170
Mitchell, D. M., (A) 765
Mitchell, I. C., (A) 617
Mitjavila, M. T., (A) 597
Mittal, A., (A) 164, (O) 526
Miyama, A., (A) 637
Mizuguchi, Y., (A) 198
Mizuno, S., (A) 637
Modlin, R. L., (A) 157, 165, 186, 191, 196, 200, 415, 427, 605, 628, 749
Modrow, S., (A) 635
Mohagheghpour, N., (A) 606, 610
Mohamed, K. N., (C) 381, (A) 602
Mohan, L., (A) 625
Molloy, A., (A) 610
Monson, J. M., (A) 606
Montaville, B., (A) 434
Montreewasuwat, N., (A) 172
Mor, N., (A) 165, (O) 681
Mora, N., (A) 748
Morais, H. M. M., (A) 619
Morales-Ortiz, R., (C) 126
Moreira, T., (A) 622
Moreno, O. S., (A) 145
Morgan, K., (A) 600
Morini, J. C., (A) 157, 416
Morley, S., (A) 177
Morley, S. M., (A) 176

Moroz, A. M., (A) 176
Morrison, R. C. A., (O) 518
Morrow, J. D., (A) 149
Moses, R. L., (A) 748
Moudgil, K. D., (A) 423, 608, 611, 749
Moulia-Pelat, J. P., (A) 147
Moulinie, J. P., (A) 597
Mueller, C., (A) 157, 196
Mukherjee, A., (A) 745, 752
Mukherjee, K., (A) 168
Mukherjee, R., (A) 170, 752
Mukhija, R. D., (A) 153, 625
Muliyil, J. P., (A) 621
Mull, D. S., (A) 595
Mull, J. D., (A) 595
Mullins, R. J., (A) 605
Munk, M. E., (A) 421, 608, 635, 768
Munn, M. W., (A) 606, 610
Munno, I., (A) 739
Murphey-Corb, M., (O) 358, (A) 431
Murray, L. P., (A) 606
Mustafa, A. S., (A) 606, 750
Muthukkaruppan, V. R., (A) 164
Mya, M. M., (A) 746
Myers, L. M., (A) 437
Myint, T., (A) 746

N'Deli, L. N., (O) 12, 281
Naafs, B., (A) 744, 749
Nadkarni, N. J., (O) 19
Nagai, S., (A) 763
Nagano, J., (A) 625
Nagarajan, M., (O) 273
Nagaraju, B., (A) 758
Nagel, R., (A) 406
Naik, S. S., (A) 759
Naimanov, A. K., (A) 769
Nair, I., (O) 540, 548
Nair, S. K., (A) 752
Nakamura, K., (A) 193
Nakamura, M., (A) 192
Nakasone, A., (A) 444
Namaambo, M. K., M., (A) 630
Namnyak, S. S., (A) 432
Nanda, A., (A) 742
Nandy, S. C., (A) 153
Narayanan, P. R., (A) 423
Narayanan, R. B., (A) 165, 608, 609, 611
Nassif, X., (A) 630
Nassos, P. S., (A) 638
Natarajan, M., (A) 165
Nath, I., (A) 164, 420, (O) 526, (A) 635
Neal, R. A., (A) 632
Neeley, S. P., (A) 444
Negesse, Y., (O) 560, (C) 722
Nel, A. E., (A) 146
Nelson, D., (A) 159
Nelson, D. L., (O) 469
Nerland, A. H., (A) 750
Newton, P., (A) 761
Ni, G.-X., (A) 406
Nickonenko, B. V., (A) 176
Nigam, P., (A) 153
Nigam, P. K., (A) 172
Nishimura, Y., (A) 191, 607
Noel, E., (A) 179
Nolte, F. S., (A) 770
Noordeen, S. K., (A) 405
Northcutt, A. D., (A) 155
Nzila, N., (A) 630

O'Brien, R. J., (A) 768
O'Brien, R. L., (A) 607
O'Reilly, L., (A) 762
O'Sullivan, J. F., (A) 406
Obara, A., (O) 697
Oftung, F., (A) 750
Ogan, A. U., (A) 738
Okamoto, A., (A) 442
Okpogba, A. N., (A) 738
Olalla Saad, S. T., (C) 384
Oliveira, R. M., (A) 425
Olsson-Liljequist, B., (A) 633
Omer, A. S., (A) 602
Onozaki, K., (A) 196
Ooms, J., (A) 629
Opromolla, D. V. A., (A) 151
Orcutt, V. L., (A) 438
Orege, P. A., (A) 150
Oren, B., (A) 769
Orme, I. M., (A) 443
Oronsky, A. L., (A) 631
Orsi-Souza, A. T., (C) 389
Ortega, I., (A) 737, 755
Orts Poveda, M. del C., (A) 598
Ostler, H. B., (O) 39
Ottenhoff, T. H. M., (A) 158, 166, 750, 750
Ovdiyenko, N. P., (A) 769
Owili, D. M., (A) 150
Ozaki, M., (O) 697

Padhee, A., (C) 382, 724
Padhye, A. A., (A) 150
Pai, R., (A) 173
Paksoy, N., (A) 408
Pal, M., (A) 409
Paliwal, A. K., (A) 600
Palmer, E., (A) 607
Palmer, G. S., (A) 440
Palmer, K. M., (A) 770
Pan, Y.-L., *et al.*, (A) 622
Panaych, J. S., (A) 739
Pancholi, P., (A) 444
Pandey, D. N., (A) 600
Pandey, R. M., (A) 752
Pandya, P. G., (A) 736
Pannikar, V. K., (C) 120
Papa, F., (A) 615

Paraashari, A., (O) 660
Parent, M., (A) 626
Parida, S. K., (A) 752
Parikh, A. C., (A) 412
Parikh, D. A., (A) 412
Park, B. K., (A) 737, 737
Park, L. K., (A) 406
Parkash, O., (C) 129
Parr, R. L., (A) 443
Passerotti, S., (A) 155
Pasten, S., (O) 651, (C) 723
Patil, M. A., (A) 169
Patil, S. A., (C) 123
Patki, A. H., (A) 412, 602
Pattyn, S. R., (A) 147, 148, (O) 641, (A) 739
Paul, C. J., (A) 595
Paul, K. S., (A) 153
Paula Motta, C., (O) 453
Pavithran, K., (C) 385
Pedroza, L., (O) 554
Peerapakorn, S., (A) 172
Pelletier, M., (A) 417
Pena, R. C., (O) 651
Perani, E. G., (O) 12, 281
Pereira, A. C., Jr., (A) 406
Pereira, M., (A) 748
Perera, C. U., (A) 630
Perez Acuna, H., (A) 425
Perez, J., (A) 748
Perez, M., (A) 748
Perumal, V. K., (A) 632
Pessolani, M. C. V., (A) 423
Pestronk, A., (A) 440
Peters, M., (A) 444
Peters, W., (A) 632
Peterson, E. M., (A) 444
Petrini, B., (A) 766
Pfaltzgraff, R. E., (C) 573
Piccolella, E., (A) 440
Pinching, A. J., (A) 765
Pinchuk, L. M., (A) 769
Pinto, B. O., (A) 406
Pinto, G., (A) 153
Pinto, M. N., (A) 425
Pirmez, C., (A) 157, 165
Pisa, P., (A) 750
Pitulle, C., (C) 130
Plichart, R., (A) 157, (O) 512
Plikayetes, B. B., (A) 197
Podapati, N. R., (A) 632
Podder, G. C., (A) 146
Pohle, H. D., (A) 444
Pokhodzei, I. V., (A) 442
Polak, J. M., (A) 756
Pollar, S., (A) 146
Pollono, A. M., (A) 73
Ponce, P., (A) 153
Ponnighaus, J. M., (A) 419
Porro, A. M., (A) 745
Portaels, F., (A) 430
Potts, R. C., (A) 176
Poulter, L. W., (A) 423
Poulton, T. A., (A) 424
Prabhakar, R., (O) 273
Prabhakaran, K., (A) 430
Prabhavalkar, A. B., (C) 573
Pradhan, H., (A) 741
Pradhan, H. M., (O) 480
Pradinaud, R., (C) 387
Prantera, C., (A) 445
Prasad, A. S., (A) 154
Prasad, H. K., (O) 526
Prasad, R., (A) 600
Pringe, D., (A) 178
Pritze, S., (A) 408, 414
Proença, N. G., (A) 178, 740
Puavilai, S., (A) 740
Pugliese, A., (A) 73
Puig, N., (A) 157
Puzo, G., (A) 170, 763

Quigley, J. M., (A) 408, 740

Rabello, F. E., (A) 424
Rabinowitz, L. G., (A) 412
Rachkova, O. F., (A) 769
Rademacher, T., (A) 159
Radl, J., (A) 426
Rafla, L., (A) 410
Rai, N., (A) 741
Rajagopalan, K., (A) 152
Rajan, M. A., (A) 74
Rajendra, M., (A) 743
Rajendran, A., (A) 409
Ram, J., (A) 739
Ramachandran, A., (C) 571
Ramanathan, V. D., (O) 31
Ramani, R., (C) 724
Ramasoota, T., (O) 1
Rambukkana, A., (A) 417
Ramdeo, I. N., (A) 447
Ramesh, V., (A) 172, 635, 745
Ramnarayan, K., (C) 115
Ramos, A., (A) 153
Ramos, G. S., (A) 426
Ramu, G., (C) 123
Ranade, A., (A) 166
Ranchoff, B. J., (A) 636
Rao, K. N., (A) 154, 751
Rao, K. S., (A) 436
Rao, S. P., (A) 760
Rapoport, B. L., (O) 518
Rasheed, R. N., (A) 167
Rastogi, N., (A) 445, 769
Rath, S., (A) 741
Ratledge, C., (A) 447, 616, 617
Rauzier, J., (A) 429
Ravi, S., (A) 745
Rawlinson, W. D., (A) 424
Raz, R., (A) 769

Rea, T. H., (A) 157, 165, 191, 196, 200, 415, 427, 605
Reddy, N. N. B., (A) 750
Reddy, R. N., (C) 379
Rees, R. J. W., (A) 419, 606
Reller, L. B., (A) 446
Resuello, R., (A) 193
Revankar, C. R., (A) 148, 148, 173, 173
Reynolds, I., (A) 600
Richard, B. M., (A) 760
Richard, L., (A) 425
Richards, P., (A) 736
Richardson, G. A., (A) 600
Richardson, J. H., (A) 409
Richez, P., (O) 512
Ridell, M., (A) 768
Ridley, D. S., (A) 422, 606
Ridley, M. J., (A) 412
Rieckmann, K. H., (A) 737
Riniker, B., (A) 771
Riviere, M., (A) 170, 763
Rivoire, B., (A) 636
Robin, J. B., (A) 615
Robinson, D., (A) 765
Robinson, M. J., (A) 413
Robinson, P., (A) 610
Roche, P. W., (O) 319, 480
Rodrigues, L. C., (A) 757
Rodriguez, O., (C) 723
Rodriguez, R., (O) 651
Rodriguez Garcia, M. A., (A) 425
Rodriguez Silveira, J., (A) 431
Rodriquez, A. V.-P., (A) 145
Rodriquez-Contreras Pelayo, R., (A) 621
Roecklein, J., (A) 766
Roger, H., (A) 770
Rohatgi, J., (A) 175
Roller, J. A., (A) 156
Rolston, K., (A) 634
Rommele, G., (A) 770
Rook, G. A. W., (A) 156, 159, 159, 425, 448, 628, 755
Rose, N. R., (Ob) 730
Rose, P., (A) 167, 173
Rosenbaum, B., (A) 634
Rosenfeld, M., (A) 147, 740
Rothbard, J. B., (A) 416
Roux, J., (A) 157
Roux, J.-F., (O) 512
Roy, R. D., (A) 615
Roy, S., (A) 409
Royston, J. P., (A) 756
Ruf, B., (A) 444
Rumjanek, F. D., (A) 423
Russell, D. A., (A) 414

Sagaro Delgado, B., (A) 425
Saha, B., (A) 410
Saha, K., (A) 154, 447, (O) 660, (A) 751
Saha, U., (O) 660
Sainis, K. B., (O) 58
Saint-André, P., (A) 611
Sainte-Marie, D., (C) 387
Saito, H., (A) 188, 199, 446, 448
Salem, J. I., (C) 389
Saleta, B., (A) 741
Salfinger, M., (A) 446
Salgame, P., (A) 186, 427, 605
Sallotti, S. R. A., (A) 155
Sampaio, E. P., (A) 161
Sampattavanich, S., (O) 1
Samson, P. D., (O) 334
Samuel, B., (A) 635
Sanbournin, R. O., (A) 145
Sanchez, A., (A) 171, 618
Sanchez, E., (A) 741
Sanders, C. A., (A) 638
Sanders, C. V., (A) 449
Sang, H.-G., (A) 618
Sankaran, R., (A) 407
Sansarricq, H., (A) 598
Santiago, M. B., (A) 425
Santos, M. F. Q., Jr., (A) 170
Santos, W. M., (A) 151
Sapp, T. M., (A) 631
Sarkar, S., (A) 146
Sarno, E. N., (A) 161, 423
Sarthou, J. L., (A) 609
Sasaki, N., (A) 194
Sasiain, M. del C., (A) 611
Sathish, M., (A) 189, 751
Sato, K., (A) 446, 448
Sattar, M. A., (A) 156, 448
Satti, M. B., (A) 602
Saúl, A., (Ob) 396
Sauvezie, B., (A) 770
Savage, J. E., (A) 146
Saxena, N., (A) 412
Saxena, S. P., (A) 153
Saxena, U., (A) 745
Schlesinger, L. S., (A) 200, 751
Schmidt, D. S., (A) 756
Schoel, B., (A) 421, 608, 635
Schoningh, R., (A) 637
Schuitema, A. R. J., (A) 765
Schuller-Levis, G. B., (A) 152, 422, (O) 503
Schulze-Robbecke, R., (A) 446
Schurmann, D., (A) 444
Schwerer, B., (A) 426
Scollard, D. M., (O) 469
Scott, G. C., (A) 414
Segal-Eiras, A., (A) 426
Seghal, S., (A) 146
Segredo, A. B. G., (A) 145
Sehgal, P. K., (A) 602
Sehgal, V. N., (C) 116, 118, (A) 154, 155, 412, 413, 602
Sela, S., (A) 190
Self, T. H., (A) 409
Sen, D. K., (A) 168
Sen, R., (A) 602, 742
Sengupta, A., (A) 598

Sengupta, S. R., (O) 44, 50, 58
Sengupta, U., (O) 31, (C) 123, 129, (A) 156, 165
Senoy, S. D., (C) 115
Serrano Ortega, A., (A) 621
Sersen, E., (A) 426, (O) 503
Ses, T. P., (A) 442
Seth, P., (A) 770
Seydel, J. K., (A) 737, 740
Seydel, U., (A) 170
Sha, H.-W., (A) 594
Shaaban, M. A., (A) 156
Shabanov, M. A., (A) 438
Shah, P. K. D., (A) 746
Shahin, A., (A) 156
Shankar, P., (A) 770
Shanmugasundaram, N., (A) 607
Shannon, E. J., (A) 753
Shantagunam, P., (A) 436, 436
Shao, K.-W., *et al.*, (A) 603, 623
Sharif, A., (A) 614
Sharma, A. K., (O) 660, (A) 752
Sharma, R. P., (A) 412
Sharma, S., (A) 447
Sharma, S. P., (A) 153
Sharma, V., (A) 154
Sharma, V. D., (A) 169
Sharma, V. K., (O) 466, (A) 739
Sharp, K., (A) 420
Shats, E. I., (A) 175
Sher, R., (O) 518
Shi, M.-Q., (A) 618
Shi, Z. R., (A) 741, 756
Shinnick, T. M., (A) 197, 750, 768
Shitova, N. A., (A) 438
Shivananda, P. G., (C) 724
Shivannavar, C. T., (A) 169
Shorey, P., (A) 155
Shriniwas, (A) 770
Shroff, K. E., (O) 44, 50, 58
Shu, H.-W., (A) 428
Shwe, T., (A) 746
Sibille, J.-C., (A) 168
Sibley, S., (O) 674
Siddalinga Swamy, M. K., (A) 436
Siddiqui, Z., (A) 156
Sikka, R., (A) 602
Sikweze, J., (A) 630
Silbaq, F., (A) 446, (O) 681
Silva, M. T., (A) 627
Silva, T. C. P. G., (A) 596
Sinchaisri, T.-A., (A) 157
Singh, G., (A) 601, 743
Singh, N. B., (A) 755
Singh, U., (A) 447, 602
Singh, V. S., (A) 412
Singhal, M., (A) 447
Sinha, S., (C) 123
Siqueira, L. F. G., (A) 170
Siu, P., (A) 606
Skamene, E., (A) 176, 417, 419
Skinsnes, O. K., (A) 194
Sloan, D., (A) 768
Small, P. H. C., (A) 171
Smelt, A. H. M., (A) 602
Smith, D. L., (A) 752
Smith, J., (A) 449
Smith, T. C., (A) 409, (O) 469
Smith, W. C. S., (O) 347
Snapper, M., (A) 168
Snapper, S., (A) 605
Snapper, S. B., (A) 201
Snehi, P. S., (A) 739
Snider, D., Jr., (A) 636
Soares, R., (A) 627
Sobol, W., (A) 151
Soder, O., (A) 750
Soggiu, A., (A) 738
Sohi, A. S., (A) 597
Solanki, R. L., (A) 447
Solf, R., (A) 770
Solomon, A. R., (A) 412
Somasundaram, P. R., (O) 273
Somse, P., (A) 432
Sonesson, A., (A) 430
Soni, N. K., (A) 603
Sorensen, B. H., (A) 148, 173
Sounis, E. L. M., (A) 615
Souteyrand, P., (A) 770
Souza, C. A., (C) 384
Spannuth, G., (A) 147
Spence, V. A., (A) 627
Spoglianti, R, (A) 739
Springall, D. R., (A) 756
Sreevatsa, (C) 129
Srinivas, C. R., (C) 115, 382, 724
Srinivasan, H., (A) 413, 413
Srinivasan, R., (A) 175
Sritharan, M., (A) 447
Sritharan, V., (A) 616
Srivastava, G., (A) 155
Srivastava, L. M., (A) 423
Srivastava, P. K., (A) 743
Stabel, L. F. E. M., (A) 753
Stackebrandt, E., (C) 130
Stainsby, K., (A) 447
Stallknecht, D. E., (A) 758
Stanford, J. L., (A) 156, 419, 426, 447, 614, 755
Steele, J., (A) 159
Steele, L. C., (A) 449
Steklovsky, V. K., (A) 147
Stelandre, M., (A) 629
Stes, P., (A) 173
Stevens, P., (A) 628
Stiefel, S. M., (A) 441
Stoker, N. G., (A) 159, 163
Stoler, M., (A) 761
Stollar, B. D., (A) 158
Stolz, E., (A) 744, 749
Stone, O. J., (A) 740
Strauchen, J., (A) 761

Strobel, M., (A) 603
Stumpe, B., (A) 413
Stuyvesant, W., (A) 171
Suarez Moreno, D., (A) 612
Suarez Moreno, O., (A) 431, 746
Subramanian, S., (A) 607
Sudhakar, K. S., (A) 156
Sugimori, G., (A) 442
Sugiyama, K., (A) 191, 607
Suite, M., (A) 409
Sukumaran, K. D., (A) 145
Sumter, G., (A) 449
Supajatura, V., (O) 311
Suresh, N. R., (A) 752
Suriyanon, V., (O) 469
Suryanwanshi, N. B., (A) 150
Suster, S., (A) 413
Suykebuyk, M. E. G., (A) 753
Suzuki, K., (A) 160
Svenson, S. B., (A) 633
Swamy, R., (C) 389
Swarts, R. P., (A) 766
Swenson, C. E., (A) 440
Swersie, S., (A) 152

'T Mannetje, W., (A) 624
Tada, K., (A) 625
Takeuchi, T., (A) 429
Talwar, G. P., (A) 423, 611, 749, 752
Tamura, T., (A) 197
Tanaka, T., (A) 197
Tang, Q.-C., (A) 406
Tangiguchi, H., (A) 198
Tausk, F. A., (A) 160
Taylor, R. B., (A) 632
Tee, R. D., (A) 428
Teepe, R. G. C., (A) 602
Teixeira, P. R., (A) 626
Terencio de las Aguas, J., (A) 434
Thakur, M., (A) 599
Thamprasert, K., (O) 469
Thangaraj, H. S., (A) 431
Thaung, U., (A) 746
Theetranont, C., (O) 469
Theuvenet, W. J., (O) 319, 480
Thevenet, J. P., (A) 770
Thole, J. E. R., (A) 189, 751, 753, 765
Thomas, A., (O) 273
Thomas, I. M., (O) 666, (A) 742
Thomas, P. A., (A) 607
Thompson, D. E., (A) 178, 437
Thornton, Y. S., (A) 155
Thuladar, L., (A) 741
Thyagarajan, S. P., (A) 607
Tieubergenov, E. T., (A) 767
Timoney, R. F., (A) 740
Timpatanapong, P., (A) 740
Todd, J. R., (A) 623
Toe, M., (A) 746
Tokunaga, T., (A) 198
Tomioka, H., (A) 188, 199, 448
Torigian, V., (A) 165, 191
Torigian, V. K., (A) 427
Torney, H. L., (A) 597
Trindade, M. A. B., (A) 626, 626
Tripathy, S. R., (O) 273
Truffot-Pernot, C., (A) 421, 448, 634
Truman, R. W., (A) 618
Trygg, C. B., (A) 431
Tsang, A. Y., (A) 636, 766
Tsang, M., (A) 606
Tsebekova, L. A., (A) 442
Tshilumba, K., (O) 641
Tsiu, S. J., (A) 409
Tsoulfa, G., (A) 448
Tsukamura, M., (A) 637
Tuma, M. F., (A) 425
Tung, K., (A) 159
Turco, S. J., (A) 168
Turcotte, C., (A) 763
Turcotte, R., (A) 167, 425
Turk, J. L., (O) 560, (A) 617, (O) 674
Turneer, M., (A) 179
Tyagi, P., (O) 31
Tyagi, P. K., (O) 660
Tzourio, C., (A) 626

Udou, T., (A) 198
Urmil, A. C., (A) 414
Utkin, V. V., (A) 766
Uyemura, K., (A) 165
Uzdejezyk, M., (A) 738

v. Ketel, R. J., (A) 637
Vachula, M., (O) 342, 534
Vadiee, A. R., (A) 753
Vainchenker, W., (A) 597
Vaishnavi, C., (A) 599, 742
Valayer, P., (A) 603
Valdes-Portela, A., (A) 427, 612
Valdes-Portela Rodriguez, A., (A) 746
Valli, P. R. T., (A) 607
Van der Meide, P. H., (A) 162
van der Zee, R., (A) 637
Van Dijk, G., (A) 749
van Eden, W., (A) 637
van Embden, J. D. A., (A) 448, 612, 637, 765
van Joost, T., (A) 744, 749
van Schooten, W. C. A., (A) 158, 612
Van Soolingen, D., (A) 765
Van Vooren, J. P., (A) 179, 629, 762
Varadkar, D., (O) 548
Varughese, P. V., (A) 759
Vasanthi, B., (A) 158
Vaz, M., (A) 409
Veenendaal, J. R., (A) 737
Vehra, V., (A) 605
Vellut, C. M., (O) 296, (A) 410
Venisse, A., (A) 763
Venkatesan, K., (A) 148

Vercellone, A., (A) 170
Verez Bencomo, V., (A) 607
Verhofstadt, R., (A) 629
Verma, L, (A) 743
Verstijnen, C. P. H. J., (A) 637
Verstynen, C. P. H. J., (A) 765
Vettom, L., (A) 414
Vieth, H., (A) 150, 155
Vigneron, E., (A) 623
Vijayalakshmi, K., (O) 674
Villishayee, R. S., (A) 758
Vinayak, V. K., (A) 444
Vincelot, P., (A) 603
Virmond, M., (A) 437
Vismara, D., (A) 438
Vithayasai, V., (O) 302, 311
Volckaert, G., (A) 629
Volinn, I. J., (A) 595
Vosbeck, K., (A) 770

Wagner, D., (A) 159
Wagner, D. K., (O) 469
Walia, R., (A) 752
Walker, F. J., (A) 738
Wallace, R. J., Jr., (A) 449
Walsh, G. P., (O) 65, (A) 161, 193, (O) 358, (A) 429, 431
Walter, J., (A) 174
Wand-Wurttenberger, A., (A) 421, 608
Wang, B., (A) 179
Wang, C.-R., (A) 613, 753
Wang, D., (A) 179
Wang, H.-Y., (A) 618
Wang, H.-Y., *et al.*, (A) 599, 618
Wang, J.-M., (A) 744
Wang, S., *et al.*, (A) 434
Wang, S.-Y., (A) 406
Wang, Y., (A) 179
Waters, M., (A) 159, 159
Wathen, C. G., (A) 407
Watson, J. D., (A) 192, 419
Wehrli, W., (A) 770
Wei, G.-R., *et al.*, (A) 603
Wei, W.-H., (O) 328, (A) 428
Weiner, I. D., (A) 155
Weis Bentzon, M., (A) 763
Weissman, I. L., (A) 157
Wempe, E. G., (A) 740
Weng, X.-M., *et al.*, (A) 613
Wentworth, E. J., (A) 758
West, B. C., (A) 623
Westblum, T. U., (A) 156
Whalen, G., (A) 766
Wheeler, P. R., (A) 616, 616, 617
White, K. E., (A) 187, 406, 596
White, N. W., (A) 410
Wigley, S. C., (A) 414
Wiker, H. G., (A) 763
Wille, R. C., (A) 149
Williams, D. L., (A) 192, 422, (O) 480
Williams, R. C., (A) 167
Winn, M. J., (A) 737, 737
Winrow, D., (A) 768
Winters, M. A., (A) 619
Wirz, G., (A) 770
Witebsky, F. G., (A) 439
Witt, D., (C) 130
Wittes, R., (A) 759
Wondimu, A., (A) 166, 750
Wong, L., (A) 427
Wood, C. S., (A) 595
Woodbury, J. L., (A) 449
Woods, S. A., (A) 617
Worobec, S., (O) 534
Wu, M., (A) 628
Wu, Q., *et al.*, (A) 427
Wu, Q.-X., (O) 328, (A) 428
Wu, Q.-X., *et al.*, (A) 613, 613, 754
Wurdel, C., (A) 156

Ximines, R., (A) 619
Xu, K.-Y., (O) 65
Xu, S., *et al.*, (A) 770
Xue, Z.-Y., (A) 428

Yadav, M. S., (A) 602
Yagupsky, P. V., (A) 770
Yajko, D. M., (A) 638
Yakrus, M. A., (A) 771
Yalisombo Study Group, (O) 641
Yamada, S., (A) 745
Yamada, Y., (A) 448
Yamamoto, Y., (A) 197
Yamashita, J. T., (A) 745
Yang, G., (A) 179
Yang, L., *et al.*, (A) 434
Yang, S. J., (A) 410
Yang, X., *et al.*, (A) 435
Yang, X.-D., (A) 771
Yang, Z., *et al.*, (A) 435
Yang, Z.-M., (A) 435
Yasui, M., (A) 429
Ye, G.-Y., (N) 138, 138, (O) 328, (A) 428, 594
Ye, S.-Z., (A) 618
Yeager, E., Jr., (A) 766
Yernault, J. C., (A) 179
Yin, K.-M., (A) 627
Yin, Y.-P., (O) 328
Yoder, L., (A) 742
Yogi, Y., (A) 193
Yong, A. J., (A) 428
Young, D. B., (A) 448
Young, L. S., (A) 628, 629, 633, 761
Young, R. A., (A) 635
Young, S. M. M., (A) 157
Yu, L.-C., (A) 618
Yuasa, Y., (O) 1
Yuengel, C., (A) 412
Yushchenko, A. A., (A) 164, 175
Yvonnet, B., (A) 603

Zabriskie, J. B., (A) 631
Zago, M. A., (A) 406
Zaheer, A. S., (A) 752
Zeng, X.-L., *et al.*, (A) 599
Zhan, T., *et al.*, (A) 771
Zhang, G.-C., (A) 627
Zhang, J.-L., (A) 406
Zhang, J.-Y., (A) 431
Zhang, X.-Q., *et al.*, (A) 614
Zhang, Y., (A) 768
Zheng, T.-S., (A) 627
Zhou, D.-S., (A) 594
Zhou, H. M., (A) 741, 756
Zhou, Y., (A) 599
Zhu, W., *et al.*, (A) 428
Zhu, X.-S., (A) 428
Zimmerman, V. R., (A) 156
Zingoni, T., (A) 178
Zumla, A., (A) 771
Zuniga G., M., (O) 453

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

Acid, fatty,
A very long-chain fatty acid elongation system in *M. avium* and a possible mode of action of isoniazid on the system. Kikuchi, S., *et al.* ..... (A) 429
Enzymes for biosynthesis *de novo* and elongation of fatty acids in mycobacteria grown in host cells: is *M. leprae* competent in fatty acid biosynthesis? Wheeler, P. R., *et al.* ..... (A) 617
The component fatty acids of chaulmoogra oil. Sengupta, A., *et al.* ..... (A) 598

Acid-fast bacilli,
Acid-fast bacilli found in sphagnum vegetation of coastal Norway containing *M. leprae*-specific phenolic gylcolipid-I. Kazda, J., *et al.* ..... (O) 353
Acid-fast bacilli in semen; correlation with bacterial index. Abraham, A., *et al.* ..... (O) 466
Cultivation of a nocardioform acid-fast chemoautotrophic bacterium from armadillo tissues infected with *M. leprae.* Dastidar, S. G. and Chakrabarty, A. N. ..... (A) 754

Acquired immunodeficiency syndrome (AIDS),
AIDS—the leprosy of the 1980s. Is there a case for quarantine? Gregory, D. R. ..... (A) 145
Geographic distribution, frequency, and specimen source of *M. avium* complex serotypes isolated from patients with acquired immunodeficiency syndrome. Yakrus, M. A. and Good, R. C. ..... (A) 771
Issues of definitions and their implications: AIDS and leprosy. Volinn, I. J. ..... (A) 595
Killing by antimycobacterial agents of AIDS-derived strains of *M. avium* complex inside cells of the mouse macrophage cell line. Yajko, D. M., *et al.* ..... (A) 638
M. avium and *M. intracellulare* infections in patients with and without AIDS. Guthertz, L. S., *et al.* ..... (A) 441
M. avium-M. intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Barbaro, D. J., *et al.* ..... (A) 438
Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Collins, F. M. ..... (A) 439
Results of blood cultures for detection of mycobacteria in AIDS patients. Truffot-Pernot, C., *et al.* ..... (A) 448
Sexually transmitted diseases in leprosy patients in north and northeastern India. A futile search for human immunodeficiency virus antibody. Saha, K., *et al.* ..... (O) 660
Spindle cell reaction to nontuberculous mycobacteriosis in AIDS mimicking a spindle cell neoplasm; evidence for dual histiocytic and fibroblast-like characteristics of spindle cells. Brandwein, M., *et al.* ..... (A) 761
Virulence of *M. avium* complex strains from acquired immune deficiency syndrome patients: relationship with characteristics of the parasite and host. Gangadharam, P. R. J., *et al.* ..... (A) 632

Adenosine triphosphate (ATP),
Application of ATP assay for *in vitro* drug screening testing against human derived *M. leprae.* Katoch, V. M., *et al.* ..... (A) 169

Africa,
[Polychemotherapy of leprosy in the Central African Republic in 1987.] Desfontaine, M., *et al.* ..... (A) 432

Algeria,
[Reflections on leprosy in Algeria: a report on an autochtonous case in the Wilaya of Tlemcen (West Algeria).] Boudghene-Stambouli, O. and Merad-Boudia, A. ..... (A) 620

Allergy,
Triethanolamine-induced allergic contact dermatitis over a tuberculoid leprosy lesion. Srinivas, C. R., *et al.* ..... (C) 382

American Leprosy Missions (ALM),
New address for American Leprosy Missions .....(N) 587

Amikacin,
Liposome-encapsulated-amikacin therapy of *M. avium* complex infection in beige mice. Cynamon, M. H., *et al.* .....(A) 440

Anemia,
Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity. Figueiredo, M. S., *et al.* .....(A) 406
Stimulation of K-Cl cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone. Haas, M. and Harrison, J. H., Jr. .....(A) 407

Ansamycin,
Comparative effect of the naphthalenic ansamycins rifamycin Sv, rifampin and cyclopentylrifampicin on murine neutrophil function. Kenny, M. T., *et al.* .....(A) 597
Rifabutin (ansamycin LM427) for the treatment of pulmonary *M. avium* complex. O'Brien, R. J., *et al.* .....(A) 768

Antibody,
A longitudinal study of the incidence of leprosy in a hyperendemic area in Zaire, with special reference to PGL-antibody results. Groenen, G., *et al.* .....(O) 641
An attempt to demonstrate antinerve antibodies in leprosy sera using rabbit nerve as antigen. Parkash, O., *et al.* .....(C) 129
Analysis of human antibody epitopes on the 65-kilodalton protein of *M. leprae* by using synthetic peptides. Meeker, H. C., *et al.* .....(A) 422
Anti-cardiolipin antibodies in Mexican lepromatous leprosy patients. Escobar-Gutierrez, A., *et al.* .....(C) 723
Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *M. leprae*. Gormus, B. J., *et al.* .....(O) 65
Antibodies to mycobacteria in healthy and tuberculous badgers from two English counties. Stainsby, K., *et al.* .....(A) 447
Antibodies to the phenolic glycolipid-1 antigen for epidemiologic investigations of enzootic leprosy in armadillos (*Dasypus novemcinctus*). Truman, R. W., *et al.* .....(A) 618
Antibody response to phenolic glycolipid I and *Mycobacterium w* antigens and its relation to bacterial load in *M. leprae*-infected mice and leprosy patients. Moudgil, K. D., *et al.* .....(A) 423
Anticardiolipin antibodies in patients with infectious diseases. Santiago, M. B., *et al.* ..(A) 425
[Antituberculous antibodies to antigens of different molecular weights in patients with active tuberculosis of the lungs.] Gilburd, B. S., *et al.* .....(A) 632
[Assay of antibodies in blood serum of patients with pulmonary tuberculosis by using mycobacterial antigen isolated by affinity.] Gilburd, B. S., *et al.* .....(A) 441
[Circulating immune complexes in multibacillary leprosy patients and their relationship with anti-*M. leprae* antibodies and the major immunoglobulin classes. Suarez Moreno, D., *et al.* .....(A) 612
Confirmation of a false-positive result associated with a competition inhibition assay used for detecting antibodies to a protein epitope of *M. leprae*. Vadiee, A. R., *et al.* (A) 753
Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Prantera, C., *et al.* .....(A) 445
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Tsoulfa, G., *et al.* .....(A) 448
Evaluation of fluorescent leprosy antibody absorption test versus enzyme-linked immunosorbent assay with phenolic glycolipid I and their use in immuno-epidemiological studies on leprosy. Wu, Q.-X., *et al.* .....(A) 428
Identification and characterization of antigenic determinants of *M. leprae* that react with antibodies in sera of leprosy patients. Sathish, M., *et al.* .....(A) 751
IgA antibodies against phenolic glycolipid I from *M. leprae* in serum of leprosy patients and contacts: subclass distribution and relation to disease activity. Schwerer, B., *et al.* .....(A) 426
IgM serum antibodies to phenolic glycolipid-I and clinical leprosy: two years' observation in a community with hyperendemic leprosy. Bagshawe, A. F., *et al.* .....(O) 25
Lack of serum antibodies to native type II collagen in leprosy. Clague, R. B., *et al.* ....(A) 600

[Ms-ELISA for detection of serum antibody level in leprosy patient—establishment of Ms-ELISA.] Wu, Q.-X., *et al.* ....(A) 613
Operational value of serological measurements in multibacillary patients: clinical and bacteriological correlates of antibody responses. Roche, P. W., *et al.* ....(O) 480
[Preliminary study on anti-nerve antibody in the sera of leprosy patients.] Huang, L., *et al.* ....(A) 411
Protein G-based enzyme-linked immunosorbent assay for anti-MPB70 antibodies in bovine tuberculosis. Harboe, M., *et al.* ....(A) 763
Quantitation of IgM antibodies to the *M. leprae* synthetic dissacharide can predict early bacterial multiplication in leprosy. Hussain, R., *et al.* ....(A) 491
Screening of anti-*M. leprae* antibodies in the blood samples eluted from filter paper blood blots. Patil, S. A., *et al.* ....(C) 123
Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. Meeker, H. C., *et al.* ....(O) 503
Toxoplasma gondii antibody in patients of lepromatous leprosy. Rao, K. N., *et al.* ....(A) 751

Antibodies, monoclonal,
Anti-*M. leprae* monoclonal antibodies cross-react with human skin: an alternative explanation for the immune responses in leprosy. Naafs, B., *et al.* ....(A) 749
[Detection of specific circulating immune complexes in leprosy patients by mouse monoclonal antibody against phenolic glycolipid-I.] Wu, Q.-X., *et al.* ....(A) 754
Generation and characterization of a human monoclonal antibody against phenolic glycolipid-I of *M. leprae.* Moudgil, K. D., *et al.* ....(A) 611
Generation of monoclonal antibodies to the specific sugar epitopes of *M. avium* complex serovars. Rivoire, B., *et al.* ....(A) 636
Immunohistologic analysis of mycobacterial antigens by monoclonal antibodies in tuberculosis and mycobacteriosis. Barbolini, G., *et al.* ....(A) 438
Production and characterization of monoclonal antibodies against specific serotypes of *M. avium* and the *M. avium-M. intracellulare-M. scrofulaceum* complex. Kolk, A. H. J., *et al.* ....(A) 178
Rapid identification of cultured *M. tuberculosis* with a panel of monoclonal antibodies in Western blot and immunofluorescence. Verstijnen, C. P. H. J., *et al.* ....(A) 637
[Study on monoclonal antibody in leprosy. I. Production of monoclonal antibody against antigenic epitope of PGL-I specific to *M. leprae.*] Wu, Q.-X., *et al.* ....(A) 613

Antigen(s),
A 38-kD *M. tuberculosis* antigen associated with infection; its isolation and serologic evaluation. Espita, C., *et al.* ....(A) 631
A comparative study on the effects of rIL-4, rIL-2, rIFN-γ, and rTNF-α on specific T-cell non-responsiveness to mycobacterial antigens in lepromatous leprosy patients *in vitro.* Ottenhoff, T. H. M., *et al.* ....(A) 750
A major immunogenic 36,000-molecular-weight antigen from *M. leprae* contains an immunoreactive region of proline-rich repeats. Thole, J. E. R., *et al.* ....(A) 753
An attempt to demonstrate antinerve antibodies in leprosy sera using rabbit nerve as antigen. Parkash, O., *et al.* ....(C) 129
Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *M. leprae.* Gormus, B. J., *et al.* ....(O) 65
Antibodies to the phenolic glycolipid-1 antigen for epidemiologic investigations of enzootic leprosy in armadillos (*Dasypus novemcinctus*). Truman, R. W., *et al.* ....(A) 618
Antibody response to phenolic glycolipid I and *Mycobacterium w* antigens and its relation to bacterial load in *M. leprae*-infected mice and leprosy patients. Moudgil, K. D., *et al.* ....(A) 423
Antigen-reactive TCR $\gamma\delta$ lymphocytes in leprosy lesions. Modlin, R. L., *et al.* ....(A) 191
[Antituberculous antibodies to antigens of different molecular weights in patients with active tuberculosis of the lungs.] Gilburd, B. S., *et al.* ....(A) 632
[Assay of antibodies in blood serum of patients with pulmonary tuberculosis by using mycobacterial antigen isolated by affinity.] Gilburd, B. S., *et al.* ....(A) 441
Cellular immune responses of leprosy contacts to fractionated *M. leprae* antigens. Lee, S. P., *et al.* ....(A) 163

Characterization of antigens associated with the cell walls of *M. leprae* and *M. tuberculosis* using T-lymphocyte clones. Mehra, V., *et al.* ..... (A) 200
Cloning and expression of *M. tuberculosis* strain Aoyama B in *Escherichia coli*—a gene encoding 15-kDa and 60-kDa antigens. Tanaka, T., *et al.* ..... (A) 197
Comparison of the immunological activity of five defined antigens from *M. tuberculosis* in seven inbred guinea pig strains. The 38-kDa antigen is immunodominant. Haslov, K., *et al.* ..... (A) 763
Development of a recombinant BCG vaccine vector; cloning and expression of foreign antigen genes in BCG. Snapper, S. B., *et al.* ..... (A) 201
Differential pattern of T cell recognition of the 65-kDa mycobacterial antigen following immunization with the whole protein or peptides. Brett, S. J., *et al.* ..... (A) 416
Enzyme-linked immunosorbent assay for distinguishing serological responses to the 29/33-kilodalton doublet and 64-kilodalton antigens of *M. tuberculosis*. Das, P. K., *et al.* ..... (A) 417
Enzyme-linked immunosorbent assay with BCG sonicate antigen for diagnostic potential of mycobacterial infection in Taiwan. Wang, C.-R., *et al.* ..... (A) 753
Evaluation of *M. leprae* antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Klatser, P. R., *et al.* ..... (A) 420
Experiences with *M. leprae*-soluble antigens in a leprosy-endemic population. Gupta, M. D., *et al.* ..... (A) 758
Failure of *M. leprae* soluble antigens to suppress delayed-type hypersensitivity reaction to tuberculin. Fine, P. E. M., *et al.* ..... (A) 419
Heterogeneity among human T cell clones recognizing an HLA-DR4, Dw4-restricted epitope from the 28-kDa antigen of *M. leprae* defined by synthetic peptides. Oftung, F., *et al.* ..... (A) 750
Heterogeneity of serological responses in paucibacillary leprosy—differential responses to protein and carbohydrate antigens and correlation with clinical parameters. Roche, P. W., *et al.* ..... (O) 319
Ia antigen expression in macrophages after phagocytosis of mycobacteria *in vitro*. Fukutomi, Y., *et al.* ..... (A) 196
Identification and characterization of antigenic determinants of *M. leprae* that react with antibodies in sera of leprosy patients. Sathish, M., *et al.* ..... (A) 751
Identification, isolation and partial characterization of *M. tuberculosis* glycoprotein antigens. Espita, C. and Mancilla, R. ..... (A) 631
Immunohistologic analysis of mycobacterial antigens by monoclonal antibodies in tuberculosis and mycobacteriosis. Barbolini, G., *et al.* ..... (A) 438
Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen. Dudani, A. K. and Gupta, R. S. ..... (A) 418
Immunological detection of mycobacterial antigens in infected fluids, cells and tissues by latex agglutination; animal model and clinical application. Cambiaso, C. L., *et al.* ..... (A) 762
In situ locations of *M. leprae*-specific antigen; immuno-electronoptical studies. Boddingius, J. and Dijkman, H. ..... (A) 415
In vitro suppression of interleukin 2 production by *M. leprae* antigen. Makonkawkeyoon, S. and Kasinrerk, W. ..... (A) 163
Influence of *M. leprae* and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Kaplan, G., *et al.* ..... (A) 161
Lymphocytes bearing antigen-specific γδ T–cell receptors accumulate in human infectious disease lesions. Modlin, R. L., *et al.* ..... (A) 165
Major histocompatibility complex class II antigen expression in nerves in leprosy; an immunoelectronmicroscopical study. Cowley, S. A., *et al.* ..... (O) 560
Particular matrix for fast atom bombardment mass spectrometric analysis of phenolic glycolipid antigens isolated from pathogen mycobacteria. Riviere, M., *et al.* ..... (A) 170
Recognition of novel glycolipid antigens from smooth variants of *M. tuberculosis*. Minnikin, D. E., *et al.* ..... (A) 768
Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-γ pretreatment: synergistic effects of interferon-γ and tumor necrosis factor on MHC class II induction. Kingston, A. E., *et al.* ..... (A) 162

[Serologic demonstration of the activity of a *M. leprae* antigen stained by chemical synthesis.] Gonzalez-Abreu Castells, E., *et al.* ....(A) 607
Streptococcal cell wall arthritis; passive transfer of disease with a T cell line and cross-reactivity of streptococcal cell wall antigens with *M. tuberculosis.* DeJoy, S. Q., *et al.* ....(A) 631
Structure and mapping of antigenic domains of protein antigen b, a 30,000-molecular-weight protein of *M. tuberculosis.* Anderson, A. B. and Hansen, E. B. ....(A) 175
T cell reactivity to the purified mycobacterial antigens p65 and p70 in leprosy patients and their household contacts. Adams, E., *et al.* ....(A) 747
T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous non-responder defect can be overcome *in vitro* by stimulation with fractionated *M. leprae* components. Ottenhoff, T. H. M., *et al.* ....(A) 166
T-cell recognition of the 18-kilodalton antigen of *M. leprae.* Dockrell, H. M., *et al.* ....(A) 159
The specific 18-kilodalton antigen of *M. leprae* is present in *M. habana* and functions as a heat-shock protein. Lamb, F. I., *et al.* ....(A) 755
The use of antigen-bearing nitrocellulose particles derived from Western blots to study proliferative responses to 27 antigenic fractions from *M. leprae* in patients and controls. Filley, E., *et al.* ....(A) 159
The Use of Synthetic Antigens for Diagnosis of Infectious Diseases; Report of a WHO Scientific Group. ....(B) 593

Armadillo(s),
Antibodies to the phenolic glycolipid-1 antigen for epidemiologic investigations of enzootic leprosy in armadillos (*Dasypus novemcinctus*). Truman, R. W., *et al.* ....(A) 618
Cultivation of a nocardioform acid-fast chemoautotrophic bacterium from armadillo tissues infected with *M. leprae.* Dastidar, S. G. and Chakrabarty, A. N. ....(A) 754
Ocular leprosy in nine-banded armadillos following intrastromal inoculation. Malaty, R., *et al.* ....(O) 554
[Pathology of the peripheral nerve lesions in infected armadillo with *M. leprae*—a light- and electron-microscopic study.] Liu, Z., *et al.* ....(A) 422
Survey for leprosy in nine-banded armadillos (*Dasypus novemcinctus*) from the southeastern United States. Howerth, E. W., *et al.* ....(A) 758
The pathology of the eye in armadillos experimentally infected with *M. leprae.* Brandt, F., *et al.* ....(A) 756

Arthritis,
A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. Billingham, M. E. J., *et al.* ....(A) 604
Current status review: role of immunity to mycobacterial stress proteins in rheumatoid arthritis. McLean, L., *et al.* ....(A) 768
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Tsoulfa, G., *et al.* ....(A) 448
HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Bahr, G. M., *et al.* ....(A) 156
In vitro responses to a 65-kilodalton mycobacterial protein by synovial T cells from inflammatory arthritis patients. Gaston, J. S. H., *et al.* ....(A) 606
Mycobacteria and rheumatoid arthritis. Rook, G., *et al.* ....(A) 755
Rifampin therapy in rheumatoid arthritis. Gabriel, S. E., *et al.* ....(A) 762
Streptococcal cell wall arthritis; passive transfer of disease with a T cell line and cross-reactivity of streptococcal cell wall antigens with *M. tuberculosis.* DeJoy, S. Q., *et al.* ....(A) 631
Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvements with dapsone treatment. Roger, H., *et al.* ....(A) 770
The mycobacterial 65 kD heat-shock protein and autoimmune arthritis. van Eden, W., *et al.* ....(A) 637
Treatment of adjuvant arthritis in rats: vaccination potential of a synthetic nonapeptide from the 65-kDa heat shock protein of mycobacteria. Yang, X.-D., *et al.* ....(A) 771
Unusual arthritis: be on the alert for leprosy. Markusse, H. M., *et al.* ....(A) 602

Asia,
1989 Asian Seminar-cum-Workshop (India). ....(N) 732

Assay(s) (see also ELISA),
Application of ATP assay for *in vitro* drug screening testing against human derived *M. leprae*. Katoch, V. M., *et al.* ....(A) 169
[Assay of antibodies in blood serum of patients with pulmonary tuberculosis by using mycobacterial antigen isolated by affinity.] Gilburd, B. S., *et al.* ....(A) 441
Confirmation of a false-positive result associated with a competition inhibition assay used for detecting antibodies to a protein epitope of *M. leprae*. Vadiee, A. R., *et al.* (A) 753
The mapping of epitopes of the 18-kDa protein of *M. leprae* recognized by murine T cells in a proliferation assay. Harris, D. P., *et al.* ....(A) 419

Autopsy,
Leprosy and malignancy: autopsy findings of 252 leprosy patients. Furuta, M., *et al.* ..(O) 697

Bacilli,
[Clinical picture and process of pulmonary tuberculosis in new cases of elderly and senile ages isolating L-forms of tubercle bacilli.] Kochetkova, E. Y. ....(A) 442
[Difficulties to detect Hansen's bacilli in lesions; a study of one case.] Valayer, P. and Strobel, M. ....(A) 603
Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. Schlesinger, L. S. and Horwitz, M. A. ....(A) 751

Bacilli, ICRC,
ICRC anti-leprosy vaccine. Deo, M. G. ....(A) 418

Bacterial index (BI),
Acid-fast bacilli in semen; correlation with bacterial index. Abraham, A., *et al.* ....(O) 466

BCG (bacille Calmette-Guérin),
BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bagshawe, A., *et al.* ....(A) 414
Crystalline cell surface layer of *M. bovis* BCG. Lounatmaa, K. and Brander, E. ....(A) 635
Development of a recombinant BCG vaccine vector; cloning and expression of foreign antigen genes in BCG. Snapper, S. B., *et al.* ....(A) 201
Dietary protein deficiency and *M. bovis* BCG affect interleukin-2 activity in experimental pulmonary tuberculosis. McMurray, D. N., *et al.* ....(A) 443
Effect of a single exposure to ultraviolet radiation on *M. bovis* bacillus Calmette-Guérin infection in mice. Jeevan, A. and Kripke, M. L. ....(A) 634
Effect of presensitization with BCG and *M. leprae* on granuloma formation to *M. leprae*. Vijayalakshmi, K., *et al.* ....(O) 674
Enzyme-linked immunosorbent assay with BCG sonicate antigen for diagnostic potential of mycobacterial infection in Taiwan. Wang, C.-R., *et al.* ....(A) 753
Extraction and localization by electron microscopy of an immunosuppressor fraction from *M. bovis* bacillus Calmette-Guérin (BCG). Hiu, I.-J. ....(A) 765
Genetic transformation of BCG. Lugosi, L., *et al.* ....(A) 430
Human phagocyte oxidative burst activation by BCG, *M. leprae*, and atypical mycobacteria: defective activation by *M. leprae* is not reversed by interferon-γ. Launois, P., *et al.* ....(A) 609
New strategies for leprosy and tuberculosis and for development of bacillus Calmette-Guérin into a multivaccine vehicle. Bloom, B. R. and Jacobs, W. R., Jr. ....(A) 747
Patterns of IL-2 production and utilization in mice heavily infected with *M. bovis* BCG reflect the phase of protective immunity being expressed. Miller, E. S. and Orme, I. M. ....(A) 443
The BCG story: lessons from the past and implications for the future. Fine, P. E. M. ..(A) 171

Belgium,
FOPERDA's 50th anniversary. ....(N) 580

Beta-glucuronidase,
On the soluble fraction of *M. scrofulaceum* HI-75, originally separated from human leproma, which combines with beta-glucuronidase. Matsuo, E., *et al.* ....(A) 194
Serum beta-glucuronidase in subtypes of leprosy. George, J., *et al.* ....(A) 743

Biopsy,
A rapid method for the detection of potentially viable *M. leprae* in human biopsies: a novel application of PCR. Woods, S. A. and Cole, S. T. ..... (A) 617

Blood,
CD1-positive epidermal Langerhans' cells in skin reactions to autologous peripheral-blood-derived mononuclear cells in leprosy patients. Narayanan, R. B., *et al.* ..... (A) 165
Differential sensitivity of peripheral blood lymphocytes of untreated leprosy patients to mitomycin C. D'Souza, D., *et al.* ..... (A) 742
Effects of lepromatous leprosy (LL) serum factor(s) on normal blood lymphocytes. D'Souza, D., *et al.* ..... (O) 666
[Examination of the subgroups of T cells in the peripheral blood in leprosy.] Deng, Y., *et al.* ..... (A) 417
Finger-prick blood collection and computer-assisted enzyme-linked immunosorbent assay for large-scale serological studies on leprosy. Chanteau, S., *et al.* ..... (A) 157
[Procoagulant activity of the lymphocytes in the peripheral blood of leprosy patients.] Li, M., *et al.* ..... (A) 421
Results of blood cultures for detection of mycobacteria in AIDS patients. Truffot-Pernot, C., *et al.* ..... (A) 448
Screening of anti-*M. leprae* antibodies in the blood samples eluted from filter paper blood blots. Patil, S. A., *et al.* ..... (C) 123
Use of eluates of filter paper blood spots in ELISA for the serodiagnosis of leprosy. Dhandayuthapani, S., *et al.* ..... (A) 158

Bone, bone marrow,
Bacillaemia and bone marrow involvement in leprosy. Sen, R., *et al.* ..... (A) 602
Nongranulomatous involvement of the bone marrow in lepromatous leprosy. Suster, S., *et al.* ..... (A) 413
Study of the turnover, traffic and function of bone-marrow-derived macrophages in the granulomas of experimental lepromatous leprosy. Krahenbuhl, J. L. and Chae, G.-T. ..... (A) 186

Book reviews,
Global Evaluation of the Introduction of Multidrug Therapy. Leprosy Epidemiological Bulletin 4 (1990). ..... (B) 734
Hanseniase; Epidemiologia e Controle. C. Lombardi, coordenador. ..... (B) 734
Implementing Multiple Drug Therapy for Leprosy by A. C. McDougall. Cook, G. C. .. (B) 592
Kalaupapa: A Portrait by Wayne Levin and Anwei Skinsnes Law. Goodman, D. D. ... (B) 591
Leprosy in India; a Statistical Compendium. ..... (B) 143
Leprosy, Racism, and Public Helath; Social Policy in Chronic Disease Control by Zachary Gussow. Hastings, R. C. ..... (B) 589
Manuale di Leprologia. E. Nunzi and D. L. Leiker, eds. Hastings, R. C. ..... (B) 735
Mycobacterial Skin Diseases. Mawali Harahap, ed. Hastings, R. C. ..... (B) 590
Mycobacterium tuberculosis; Interactions with the Immune System. M. Bendinelli and H. Friedman, eds. Hastings, R. C. ..... (B) 143
The Biology of the Mycobacteria, Volume 3. C. Ratledge, J. Stanford and J. Grange, eds. Hastings, R. C. ..... (B) 403
The Indian Leprologists Look Back by Acworth Leprosy Hospital Society for Research, Rehabilitation and Education in Leprosy. ..... (B) 735
The Use of Synthetic Antigens for Diagnosis of Infectious Diseases; Report of a WHO Scientific Group. ..... (B) 593
Vaccines for Leprosy—Present Status and Future Prospects by Rama Mukherjee. ..... (B) 143

Borderline leprosy,
A case of borderline tuberculoid leprosy presenting with papulonodular lesions. Ramachandran, A. and Laxman, R. ..... (C) 571
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL South Indian patients: a five-year report. Thomas, A., *et al.* .... (O) 273
Multiple cold abscesses in a borderline lepromatous patient on multidrug therapy. Kulkarni, V., *et al.* ..... (A) 601

Brazil,
[Detection of hanseniasis in Maringa, Parana, Brazil, 1977–1988.] Lombardi, C., *et al.*, ... (A) 622
[Epidemiological study of the slum Vila Nova in the city of Duque de Caxias, Rio de Janeiro State, July 1988.] Moreira, T. and Almeida, J. ..... (A) 622
[Epidemiology of Leprosy in Rio Grande do Sul State, Brazil.] Cestari, T. F., *et al.* ..... (A) 432
[Increase in leprosy in the northeastern region of Brazil.] Albuquerque, M. de F. P. M., *et al.* ..... (A) 619
Report and evaluation of Brazilian experience in the rehabilitation of patients with leprosy. Virmond, M., *et al.* ..... (A) 437
[Secondary sulfone resistance related to a case of hanseniasis in Rio de Janeiro, Brazil.] Gallo, M. E. N., *et al.* ..... (A) 596
[The status of the hanseniasis endemic in the city of Rondonópolis-MT.] Gobel, M., *et al.* ..... (A) 172
Time trends of Hansen's disease in Brazil. Paula Motta, C. and Zuniga G., M. ..... (O) 453

Burma,
Indeterminate leprosy in a population survey and in the subsequent follow-ups of children in Burma. Bechelli, L. M. ..... (A) 620

Canada,
Leprosy in Canada to 1988. Varughese, P. V., *et al.* ..... (A) 759

Cell(s),
A complex component modulating immune-deficient cells in leprosy patients leading to loss of viabilitiy of *M. leprae*—a possible vaccine. Marolia, J., *et al.* ..... (A) 610
Association of pure red cell aplasia and lepromatous leprosy. Olalla Saad, S. T., *et al.* (C) 384
Cell subset analysis of cutaneous infiltrate in atypic mycobacteria ulcerations. Esterre, V. P., *et al.* ..... (C) 387
Immunological detection of mycobacterial antigens in infected fluids, cells and tissues by latex agglutination; animal model and clinical application. Cambiaso, C. L., *et al.* ..... (A) 762
In vitro studies on dermal leprosy granulomas: assessment of division and protein synthesis of cells. Narayanan, R. B. and Girdhar, B. K. ..... (A) 611
Isolation and characterization of cells in granulomas of nerves of leprosy patients. Kehrer, D., *et al.* ..... (A) 608
Killing by antimycobacterial agents of AIDS-derived strains of *M. avium* complex inside cells of the mouse macrophage cell line. Yajko, D. M., *et al.* ..... (A) 638
Mast cells in histoid lepromatous lesions. Kumar, R. ..... (A) 163
Mast cells in leprosy skin lesions. Cree, I. A., *et al.* ..... (A) 747
Monitoring of bacterial drug response by mass spectrometry of single cells. Seydel, U. and Lindner, B. ..... (A) 170
Phagocytosis of *M. leprae* by cardiac muscle cells—a preliminary report. Job, C. K., *et al.* ..... (A) 748
Rifampicin-induced pure red cell aplasia. Mariette, X., *et al.* ..... (A) 597
Spindle cell reaction to nontuberculous mycobacteriosis in AIDS mimicking a spindle cell neoplasm; evidence for dual histiocytic and fibroblast-like characteristics of spindle cells. Brandwein, M., *et al.* ..... (A) 761
Stimulation of K-Cl cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone. Haas, M. and Harrison, J. H., Jr. ..... (A) 407
Studies of human leprosy lesions *in situ* using suction-induced blisters. 2. Cell changes and soluble interleukin 2 receptor (Tac peptide) in reversal reactions. Scollard, D. M., *et al.* ..... (O) 469
The effect of intracellular parasitism on cell phenotype. Poulter, L. W. and Condez, A. (A) 423
Variation in immunogenicity of mycobacteria: role of antigen-presenting cells. Shroff, K. E., *et al.* ..... (O) 58

Cells, Langerhans' (giant),
CD1-positive epidermal Langerhans cells in skin reactions to autologous peripheral-blood-derived mononuclear cells in leprosy patients. Narayanan, R. B., *et al.* ..... (A) 165
[Determination of Langerhans' cells in the skin lesions of leprosy cases with immunohistochemical technique using wheat-germ agglutinin.] Liang, Z., *et al.* ..... (A) 749

Differential expression of Langerhans cells in the epidermis of patients with leprosy. Gimenez, M. F., *et al.* ....(A) 160

Cells, mononuclear,
CD1-positive epidermal Langerhans cells in skin reactions to autologous peripheral-blood-derived mononuclear cells in leprosy patients. Narayanan, R. B., *et al.* ....(A) 165

Cells, natural killer (NK),
Natural killer cell-mediated lysis of *M. avium* complex-infected monocytes. Katz, P., *et al.* ....(A) 766
[Natural killer cells of blood in patients with limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* ....(A) 442

Cells, Schwann,
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro*. Choudhury, A., *et al.* ....(A) 169
Role of S-100 protein as a marker for Schwann cells in the diagnosis of tuberculoid leprosy. Job, C. K., *et al.* ....(C) 392
Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-γ pretreatment: synergistic effects of interferon-γ and tumor necrosis factor on MHC class II induction. Kingston, A. E., *et al.* ....(A) 162

Cells, T,
A comparative study on the effects of rIL-4, rIL-2, rIFN-γ, and rTNF-α on specific T-cell non-responsiveness to mycobacterial antigens in lepromatous leprosy patients *in vitro*. Ottenhoff, T. H. M., *et al.* ....(A) 750
Accessory cell heterogeneity in lepromatous leprosy; dendritic cells and not monocytes support T cell responses. Mittal, A., *et al.* ....(A) 164
Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of *M. tuberculosis*. Barnes, P. F., *et al.* ....(A) 628
Crossreactivity of *M. leprae* and *M. tuberculosis* and the implications for assessment of *in vitro* T cell function in leprosy patients. Rawlinson, W. D. and Basten, A. ....(A) 424
Differential pattern of T cell recognition of the 65-kDa mycobacterial antigen following immunization with the whole protein or peptides. Brett, S. J., *et al.* ....(A) 416
DR3-restricted T cells from different HLA-DR3-positive individuals recognize the same peptide (amino acids 2-12) of the mycobacterial 65-kDa heat-shock protein. van Schooten, W. C. A., *et al.* ....(A) 612
Epitopes of the mycobacterial heat shock protein 65 for human T cells comprise different structures. Munk, M. E., *et al.* ....(A) 768
[Examination of the subgroups of T cells in the peripheral blood in leprosy.] Deng, Y., *et al.* ....(A) 417
Heterogeneity among human T cell clones recognizing an HLA-DR4,Dw4-restricted epitope from the 28-kDa antigen of *M. leprae* defined by synthetic peptides. Oftung, F., *et al.* ....(A) 750
Impairment of alternate pathway (CD2) of T cell activation in leprosy. Malarkannan, S., *et al.* ....(A) 164
In situ characterization of cellular infiltrates in lupus vulgaris indicates lesional T-cell activation. Ramesh, V., *et al.* ....(A) 635
In vitro responses to a 65-kilodalton mycobacterial protein by synovial T cells from inflammatory arthritis patients. Gaston, J. S. H., *et al.* ....(A) 606
Limiting dilution analysis of T cell unresponsiveness to mycobacteria in advanced disseminated tuberculosis. Gilardini Montani, M. S., *et al.* ....(A) 440
Lymphocytes bearing antigen-specific gamma/delta T-cell receptors accumulate in human infectious disease lesions. Modlin, R. L., *et al.* ....(A) 165
M. leprae reactive T cell clones from lepromatous leprosy patients after prolonged dapsone chemotherapy. Gill, H. K., *et al.* ....(A) 606
On the mechanism of T-cell suppression in leprosy. Salgame, P., *et al.* ....(A) 186
Phenotypic and functional characterization of human suppressor T-cell clones: II. Activation of *M. leprae* presented by HLA-Dr molecules to αβ T-cell receptors. Li, S. G., *et al.* ....(A) 748

Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-γ pretreatment: synergistic effects of interferon-γ and tumor necrosis factor on MHC class II induction. Kingston, A. E., *et al.* ....(A) 162
Streptococcal cell wall arthritis; passive transfer of disease with a T cell line and cross-reactivity of streptococcal cell wall antigens with *M. tuberculosis.* DeJoy, S. Q., *et al.* ....(A) 631
Suppression of T-cell proliferation by *M. leprae* and its products: the role of lipopolysaccharide. Malloy, A., *et al.* ....(A) 610
Suppression of the increase in free cytosolic calcium during the inhibition of T-cell activation by an autoantibody present in the serum of leprosy patients. Poulton, T. A., *et al.* ....(A) 424
T cell reactivity to the purified mycobacterial antigens p65 and p70 in leprosy patients and their household contacts. Adams, E., *et al.* ....(A) 747
T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous non-responder defect can be overcome *in vitro* by stimulation with fractionated *M. leprae* components. Ottenhoff, T. H. M., *et al.* ....(A) 166
T cells against a bacterial heat shock protein recognize stressed macrophages. Koga, T., *et al.* ....(A) 421
T-cell recognition of the 18-kilodalton antigen of *M. leprae.* Dockrell, H. M., *et al.* ....(A) 159
The mapping of epitopes of the 18-kDa protein of *M. leprae* recognized by murine T cells in a proliferation assay. Harris, D. P., *et al.* ....(A) 419
The role of T cell-macrophage interactions in tuberculosis. Kaufmann, S. H. E. and Flesch, I. E. A. ....(A) 161

Cell-mediated immunity (CMI),
[Cell-mediated immunity in patients with leprosy treated with rifampin.] Valdes-Portela, A. and de la Cruz, F. ....(A) 427
Cell-mediated immunity to mycobacteria: a double-sided sword? Kaufmann, S. H. E., *et al.* ....(A) 608

Chemotherapy (see also Therapy),
Antibacterial properties of propolis (bee glue). Grange, J. M. and Davey, R. W. ....(A) 633
Effect of simultaneous administration of interferon-γ and chemotherapy against *M. leprae* in experimental infection in nude mice. Banerjee, D. K. and McDermott-Lancaster, R. D. ....(O) 690
Evaluation of *M. leprae* antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Klatser, P. R., *et al.* ....(A) 420
Is thiacetazone necessary or useful in the intensive phase of anti-tuberculous chemotherapy? McLead, D. T., *et al.* ....(A) 178
Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines, and Korea. Cellona, R. V., *et al.* ....(O) 1
M. leprae reactive T cell clones from lepromatous leprosy patients after prolonged dapsone chemotherapy. Gill, H. K., *et al.* ....(A) 606
[Observations on the therapeutic effect of short-term combined chemotherapy in multibacillary leprosy—review of 80 cases during treatment and 33 months after treatment in Shandong and Yunnan Provinces.] Li, H.-Y., *et al.* ....(A) 597
Peripheral blood T lymphocyte subpopulations in patients with tuberculosis and the effect of chemotherapy. Singhal, M., *et al.* ....(A) 447
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Lecoeur, H. F., *et al.* ....(A) 421
The chemotherapy of leprosy. McDougall, A. C. and Georgiev, G. D. ....(A) 598
The chemotherapy of leprosy. Part 1. Ellard, G. A. ....(E) 704
The pathogenicity of *M. tuberculosis* during chemotherapy. Clancy, L. J., *et al.* ....(A) 762
Therapeutic response of modern chemotherapy in hansenology. Krishnan, S. ....(A) 597
[Tuberculous chemotherapy in combination with corticosteroids and immunomodulators.] Khomenko, I. S., *et al.* ....(A) 766

Children,
A clinico-bacteriological profile of leprosy in children. Dayal, R., *et al.* ....(A) 600

[Analysis of childhood leprosy in Fujian.] Shao, K.-W., *et al.* ....(A) 603
Indeterminate leprosy in a population survey and the subsequent follow-ups of children in Burma. Bechelli, L. M. ....(A) 620
Leprosy in Childhood (revised edition) published. ....(N) 587
Leprosy in children: correlation of clinical, histopathological, bacteriological and immunological parameters. Sehgal, V. N. and Joginder ....(A) 413
Neonatal hyperbilirubinemia after treatment of maternal leprosy. Thornton, Y. S. and Bowe, E. T. ....(A) 155

China, People's Republic of,
Commemorative meeting of Dr. Ma Haide's (George Hatem) death. Ye, G.-Y. ....(N) 140
[Leprosy has been basically eradicated in Ningxia Province (China).] Wang, S., *et al.* ..(A) 434
[Possibility of leprosy eradication in Shandong Province by year 2000.] Pan Y.-L., *et al.* ....(A) 622
The leprosy control programme in the People's Republic of China. Mathias, T. ....(A) 436

Chromatography,
[Identification of mycobacterium species by gas-liquid chromatography.] Pinchuk, L. M., *et al.* ....(A) 769
Two-dimensional gas chromatography with electron capture detection for the sensitive determination of specific mycobacterial lipid constituents. Larsson, L., *et al.* ....(A) 430

Ciprofloxacin,
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Wallace, R. J., Jr., *et al.* ....(A) 449

Classification,
Relationship between radiological classification and the serological and haematological features of untreated pulmonary tuberculosis in Indonesia. Caplin, M., *et al.* ....(A) 177
Testicular dysfunction in leprosy: relationships of FSH, LH and testosterone to disease classification, activity and duration. Levis, W. R., *et al.* ....(A) 152

Clinic(s),
A study of morbidity pattern among prostitutes attending a municipal clinic in Pune (India). Urmil, A. C., *et al.* ....(A) 414
Torque range of motion in the hand clinic. Breger-Lee, D., *et al.* ....(A) 625

Clinical,
[A follow-up of 23 patients with SCLE.] Xu, S., *et al.* ....(A) 770
A papulosquamous eruption in a 12-year-old Cambodian boy. Rabinowitz, L. G., *et al.* (A) 412
A qualitative study of the relationship between systemic and histological parameters of immunity in individual leprosy patients. Cree, I. A., *et al.* ....(O) 347
Acetylation polymorphism and leprosy. Eze, L. C., *et al.* ....(A) 738
An immunohistochemical and morphological study of amyloidosis complicating leprosy in Malaysian patients. Looi, L. M., *et al.* ....(A) 152
[Association of virchowian hanseniasis dermatopoly.] Porro, A. M., *et al.* ....(A) 745
Cervical perineurial cyst, a red herring (case report). Bansal, S. K., *et al.* ....(E) 717
[Clinical and electrophysiological evidence of axonal multineuritis in lepromatous leprosy.] Tzourio, C., *et al.* ....(A) 626
Clinical assessment of paucibacillary leprosy under multidrug therapy—three years follow-up study. Revankar, C. R., *et al.* ....(A) 148
[Clinical observation on the treatment of cutaneous vasculitis with clofazimine.] Zhan, T., *et al.* ....(A) 771
Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Venkatesan, K. ....(A) 148
[Clinical picture and process of pulmonary tuberculosis in new cases of elderly and senile ages isolating L-forms of tubercle bacilli.] Kochetkova, E. Y. ....(A) 442
Comparison of improved BACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. Anarygyros, P., *et al.* ....(A) 760
Eleven years of follow-up of the pattern of leprosy complications at Alupe Leprosy Hospital. Adallah, S. O., *et al.* ....(A) 150
Glucose tolerance test in leprosy. Garg, R., *et al.* ....(A) 743

Hansen's disease: a cause of lymphoadenopathy in endemic areas. Satti, M. B., *et al.* ..(A) 602
Heterogeneity of serological responses in paucibacillary leprosy—differential responses to protein and carbohydrate antigens and correlation with clinical parameters. Roche, P. W., *et al.* .....(O) 319
Hormone profile in leprosy. Garg, R., *et al.* .....(A) 601
IgM serum antibodies to phenolic glycolipid-I and clinical leprosy: two years' observation in a community with hyperendemic leprosy. Bagshawe, A. F., *et al.* .....(O) 25
Immunological detection of mycobacterial antigens in infected fluids, cells and tissues by latex agglutination; animal model and clinical application. Cambiaso, C. L., *et al.* .....(A) 762
Inappropriate ADH secretion in a patient with leprosy. Clark, C. E. and Richardson, G. A. .....(A) 600
Labial and gingival enlargement in leprosy. High, A. S. and Lansley, C. V. .....(A) 151
Leprosy and glomerulonephritis: a case report and review of the literature. Weiner, I. D. and Northcutt, A. D. .....(A) 155
Leprosy in children: correlation of clinical, histopathological, bacteriological and immunological parameters. Sehgal, V. N. and Joginder. .....(A) 413
[Leprous peripheral neuropathy: clinical observation in 11 cases and ultrastructural study of nerve in 2 cases.] Guo, Y.-P., *et al.* .....(A) 744
Neonatal hyperbilirubinemia after treatment of maternal leprosy. Thornton, Y. S. and Bowe, E. T. .....(A) 155
[New criteria for the characterization of facies leprosa.] Freitas, J. A. de S., *et al.* .....(A) 151
Operational value of serological measurements in multibacillary patients: clinical and bacteriological correlates of antibody responses. Roche, P. W., *et al.* .....(O) 480
Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Brisson-Noel, A., *et al.* .....(A) 630
Reactions in leprosy—a prospective study of clinical, bacteriological, immunological and histopathological parameters in 35 Indians. Sehgal, V. N. and Sharma, V. .....(A) 154
Registration of the number of macules in paucibacillary leprosy for evaluation of early diagnosis and individual prognosis. Deguerry, M., *et al.* .....(A) 410
Relapses in paucibacillary leprosy after MDT—a clinical study. Grugni, A., *et al.* .....(O) 19
Relative efficacy of commonly used clinical and laboratory methods for the diagnosis of leprosy. Prasad, A. S. .....(A) 154
Rheumatoid factors in leprosy and parasitic diseases. Harboe, M. .....(A) 161
Rheumatoid factors in subacute bacterial endocarditis and other infectious diseases. Williams, R. C. .....(A) 167
Sarcoidosis and leprosy—an epidemiological, clinical, pathological and immunological comparison. Zumla, A. and James, G. D. .....(A) 771
[Think of leprosy again and more frequently.] Zimmerman, V. R., *et al.* .....(A) 156

Clofazimine,

Activity of rifabutin alone and in combination with clofazimine, kanamycin, and ethambutol against *M. intracellulare* infections in mice. Saito, H. and Sato, K. .....(A) 446
Antileishmanial effects of clofazimine and other antimycobacterial agents. Evans, A. T., *et al.* .....(A) 632
Apparent involvement of phospholipase A2, but not protein kinase C, in the pro-oxidative interactions of clofazimine with human phagocytes. Anderson, R., *et al.* ..(A) 146
[Clinical observation on the treatment of cutaneous vasculitis with clofazimine.] Zhan, T., *et al.* .....(A) 771
Clofazimine and liposomes enhance the susceptibility of intracellular *M. avium* toward rifabutin. Jansons, V. K. and Soggiu, A. .....(A) 738
Clofazimine induced nail changes. Dixit, V. B., *et al.* .....(A) 596
[Clofazimine poisoning of the eighth cranial nerves in eight cases of leprosy.] Lin, C. ..(A) 408
Effect of clofazimine on eye in multibacillary leprosy. Kaur, I., *et al.* .....(A) 739
[Histological chemistry study and quantitative measurement on skin pigmentation of B663 in leprosy.] Gu, C., *et al.* .....(A) 407
Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper (*sic*). Font, R. L., *et al.* .....(A) 151
Temperature dependence and thermodynamics of partitioning of clofazimine analogues in the n-octanol/water system. Quigley, J. M., *et al.* .....(A) 740
The effect of ionization on the partitioning of clofazimine in the 2, 2, 4-trimethylpentane-water system. Quigley, J. M., *et al.* .....(A) 408

Cloning,
Characterization of antigens associated with the cell walls of *M. leprae* and *M. tuberculosis* using T-lymphocyte clones. Mehra, V., *et al.* ....(A) 200
Cloned antigenic determinants of *M. leprae* that react with leprosy patients' sera: their characterization and ability to elicit delayed-type hypersensitivity responses in mice following immunization. Sathish, M., *et al.* ....(A) 189
Cloning and expression of *M. tuberculosis* strain Aoyama B in *Escherichia coli*—a gene encoding 15-kDa and 60-kDa antigens. Tanaka, T., *et al.* ....(A) 197
Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of *M. tuberculosis*. Borremans, M., *et al.* ....(A) 629
Development of a recombinant BCG vaccine vector; cloning and expression of foreign antigen genes in BCG. Snapper, S. B., *et al.* ....(A) 201
Heterogeneity among human T cell clones recognizing an HLA-DR4,Dw4-restricted epitope from the 28-kDa antigen of *M. leprae* defined by synthetic peptides. Oftung, F., *et al.* ....(A) 750
M. leprae reactive T cell clones from lepromatous leprosy patients after prolonged dapsone chemotherapy. Gill, H. K., *et al.* ....(A) 606
Phenotypic and functional characterization of human suppressor T-cell clones: II. Activation of *M. leprae* presented by HLA-Dr molecules to $\alpha\beta$ T-cell receptors. Li, S. G., *et al.* ....(A) 748

Complement,
Activation of complement by circulating immune complexes isolated from leprosy patients. Tyagi, P., *et al.* ....(O) 31
Complement receptors and complement component C3 mediate phagocytosis of *M. tuberculosis* and *M. leprae*. Schlesinger, L. S. and Horwitz, M. A. ....(A) 200
[Deposition of immunoglobulin and complement in the skin of leprosy patients.] Zhang, X.-Q., *et al.* ....(A) 614
Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. Schlesinger, L. S. and Horwitz, M. A. ....(A) 751

Concanavalin A (ConA),
Unresponsiveness to ConA in spleen cell cultures of *M. lepraemurium*-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production. Turcotte, R. and Lemieux, S. ....(A) 167

Congresses,
1993 ILA Congress dates. ....(N) 587
III Congrès International de Médecine Tropicale de Langue Française (Togo). ....(N) 140
VIIè Congrès International des Léproloques de Langue Française. ....(N) 399
3rd Congress on Hansenology of Endemic Countries. ....(N) 141
European Congress of Clinical Microbiology and Infectious Diseases. ....(N) 732
Second Congress of China Leprosy Association. Ye, G.-Y. ....(N) 140

Control of leprosy,
Changes in epidemiological indices following the introduction of WHO MDT into the Guyana leprosy control programme. Rose, P. ....(A) 173
Experience in leprosy control in a developing country: Vietnam. Le Kinh Due ....(A) 622
Leprosy control in India: international cooperation. Max, E. ....(A) 594
Leprosy Control Project Annual Report (Nepal). ....(N) 138
Leprosy control: the rationale of integration. Loretti, A. ....(A) 411
[Leprosy has been basically eradicated in Ningxia Province (China).] Wang, S., *et al.* ..(A) 434
Management information system for leprosy eradication programme—an alternative information system. Revankar, C. R., *et al.* ....(A) 173
[Possibility of leprosy eradication in Shandong Province by year 2000.] Pan. Y.-L., *et al.* ....(A) 622
[Prevalence and control of leprosy in large cities of China.] Yang, L., *et al.* ....(A) 434
Priorities in leprosy control. McDougall, A. C. and Georgiev, G. D. ....(A) 405
Reliability of skin smear results: experiences with quality control of skin smears in different routine services in leprosy control programmes. Vettom, L. and Pritze, S. ..(A) 414
Technical problems related to multidrug therapy in leprosy control. Sansarricq, H. ....(A) 598

Technology for leprosy control—progress and prospects (Kellersberger Memorial Lecture, 1988). Noordeen, S. K. ..... (A) 405
The leprosy control programme in the People's Republic of China. Mathias, T. ..... (A) 436
The need for new drugs in the treatment and control of leprosy. Baker, R. J. ..... (E) 78
The status of leprosy control in Malaysia. Sukumaran, K. D. ..... (A) 145
WHO Report on the Consultation on Leprosy Control Within Urban Primary Health Care. ..... (N) 141
Will the leprosy endemic in Rwanda soon be under control? Stes, P. and Malatre, X. ..... (A) 173

Corticosteroids,
[Tuberculous chemotherapy in combination with corticosteroids and immunomodulators.] Khomenko, I. S., *et al.* ..... (A) 766

Cuba,
[A study of the incidence of leprosy in the city of Camaguey, Cuba.] Carrazana Hernandez, G. B. and Ferra Torres, T. M. ..... (A) 757
[Epidemiologic indicators of leprosy in the city of Camaguey, Cuba.] Carrazana Hernandez, G. E. and Ferra Torres, T. M. ..... (A) 757

Cultivation,
Cultivation of a nocardioform acid-fast chemoautotrophic bacterium from armadillo tissues infected with *M. leprae.* Dastidar, S. G. and Chakrabarty, A. N. ..... (A) 754
Cultivation of *M. leprae* in artificial culture medium. Biswas, S. K. ..... (A) 754

Cutaneous,
Cell subset analysis of cutaneous infiltrate in atypic mycobacteria ulcerations. Esterre, V. P., *et al.* ..... (C) 387
[Clinical observation on the treatment of cutaneous vasculitis with clofazimine.] Zhan, T., *et al.* ..... (A) 771
Cutaneous delayed-type hypersensitivity in patients with human immunodeficiency virus infection in Zaire. Coleblunders, R. L., *et al.* ..... (A) 630
Cutaneous lymphoma masquerading as lepromatous leprosy. Balachandran, C., *et al.* ..... (C) 115
Cutaneous *M. thermoresistibile* infection in a heart transplant patient. Neeley, S. P. and Denning, D. W. ..... (A) 444
Cutaneous vasculitis associated with rifampin therapy. Iredale, J. P., *et al.* ..... (A) 407
Influence of *M. leprae* and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Kaplan, G., *et al.* ..... (A) 161
Multiple cutaneous nerve abscesses on a healed tuberculoid patch. Saxena, U., *et al.* ..... (A) 745
The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement of the cutaneous administration of interleukin 2. Hancock, G. E., *et al.* ..... (A) 160
[The interpretation of the Mitsuda and Kveim tests in the differential diagnosis between tuberculoid leprosy and cutaneous sarcoidosis.] Guimaraes Proença, N. ..... (A) 601

Damien-Dutton Society,
1989 Damien-Dutton Award to Catholic Medical Mission Board. ..... (N) 579

Dapsone (DDS),
Antagonism between dapsone and rifampicin in experimental *M. leprae* infections in mice. Millan, J. P. and Moulia-Pelat, J. P. ..... (A) 147
Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Coleman, M. D., *et al.* ..... (A) 406
Blister calendar packs for dapsone monotherapy. McDougall, A. C. ..... (C) 121
Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. Wille, R. C. and Morrow, J. D. ..... (A) 149
Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Prantera, C., *et al.* ..... (A) 445
Dapsone drug compliance study among leprosy patients: a comparison between qualitative and quantitative methods. Bhainagar, P., *et al.* ..... (A) 146
Dapsone induced psychosis. Balkrishna and Bhatia, M. S. ..... (A) 741
Dapsone-induced erythroderma with Beau's lines. Patki, A. H. and Mehta, J. M. ..... (A) 412
Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity. Figueiredo, M. S., *et al.* ..... (A) 406

DDS-induced photosensitivity with reference to six case reports. Dhanapaul, S. .....(A) 146
Design and *in vitro* evaluation of dapsone-loaded micropellets of ethyl cellulose. Roy, S., *et al.* .....(A) 409
Evaluation of five treatment regimens, using either dapsone monotherapy or several doses of rifampicin in the treatment of paucibacillary leprosy. Pattyn, S. R., *et al.* ...(A) 739
Evaluation of *M. leprae* antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Klatser, P. R., *et al.* .....(A) 420
Histopathological findings in the iris of dapsone treated leprosy patients. Brandt, F., *et al.* .....(A) 741
Idiosyncratic dapsone induced manic depression. Carmichael, A. J. and Paul, C. J. ...(A) 595
In vitro and *in vivo* experiments with the new inhibitor of *M. leprae* brodimoprim alone and in combination with dapsone. Seydel, J. K., *et al.* .....(A) 740
In-vitro activity of dapsone and two potentiators against *M. avium* complex. Gonzalez, A. H., *et al.* .....(A) 177
Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Richardson, J. H. and Smith, T. C. .....(A) 409
Inhibition of dapsone-induced methaemoglobinaemia in the rat. Coleman, M. D., *et al.* (A) 737
[Lichenoid eruption due to dapsone in a leprosy patient.] Cestari, T., *et al.* .....(A) 406
M. leprae reactive T cell clones from lepromatous leprosy patients after prolonged dapsone chemotherapy. Gill, H. K., *et al.* .....(A) 606
Manic depression induced by dapsone in patients with dermatitis herpetiformis. Gawkrodger, D. .....(A) 596
Multiple-dose kinetics in healthy volunteers and *in vitro* antimalarial activity of proguanil plus dapsone. Edstein, M. D., *et al.* .....(A) 737
New multidrug regimen with indigenous drugs and dapsone in the treatment of lepromatous leprosy (preliminary report). Chaudhury, S., *et al.* .....(A) 146
Primary dapsone resistance as assessed by uptake of labelled thymidine by the macrophage resident *M. leprae.* Thakur, M., *et al.* .....(A) 599
Primary dapsone resistance in China. Chen, J.-K., *et al.* .....(A) 406
Sex-dependent sensitivity to dapsone-induced methaemoglobinaemia in the rat. Coleman, M. D., *et al.* .....(A) 737
Stimulation of K-Cl cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone. Haas, M. and Harrison, J. H., Jr. .....(A) 407
Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvements with dapsone treatment. Roger, H., *et al.* .....(A) 770

Deformity, disability,
Employment status of leprosy patients with deformitites in a suburban slum. Chaturvedi, R. M. and Kartikeyan, S. .....(A) 759
[Follow up of 64 leprosy patients with deformities accepting surgical operation.] Yin, K.-M. .....(A) 627
Leprosy deformities: experience in Molai Leprosy Hospital, Maiduguri, Nigeria. Iyere, B. B. .....(A) 760
Pattern of leprosy disabilities in Gorakhpur (Uttar Pradesh). Girdhar, M., *et al.* .....(A) 625
[Physical disabilities in hanseniasis at the time of diagnosis. I. Evaluation of the disabilities.] Trindade, M. A. B., *et al.* .....(A) 626
[Physical disabilities in hanseniasis at the time of diagnosis. II. An index of the evaluation of the hanseniasis control program.] Trindade, M. A. B., *et al.* .....(A) 626

Dermal,
In vitro studies on dermal leprosy granulomas: assessment of division and protein synthesis of cells. Narayanan, R. B. and Girdhar, B. K. .....(A) 611

Dermatology,
Dermatological disorders resembling leprosy. Mohamed, K. N. .....(A) 602
[Thalidomide: an eclectic medication in dermatology.] Proença, N. G. .....(A) 740

Drugs (see also specific drugs),
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Wallace, R. J., Jr., *et al.* .....(A) 449

An *in vitro* culture method for screening new drugs against *M. leprae*. Dhople, A. M. and Ortega, I. ..... (A) 755
Application of ATP assay for *in vitro* drug screening testing against human derived *M. leprae*. Katoch, V. M., *et al.* ..... (A) 169
Dapsone drug compliance study among leprosy patients: a comparison between qualitative and quantitative methods. Bhainagar, P., *et al.* ..... (A) 146
Different correlations of drug susceptibilities to colonial morphology in *M. avium* complex strains. Tsukamura, M., *et al.* ..... (A) 637
Drug action against intracellularly growing *M. xenopi*. Rastogi, N., *et al.* ..... (A) 445
Drug susceptibility testing of *M. leprae* in the BACTEC 460 system. Franzblau, S. G. ..... (A) 738
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro*. Choudhury, A., *et al.* ..... (A) 169
Enhancement of drug susceptibility of *M. avium* by inhibitors of cell envelope synthesis. Rastogi, N., *et al.* ..... (A) 769
[Immunocorrecting characteristics of new antileprosy drugs.] Goloshchapova, E. N. ..... (A) 596
Implementing Multiple Drug Therapy for Leprosy by A. C. McDougall. Cook, G. C. .. (B) 592
Inhibition of *Pneumocystis carinii* dihydropteroate synthetase by sulfa drugs. Merali, S., *et al.* ..... (A) 768
Monitoring of bacterial drug response by mass spectrometry of single cells. Seydel, U. and Lindner, B. ..... (A) 170
New multidrug regimen with indigenous drugs and dapsone in the treatment of lepromatous leprosy (preliminary report). Chaudhury, S., *et al.* ..... (A) 146
Short-course multi-drug therapy for leprosy patients. Puavilai, S. and Timpatanapong, P. ..... (A) 740
[Sulfone—pharmacological aspects, new indications besides hanseniasis, drug resistance.] da Costa Rocha, A. L., *et al.* ..... (A) 406
Susceptibility of *M. avium* and *M. intracellulare* to various antibacterial drugs. Tomioka, H., *et al.* ..... (A) 448
The activity of a beta-lactamase inhibitor, Augmentin®, against *M. leprae* in mice: a novel and promising target for drug development. Gelber, R. H. ..... (A) 187
The need for new drugs in the treatment and control of leprosy. Baker, R. J. ..... (E) 78

Egypt,
T lymphocyte subsets in leprosy; a study of 24 Egyptian patients. Ashmalla, L., *et al.* ..... (A) 410

Electron microscopy (see also Ultrastructure),
[Electron microscopic observation on spleen T lymphocyte in animal models of lepromatous leprosy.] Wong, B., *et al.* ..... (A) 179
Protein G-based enzyme-linked immunosorbent assay for anti-MPB70 antibodies in bovine tuberculosis. Harboe, M., *et al.* ..... (A) 763
Sensitivity, specificity, reliability of positive and negative indirect ELISA and gelatin particle agglutination test for serodiagnosis of leprosy. Izumi, S., *et al.* ..... (A) 191
Serodiagnosis of leprosy in patients' contacts by enzyme-linked immunosorbent assay. Gonzalez-Abeu, E., *et al.* ..... (A) 748
Use of eluates of filter paper blood spots in ELISA for the serodiagnosis of leprosy. Dhandayuthapani, S., *et al.* ..... (A) 158

Enzyme(s),
Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Coleman, M. D., *et al.* ..... (A) 406
Enzymes for biosynthesis *de novo* and elongation of fatty acids in mycobacteria grown in host cells: is *M. leprae* competent in fatty acid biosynthesis? Wheeler, P. R., *et al.* ..... (A) 617
Extraction and localization by electron microscopy of an immunosuppressor fraction from *M. bovis* bacillus Calmette-Guérin (BCG). Hiu, I.-J. ..... (A) 765

ELISA (enzyme-linked immunosorbent assay) tests,
Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of *M. leprae* infection in populations of the South Pacific islands. Cartel, J.-L., *et al.* ..... (O) 512
Comparative evaluation of enzyme immunoassays based on synthetic glycoconjugates and phenolic glycolipid-I for immunodiagnosis of leprosy. Moudgil, K. D., *et al.* ... (A) 749

Enzyme-linked immunosorbent assay for distinguishing serological responses to the 29/33-kilodalton doublet and 64-kilodalton antigens of *M. tuberculosis*. Das, P. K., *et al.* ..... (A) 417
Enzyme-linked immunosorbent assay with BCG sonicate antigen for diagnostic potential of mycobacterial infection in Taiwan. Wang, C.-R., *et al.* ..... (A) 753
Evaluation of fluorescent leprosy antibody absorption test versus enzyme-linked immunosorbent assay with phenolic glycolipid I and their use in immuno-epidemiological studies on leprosy. Wu, Q.-X., *et al.* ..... (A) 428
Evaluation of enzyme immunoassays using purified protein derivative (PPD) and its pool fractions 3 and 4 for diagnosis of pulmonary tuberculosis. Kapor, J., *et al.* ..... (A) 608
[Evaluation of Ms-ELISA as a screening test for leprosy.] Weng, X.-M., *et al.* ..... (A) 613
Finger-prick blood collection and computer-assisted enzyme-linked immunosorbent assay for large-scale serological studies on leprosy. Chanteau, S., *et al.* ..... (A) 157
[FLA-ABS T/PGL-ELISA and their uses in immuno-epidemiological studies for leprosy.] Wu, Q., *et al.* ..... (A) 427
[Ms-ELISA for detection of serum antibody level in leprosy patient—establishment of Ms-ELISA.] Wu, Q.-X., *et al.* ..... (A) 613

Epidemiology,
[Ameliorative catalytic model of age-specific prevalence of leprosy simulated by using microcomputer.] Yang, Z.-M. ..... (A) 435
Antibodies to the phenolic glycolipid-1 antigen for epidemiologic investigations of enzootic leprosy in armadillos (*Dasypus novemcinctus*). Truman, R. W., *et al.* ..... (A) 618
[Calculation of leprosy spread trend with the model of exponential function.] Yang, Z., *et al.* ..... (A) 435
Changes in epidemiological indices following the introduction of WHO MDT into the Guyana leprosy control programme. Rose, P. ..... (A) 173
Correlation between occurrence of leprosy and fossil fuels: role of fossil fuel bacteria in the origin and global epidemiology of leprosy. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 620
[Epidemiologic indicators of leprosy in the city of Camaguey, Cuba.] Carrazana Hernandez, G. E. and Ferra Torres, T. M. ..... (A) 757
[Epidemiologic risk of tuberculosis-affected cattle for people living in the northern regions of Kazakh, SSR.] Kurmanbayev, K. K., *et al.* ..... (A) 767
[Epidemiological aspects of hanseniasis in the 10th Regional Department of Health of Presidente Prudente, State of São Paulo in December 1984.] Galvão, E. C. ..... (A) 171
[Epidemiological aspects of leprosy in the province of Jaen, Spain.] Delgado Rodriguez, M., *et al.* ..... (A) 621
[Epidemiological study of the slum Vila Nova in the city of Duque de Caxias, Rio de Janeiro State (Brazil), July 1988.] Moreira, T. and Almeida, J. ..... (A) 622
[Epidemiology of leprosy in Rio Grande do Sul State, Brazil.] Cestari, T. F., *et al.* ..... (A) 432
Evaluation of fluorescent leprosy antibody absorption test versus enzyme-linked immunosorbent assay with phenolic glycolipid I and their use in immune-epidemiological studies on leprosy. Wu, Q.-X., *et al.* ..... (A) 428
Evaluation of leprosy epidemiology in 12 countries of the Americas, 1980–1983. Lombardi, C. ..... (A) 433
[FLA-ABS T/PGL-ELISA and their uses in immuno-epidemiological studies for leprosy.] Wu, Q., *et al.* ..... (A) 427
Hanseniase; Epidemiologia e Controle. Lombardi, C., coordenador. ..... (B) 734
Leprosy in Portugal 1946–80: epidemiologic patterns observed during declining incidence rates. Irgens, L. M., *et al.* ..... (A) 621
Modeling the age-of-onset function in segregation analysis: a causal scheme for leprosy. Abel, L., *et al.* ..... (A) 431
Sarcoidosis and leprosy—an epidemiological, clinical, pathological and immunological comparison. Zumla, A. and James, G. D. ..... (A) 771
Selection of MDT strategies through epidemiometric modeling. Lechat, M. F., *et al.* ..... (O) 296
The epidemiological transition in an overseas territory: disease mapping in French Polynesia. Vigneron, E. ..... (A) 623
The role of intrahousehold contact in the transmission of leprosy. George, K., *et al.* ..... (A) 621
[Trends of epidemics of leprosy in Fujian Province.] Shao, K.-W., *et al.* ..... (A) 623

Erythema nodosum leprosum (ENL),
A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum. Filley, E., *et al.* ....(A) 159
HLA antigens and erythema nodosum leprosum (ENL). Agrewala, J. N., *et al.* ....(A) 156
Rapidly progressive (concentric) glomerulonephritis in erythema nodosum leprosum: case report. Nigam, P., *et al.* ....(A) 153

Escherichia coli,
Cloning and expression of *M. tuberculosis* strain Aoyama B in *Escherichia coli*—a gene encoding 15-kDa and 60-kDa antigens. Tanaka, T., *et al.* ....(A) 197
Resistance of *Escherichia coli* to rifampicin and sorangicin A—a comparison. Rommele, G., *et al.* ....(A) 770

Ethambutol,
Activity of rifabutin alone and in combination with clofazimine, kanamycin, and ethambutol against *M. intracellulare* infections in mice. Saito, H. and Sato, K. ....(A) 446
In vitro synergistic activity between ethambutol and fluorinated quinolones against *M. avium* complex. Hoffner, S. E., *et al.* ....(A) 633

Ethiopia,
Physican needed at ALERT. ....(N) 580

Experimental leprosy,
Preliminary observations on experimental leprosy in tupaias (*Tupaia belangeri yunalis*). Wang, H.-Y., *et al.* ....(A) 618
The MRL/lpr mouse as an experimental leprosy model (continued). Nakamura, K. and Yogi, Y. ....(A) 193

Eye(s),
Blindness in leprosy—a forgotten complication. ffytche, T. ....(A) 600
Conjunctival microbial flora in leprosy. Garg, S. P., *et al.* ....(A) 743
Corneal ulcer caused by *Bipolaris hawaiiensis.* Anandi, V., *et al.* ....(A) 150
[Correction of lagophthalmos in leprosy by transferring of temporalis muscle bundle and fascial sling—report of 26 cases.] Zhang, G.-C. and Zheng, T.-S. ....(A) 627
Effect of clofazimine on eye in multibacillary leprosy. Kaur, I., *et al.* ....(A) 739
[Evaluation and treatment of the dry eye in hanseniasis.] Vieth, H., *et al.* ....(A) 155
Eye in multidrug therapy. Rajan, M. A. ....(A) 74
Importance of early diagnosis of ocular leprosy. ffytche, T. ....(A) 743
Intraocular pressure and iris denervation in Hansen's disease. Lewallen, S., *et al.* ....(O) 39
[Nursing routine in the evaluation of ocular injuries in hanseniasis.] Cristofolini, L., *et al.* ....(A) 150
Ocular autonomic dysfunction and intraocular pressure in leprosy. Lewallen, S., *et al.* (A) 601
Ocular changes in reactions in leprosy. Shorey, P., *et al.* ....(A) 155
Ocular leprosy in Kenya. Adala, H. S. and Kagame, K. ....(A) 150
Ocular leprosy in nine-banded armadillos following instrastromal inoculation. Malaty, R., *et al.* ....(O) 554
Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper (*sic*). Font, R. L., *et al.* ....(A) 151
Surgical management in ocular leprosy. Lamba, P. A., *et al.* ....(A) 175
[Survey of ocular diseases among 1692 cases of leprosy in Guangdong Province.] Lu, B.-X., *et al.* ....(A) 745
The pathology of the eye in armadillos experimentally infected with *M. leprae.* Brandt, F., *et al.* ....(A) 756

Face,
New criteria for the characterization of facies leprosa. Freitas, J. A. de S., *et al.* ....(A) 151

Family,
Impact of leprosy on the family and intimate relationships. Ashmalla, L. ....(A) 624

Finger(s),
Correction of hypermobile claw fingers in leprosy by pulley insertion procedure. Malaviya, G. N., *et al.* ....(A) 436

FLA-ABS test,
[FLA-ABS T/PGL-ELISA and their uses in immuno-epidemiological studies for leprosy.] Wu, Q., *et al.* ..... (A) 427

Foot,
Plastic footwear for leprosy. Antia, N. H. ..... (A) 624
Sensory recovery in the plantar aspect of the foot after surgical decompression of posterior tibial nerve. Possible role of steroids along with decompression. Rao, K. S. and Siddalinga Swamy, M. K. ..... (A) 436

Foot pad(s),
Doubling time of *M. lepraemurium* in mouse foot pads. Silbaq, F., *et al.* ..... (A) 446
Effect of brodimoprim on *M. leprae in vitro* and in mouse foot pads. Dhople, A. M., *et al.* ..... (A) 737
Effect of diet on growth of *M. leprae* in mouse footpads. Foster, R. L., *et al.* ..... (A) 171
[Effect of the suppression of the popliteal ganglion in the reproduction of *M. leprae* in the foot pad of mice. Preliminary report.] Suarez Moreno, O. and Rodriguez Silveira, J. ..... (A) 431
Effects of dietary composition on growth of *M. leprae* in mouse footpads. Sanchez, A. and Foster, R. L. ..... (A) 618
The disease of CBA and BALB/c mice that follows inoculation of a small number of *M. lepraemurium* into the hind foot pad. Silbaq, F., *et al.* ..... (O) 681

Genetics,
Genetic aspects of innate resistance and acquired immunity to mycobacteria in inbred mice. Buschman, E., *et al.* ..... (A) 176
Genetic recombination of spheroplast fusion of sterol-transforming *Mycobacterium* strains. Jekkel, A., *et al.* ..... (A) 441
Genetic transformation of BCG. Lugosi, L., *et al.* ..... (A) 430
Killing of *M. smegmatis* by macrophages from genetically susceptible and resistant mice. Denis, M., *et al.* ..... (A) 417
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Lecoeur, H. F., *et al.* ..... (A) 421
Viability of *M. leprae* inside macrophages from different strains of mice and possible genetic control. Nair, I., *et al.* ..... (O) 548

Genome,
Conservation of genomic sequences among isolates of *M. leprae.* Clark-Curtiss, J. E. and Walsh, G. P. ..... (A) 429

Germany,
30 years of the Hartdegen Fund for Thailand's leprosy sufferers. ..... (N) 397
Armauer Hansen Institute. ..... (N) 397
Dr. Ruth Pfau honored by Pakistan. ..... (N) 397
GLRA and ILEP. ..... (N) 397
GLRA—a forerunner of leprosy integration. ..... (N) 397
International Youth Workshop. ..... (N) 136

Granuloma(s),
An experimental animal model of granulomatous bowel disease. Mitchell, I. C. and Turk, J. L. ..... (A) 617
Comparison of the characteristics of infiltrates in skin and nerve granulomas of leprosy. Kumar, V., *et al.* ..... (A) 609
Effect of presensitization with BCG and *M. leprae* on granuloma formation to *M. leprae.* Vijayalakshmi, K., *et al.* ..... (O) 674
Granuloma multiforme in India. Cherian, S. ..... (E) 719
In vitro studies on dermal leprosy granulomas: assessment of division and protein synthesis of cells. Narayanan, R. B. and Girdhar, B. K. ..... (A) 611
Isolation and characterization of cells in granulomas of nerves of leprosy patients. Kehrer, D., *et al.* ..... (A) 608
Study of the turnover, traffic and function of bone-marrow-derived macrophages in the granulomas of experimental lepromatous leprosy. Krahenbuhl, J. L. and Chae, G.-T. ..... (A) 186

Guinea-Bissau,
Pope celebrates World Leprosy Day. ....(N) 580

Haiti,
XXII Congrès des Médecins de Langue Française de l'Hémisphére Américain. ....(N) 136

Hand(s),
A kinematic model of the flexor tendons of the hand. Thompson, D. E. and Giurintano, D. J. ....(A) 178
Advances in hand biomechanics simulation. Thompson, D. E., *et al.* ....(A) 437
[Ischemic contracture of intrinsic muscles of the hand in leprosy.] Carayon, A. ....(A) 436
Torque range of motion in the hand clinic. Breger-Lee, D., *et al.* ....(A) 625

Hepatitis,
Hepatitis B virus infection in lepromatous and tuberculoid patients from Senegal. Yvonnet, B., *et al.* ....(A) 603

Histoid leprosy,
[Histoid leproma is not rare—report on eight cases.] Wei, G.-R., *et al.* ....(A) 603
Histoid leprosy: a prospective study in 38 patients. Sehgal, V. N. and Srivastava, G. ..(A) 155

Histopathology,
A qualitative study of the relationship between systemic and histological parameters of immunity in individual leprosy patients. Cree, I. A., *et al.* ....(O) 347
[Importance of histopathology in the immunologic spectrum of leprosy. Practical application.] Sagaro Delgado, B., *et al.* ....(A) 425
The use of histopathology in leprosy diagnosis and research. Lucas, S. B. and Ridley, D. S. ....(A) 422

History of leprosy,
A History of Leprosy in Tanzania published. ....(N) 584
Kalaupapa: A Portrait by Wayne Levin and Anwei Skinsnes Law. Goodman, D. D. ....(B) 591
Leprosy: myth, melodrama and mediaevalism (The FitzPatrick Lecture 1989). Richards, P. ....(A) 736
The Melton Mowbray "leper head": an historical and medical investigation. Marcombe, D. and Manchester, K. ....(A) 736
[The origin of leprosy in the Americas and its present status.] Terencio de las Aguas, J. ....(A) 434

HLA,
DR3-restricted T cells from different HLA-DR3-positive individuals recognize the same peptide (amino acids 2-12) of the mycobacterial 65-kDa heat-shock protein. van Schooten, W. C. A., *et al.* ....(A) 612
Heterogeneity among human T cell clones recognizing an HLA-DR4,Dw4-restricted epitope from the 28-kDa antigen of *M. leprae* defined by synthetic peptides. Oftung, F., *et al.* ....(A) 750
HLA antigens and erythema nodosum leprosum (ENL). Agrewala, J. N., *et al.* ....(A) 156
HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Bahr, G. M., *et al.* ....(A) 156
Human leukocyte antigen (HLA) and mycobacterial disease. de Vries, R. R. P., *et al.* ....(A) 158
Human leukocyte antigen and leprosy: study in northern Louisiana and review. Todd, J. R., *et al.* ....(A) 623
Phenotypic and functional characterization of human suppressor T-cell clones: II. Activation of *M. leprae* presented by HLA-Dr molecules to $\alpha\beta$ T-cell receptors. Li, S. G., *et al.* ....(A) 748

Hypersensitivity,
Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by *in situ* hybridization. Cooper, C. L., *et al.* ....(A) 157
Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. Wille, R. C. and Morrow, J. D. ....(A) 149
Cloned antigenic determinants of *M. leprae* that react with leprosy patients' sera: their characterization and ability to elicit delayed-type hypersensitivity responses in mice following immunization. Sathish, M., *et al.* ....(A) 189

[Comparative study of delayed hypersensitivity induced by *M. tuberculosis* and by protein fractions isolated by them.] Badukshanova, N. M., *et al.* ....(A) 438
Cutaneous delayed-type hypersensitivity in patients with human immunodeficiency virus infection in Zaire. Coleblunders, R. L., *et al.* ....(A) 630
Failure of *M. leprae* soluble antigens to suppress delayed-type hypersensitivity reaction to tuberculin. Fine, P. E. M., *et al.* ....(A) 419
Identification of interferon-gamma mRNA and human serine esterase mRNA in spontaneously occurring DTH reactions in leprosy skin lesions by *in situ* hybridization. Rea, T. H., *et al.* ....(A) 196
Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Richardson, J. H. and Smith, T. C. ....(A) 409

ILEP (International Federation of Anti-Leprosy Associations),
GLRA and ILEP. ....(N) 397
ILEP former President Farine retires. ....(N) 586
ILEP personality (Dr. Enrico Pupulin) moves to WHO. ....(N) 584

IMMLEP (WHO Immunology of Leprosy Scientific Working Group),
THELEP and IMMLEP 1990 meeting schedule. ....(N) 401

Immune complexes,
A simple method to quantitate circulating immune complexes in different diseases. Jayapal, N., *et al.* ....(A) 607
Activation of complement by circulating immune complexes isolated from leprosy patients. Tyagi, P., *et al.* ....(O) 31
[Circulating immune complexes in multibacillary leprosy patients and their relationship with anti-*M. leprae* antibodies and the major immunoglobulin classes.] Suarez Moreno, D., *et al.* ....(A) 612
Demonstration of acid fast bacilli in the circulating immune complex of leprosy cases and contacts. Chaudhury, S., *et al.* ....(A) 410
[Detection of specific circulating immune complexes in leprosy patients by mouse monoclonal antibody against phenolic glycolipid-I.] Wu, Q.-X., *et al.* ....(A) 754
[Evaluation of circulating immune complexes in psoriasis, lichen planus, atopic eczema, leprosy, leukocytoclastic vasculitis, and pyoderma gangrenosum (review of the literature).] Fernandez Bussy, R., *et al.* ....(A) 418
[Isolation and characterization of immune complexes associated with malignant tumors and leprosy.] Segal-Eiras, A., *et al.* ....(A) 426
[Levels of circulating immune complexes in a patient with lepromatous leprosy during a type 2 reaction.] Suarez Moreno, O., *et al.* ....(A) 746
The leukocyte inhibitory factor and circulating immune complex in leprosy patients. Kim, S. J., *et al.* ....(A) 162

Immune responses,
Anti-*M. leprae* monoclonal antibodies cross-react with human skin: an alternative explanation for the immune responses in leprosy. Naafs, B., *et al.* ....(A) 749
Cellular immune responses of leprosy contacts to fractionated *M. leprae* antigens. Lee, S. P., *et al.* ....(A) 163
Effects of ofloxacin on cell-mediated immune response and lymphokine production. Biglino, A., *et al.* ....(A) 73

Immunoglobulins,
A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum. Filley, E., *et al.* ....(A) 159
Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of *M. leprae* infection in populations of the South Pacific islands. Cartel, J.-L., *et al.* ....(O) 512
Atopy and IgE in patients with leprosy. Smith, D. L., *et al.* ....(A) 752
[Circulating immune complexes in multibacillary leprosy patients and their relationship with anti-*M. leprae* antibodies and the major immunoglobulin classes.] Suarez Moreno, D., *et al.* ....(A) 612
[Deposition of immunoglobulin and complement in the skin of leprosy patients.] Zhang, X.-Q., *et al.* ....(A) 614

Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Tsoulfa, G., *et al.* ..... (A) 448
IgA antibodies against phenolic glycolipid I from *M. leprae* in serum of leprosy patients and contacts: subclass distribution and relation to disease activity. Schwerer, B., *et al.* ..... (A) 426
IgM serum antibodies to phenolic glycolipid-I and clinical leprosy: two years' observation in a community with hyperendemic leprosy. Bagshawe, A. F., *et al.* ..... (O) 25
Quantitation of IgM antibodies to the *M. leprae* synthetic dissacharide can predict early bacterial multiplication in leprosy. Hussain, R., *et al.* ..... (A) 491
Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvements with dapsone treatment. Roger, H., *et al.* ..... (A) 770
The recurrent expression of variable region segments in human IgM anti-DNA autoantibodies. Dersimonian, H., *et al.* ..... (A) 158
The role of cytokines in the immunopathology of tuberculosis and the regulation of agalactosyl IgG. Rook, G. A. W., *et al.* ..... (A) 425
Total and antimycobacterial IgE levels in serum from patients with tuberculosis and leprosy. Yong, A. J., *et al.* ..... (A) 428

Immunology,

Colloqium: new developments in immunoblotting and associated detection. ..... (A) 417
Comparison of the immunological activity of five defined antigens from *M. tuberculosis* in seven inbred guinea pig strains. The 38-kDa antigen is immunodominant. Haslov, K., *et al.* ..... (A) 763
Immunologic defects in leprosy patients. 1. Evidence of immune aberration of suppressor-T lymphocytes in lepromatous leprosy. Makonkawkeyoon, S., *et al.* ..... (O) 302
Immunologic defects in leprosy patients. II. Interleukin 1, interleukin 2, and interferon production in leprosy patients. Makonkawkeyoon, S., *et al.* ..... (O) 311
[Immunological aspects of leprosy.] Ayed, K. ..... (A) 604
Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen. Dudani, A. K. and Gupta, R. S. ..... (A) 418
Immunological detection of mycobacterial antigens in infected fluids, cells and tissues by latex agglutination; animal model and clinical application. Cambiaso, C. L., *et al.* ..... (A) 762
Immunological study of the defined constituents of mycobacteria. Ivanyi, J., *et al.* ..... (A) 420
Immunopathology of leprosy. Bottasso, O. A. and Morini, J. C. ..... (A) 416
Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, *Mycobacterium w*, in multibacillary leprosy patients. Talwar, G. P., *et al.* ..... (A) 752
Leprosy in children: correlation of clinical, histopathological, bacteriological and immunological parameters. Sehgal, V. N. and Joginder. ..... (A) 413
Mechanisms of immunological unresponsiveness in the spectra of leprosy and leishmaniasis. Bloom, B. R., *et al.* ..... (A) 415
Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Chan, J., *et al.* ..... (A) 168
Prospective immunological follow-up in household contacts of Mexican leprosy patients. Amezcua, M. E., *et al.* ..... (O) 651
Reactions in leprosy—a prospective study of clinical, bacteriological, immunological and histopathological parameters in 35 Indians. Sehgal, V. N. and Sharma, V. ..... (A) 154
Sarcoidosis and leprosy—an epidemiological, clinical, pathological and immunological comparison. Zumla, A. and James, G. D. ..... (A) 771
Structural and immunological properties of the phenolic glycolipids from *M. gastri* and *M. kansasii*. Gilleron, M., *et al.* ..... (A) 763
Thalidomide—a therapy for the immunological consequences of HIV infection? Gunzler, V. ..... (A) 441
The role of rIL-2 in the immune modulation of leprosy. Kaplan, G. and Cohn, Z. ..... (A) 198
The native proteins of *M. leprae*: preliminary results on subcellular location, isolation and chemical and immunological characterization. Hunter, S. W. and Brennan, P. J. ..... (A) 190
Vaccine development; on relating immunology to the Third World: some studies on leprosy. Bloom, B. R., *et al.* ..... (A) 605

Immunosuppression,
Immunosuppression and mycobacteria other than *M. tuberculosis*: results from patients with and without HIV infection. Peters, M., *et al.* ..... (A) 444
[Immunosuppression in leprosy.] Sasiain, M. del C. and de la Barrera, S. ..... (A) 611
Induction of non-specific immunosuppression in mice by mycobacterial infections and its relationship to macrophage activation. Appelberg, R., *et al.* ..... (A) 627
Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Collins, F. M. ..... (A) 439

Immunotherapy,
Immunotherapy for leprosy and tuberculosis. Stanford, J. L. ..... (A) 426

Indeterminate leprosy,
Clinico-histopathological study of multidrug therapy in indeterminate leprosy. Kar, P. K., *et al.* ..... (A) 739
Indeterminate leprosy in a population survey and in the subsequent follow-ups of children in Burma. Bechelli, L. M. ..... (A) 620

India,
1989 All-India Workshop held at Hyderabad. ..... (N) 732
1989 Asian Seminar-cum-Workshop. ..... (N) 732
1989 Indo-U.K. Workshop on Leprosy Research. ..... (N) 732
A study of leprosy affected beggars in Aska. Krishnamurthy, K. V. and Rao, S. P. ..... (A) 760
A study of morbidity pattern among prostitutes attending a municipal clinic in Pune. Urmil, A. C., *et al.* ..... (A) 414
A study of relapse in paucibacillary leprosy in a multidrug therapy project, Baroda District, India. Chopra, N. K., *et al.* ..... (A) 736
Annual General Meeting of the Hind Kusht Nivaran Sangh. ..... (N) 731
Best scientific film award 1989. ..... (N) 398
Bombay Leprosy Project Report of Activities: 1976–1989. ..... (N) 580
Comprehensive Leprosy Care Project. ..... (N) 136
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL South Indian patients: a five-year report. Thomas, A. ..... (O) 273
Dr. Joseph Ponniah, SLR&TC, Karigiri. ..... (N) 398
Dr. S. B. Roy Chaudhury new Honorary Secretary of HKNS. ..... (N) 398
Granuloma multiforme in India. Cherian, S. ..... (E) 719
IAL elects new officers. ..... (N) 732
ICMR Annual Report of the Director-General, 1987–1988. ..... (N) 137
International Gandhi Award 1990. ..... (N) 398
LEPRA launches sister organization in India. ..... (N) 581
Leprosy control in India: international cooperation. Max, E. ..... (A) 594
Leprosy in India; a Statistical Compendium. ..... (B) 143
Leprosy in low endemic areas of India: an appraisal and suggested measures for control. Misra, R. S., *et al.* ..... (A) 172
Leprosy survey in industries in Bombay. Revankar, C. R., *et al.* ..... (A) 173
Leprosy survey in night high schools in greater Bombay. Naik, S. S., *et al.* ..... (A) 759
Leprosy vaccine trials. Jayaraman, K. S. ..... (N) 137
MLSM Anti-Leprosy Week Celebration, 1990. ..... (N) 582
NASEOH celebrates 30th World Day of the Disabled, 1990, and presents awards. ..... (N) 583
Poona District Leprosy Committee Annual Report, 1988–1989. Mehta, J. ..... (N) 583
Reactions in leprosy—a prospective study of clinical, bacteriological, immunological and histopathological parameters in 35 Indians. Sehgal, V. N. and Sharma, V. ..... (A) 154
Report of the Indo-European Community Joint Symposium "Leprosy and Other Mycobacterial Diseases," Lonavla, India, 6–9 November 1989. Kaufmann, S. H. E. and Deo, M. G. ..... (E) 566
Sexually transmitted diseases in leprosy patients in north and northeastern India. A futile search for human immunodeficiency virus antibody. Saha, K., *et al.* ..... (O) 660
Srinivasan new Editor of Indian Journal of Leprosy. ..... (N) 399
The Indian Leprologists Look Back by Ackworth Leprosy Hospital Society for Research, Rehabilitation and Education in Leprosy. ..... (B) 735

Indonesia,
Relationship between radiological classification and the serological and haematological features of untreated pulmonary tuberculosis in Indonesia. Caplin, M., *et al.* .....(A) 177

Inoculation,
Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *M. leprae*. Gormus, B. J., *et al.* .....(O) 65
Inoculation leprosy; current status. Sehgal, V. N. .....(A) 413
Interactions between simian immunodeficiency virus and *M. leprae* in experimentally inoculated rhesus monkeys. Gormus, B. J., *et al.* .....(A) 431
Ocular leprosy in nine-banded armadillos following instrastromal inoculation. Malaty, R., *et al.* .....(O) 554
[Study on inoculation of *M. leprae* to the tree shrew.] Wang, H.-Y., *et al.* .....(A) 618
The disease of CBA and BALB/c mice that follows inoculation of a small number of *M. lepraemurium* into the hind foot pad. Silbaq, F., *et al.* .....(O) 681

Interferon,
Effect of *M. leprae*'s phenolic glycolipid-I on interferon-gamma augmentation of monocyte oxidative responses. Vachula, M., *et al.* .....(O) 342
Effect of multiple interferon-γ injections on the disposal of *M. leprae*. Kaplan, G., *et al.* .....(A) 420
Effect of simultaneous administration of interferon-γ and chemotherapy against *M. leprae* in experimental infection in nude mice. Banerjee, D. K. and McDermott-Lancaster, R. D. .....(O) 690
Enhancement of growth of *M. lepraemurium* in macrophages by gamma interferon. Mor, N., *et al.* .....(A) 165
Human phagocyte oxidative burst activation by BCG, *M. leprae*, and atypical mycobacteria: defective activation by *M. leprae* is not reversed by interferon-γ. Launois, P., *et al.* .....(A) 609
Identification of interferon-gamma mRNA and human serine esterase mRNA in spontaneously occurring DTH reactions in leprosy skin lesions by *in situ* hybridization. Rea, T. H., *et al.* .....(A) 196
Immunologic defects in leprosy patients. II. Interleukin 1, interleukin 2, and interferon production in leprosy patients. Makonkawkeyoon, S., *et al.* .....(O) 311
Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-γ pretreatment: synergistic effects of interferon-γ and tumor necrosis factor on MHC class II induction. Kingston, A. E., *et al.* .....(A) 162

Interleukin(s),
A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodusum leprosum. Filley, E., *et al.* .....(A) 159
Detection of interleukin-2 receptor (IL-2r) by indirect immunofluorescence with anti-Tac monoclonal antibody on the surface of T lymphocytes from patients with lepromatous leprosy. Fafutis-Morris, M., *et al.* .....(C) 126
Dietary protein deficiency and *M. bovis* BCG affect interleukin-2 activity in experimental pulmonary tuberculosis. McMurray, D. N., *et al.* .....(A) 443
Generation of antigen-specific, MHC-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement by cutaneous administration of IL-2. Hancock, G. E., *et al.* .....(A) 195
Immunologic defects in leprosy patients. II. Interleukin 1, interleukin 2, and interferon production in leprosy patients. Makonkawkeyoon, S., *et al.* .....(O) 311
In vitro suppression of interleukin 2 production by *M. leprae* antigen. Makonkawkeyoon, S. and Kasinrerk, W. .....(A) 163
Influence of *M. leprae* and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Kaplan, G., *et al.* .....(A) 161
Patterns of IL-2 production and utilization in mice heavily infected with *M. bovis* BCG reflect the phase of protective immunity being expressed. Miller, E. S. and Orme, I. M. .....(A) 443
Studies of human leprosy lesions *in situ* using suction-induced blisters. 2. Cell changes and soluble interleukin 2 receptor (Tac peptide) in reversal reactions. Scollard, D. M., *et al.* .....(O) 469

The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement of the cutaneous administration of interleukin 2. Hancock, G. E., *et al.* ....(A) 160
The role of rIL-2 in the immune modulation of leprosy. Kaplan, G. and Cohn, Z. A. ..(A) 198
Treatment of experimental disseminated *M. avium* complex infection in mice with recombinant IL-2 and tumor necrosis factor. Bermudez, L. E. M., *et al.* ....(A) 628
Unresponsiveness to ConA in spleen cell cultures of *M. lepraemurium*-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production. Turcotte, R. and Lemieux, S. ....(A) 167

International Journal of Leprosy (IJL),
Index to Volume 57. ....(—) 203
Index to Volume 58. ....(—) 779
Reviewers for Volume 58. ....(—) 773
Statement of Financial Condition. ....(—) 774
Statement of Ownership, Management and Circulation. ....(—) 777
The 1989 Journal—a continuing perspective. Hastings, R. C. ....(E) 98

International Leprosy Association (ILA),
1993 ILA Congress dates. ....(N) 587

Intestine(s),
An experimental animal model of granulomatous bowel disease. Mitchell, I. C. and Turk, J. L. ....(A) 617

Isoniazid,
A very long-chain fatty acid elongation system in *M. avium* and a possible mode of action of isoniazid on the system. Kikuchi, S., *et al.* ....(A) 429
Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Jenner, P. J. and Ellard, G. A. ....(A) 177
New forms of multidrug therapy for the treatment of leprosy. First report on the practice of rifampicin + sulfamethoxazole-thrimethoprim + prothionamide and rifampicin + sulfamethoxazole-trimethoprim + isoniazid. Freerksen, E., *et al.* ....(A) 147

Italy,
ILEP personality (Dr. Enrico Pupulin) moves to WHO. ....(N) 584

Kanamycin,
Activity of rifabutin alone and in combination with clofazimine, kanamycin, and ethambutal against *M. intracellulare* infections in mice. Saito, H. and Sato, K. ....(A) 446

Kidney(s),
Renal involvement in leprosy. Ponce, P., *et al.* ....(A) 153
Thalidomide, pregnancy and renal failure. Brown, M. A., *et al.* ....(A) 761

Korea,
Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines, and Korea. Cellona, R. V., *et al.* ....(O) 1

Leishmaniasis,
Mechanisms of immunological unresponsiveness in the spectra of leprosy and leishmaniasis. Bloom, B. R., *et al.* ....(A) 415
Serum tumor necrosis factor levels and leishmaniasis. Pisa, P., *et al.* ....(A) 750

Lepromatous leprosy,
[A case of lepromatous lepra.] Kazantseva, I. A., *et al.* ....(A) 601
A comparative study on the effects of rIL-4, rIL-2, rIFN-γ, and rTNF-α on specific T-cell non-responsiveness to mycobacterial antigens in lepromatous leprosy patients *in vitro*. Ottenhoff, T. H. M., *et al.* ....(A) 750
An unusual case of Hansen's disease (lepromatous leprosy) with circulating anticoagulant and macroglobulinemia. Desai, R. G. ....(O) 462
Anti-cardiolipin antibodies in Mexican lepromatous leprosy patients. Escobar-Gutierrez, A., *et al.* ....(C) 723
Antroscopic study of the maxillary antrum in lepromatous leprosy. Soni, N. K. ....(A) 603
Association of pure red cell aplasia and lepromatous leprosy. Olalla Saad, S. T., *et al.* ....(C) 384

Cardiovascular dysautonomia in patients with lepromatous leprosy. Shah, P. K. D., *et al.* ....(A) 746
CD2 expression and function in lepromatous leprosy. Wong, L., *et al.* ....(A) 427
[Clinical and electrophysiological evidence of axonal multineuritis in lepromatous leprosy.] Tzourio, C., *et al.* ....(A) 626
Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Grosset, J. H., *et al.* ....(O) 281
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL South Indian patients: a five-year report. Thomas, A., *et al.* ....(O) 273
Cutaneous lymphoma masquerading as lepromatous leprosy. Balachandran, C., *et al.* ....(C) 115
Detection of interleukin-2 receptor (IL-2r) by indirect immunofluorescence with anti-Tac monoclonal antibody on the surface of T lymphocytes from patients with lepromatous leprosy. Fafutis-Morris, M., *et al.* ....(C) 126
Effectiveness of pefloxacin in the treatment of lepromatous leprosy. N'Deli, L., *et al.* ..(O) 12
Effects of lepromatous leprosy (LL) serum factor(s) on normal blood lymphocytes. D'Souza, D., *et al.* ....(O) 666
[Electron microscopic observation on spleen T lymphocyte in animal models of lepromatous leprosy.] Wang, B., *et al.* ....(A) 179
Immunologic defects in leprosy patients. 1. Evidence of immune aberration of suppressor-T lymphocytes in lepromatous leprosy. Makonkawkeyoon, S., *et al.* ....(O) 302
Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines, and Korea. Cellona, R. V., *et al.* ....(O) 1
Lepromatous leprosy and dementia. Mohamed, K. N. ....(C) 381
[Levels of circulating immune complexes in a patient with lepromatous leprosy during a type 2 reaction.] Suarez Moreno, O., *et al.* ....(A) 746
M. leprae reactive T cell clones from lepromatous leprosy patients after prolonged dapsone chemotherapy. Gill, H. K., *et al.* ....(A) 606
New multidrug regimen with indigenous drugs and dapsone in the treatment of lepromatous leprosy (preliminary report). Chaudhury, S., *et al.* ....(A) 146
Nongranulomatous involvement of the bone marrow in lepromatous leprosy. Suster, S., *et al.* ....(A) 413
Response by Dr. Job, *et al.* (lepromatous leprosy mode of origin). Job, C. K., *et al.* ...(C) 117
Saber tibiae in lepromatous leprosy. Pavithran, K. ....(C) 385
Single lesion subpolar lepromatous leprosy and its possible mode of origin. Sehgal, V. N. and Bhattacharya, S. N. ....(C) 116
Study of the turnover, traffic and function of bone-marrow-derived macrophages in the granulomas of experimental lepromatous leprosy. Krahenbuhl, J. L. and Chae, G.-T. ....(A) 186
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ....(A) 756
Toxoplasma gondii antibody in patients of lepromatous leprosy. Rao, K. N., *et al.* ....(A) 751
Undernutrition in lepromatous leprosy: nutritional deficit in lepromatous patients co-infected with pulmonary tuberculosis. Saha, K. and Rao, K. N. ....(A) 154

Lepromin,
The post-lepromin scar and its significance in the control of HD. Walter, J. ....(A) 174

Lesion(s),
A case of borderline tuberculoid leprosy presenting with papulonodular lesions. Ramachandran, A. and Laxman, R. ....(C) 571
Antigen-reactive TCR γδ lymphocytes in leprosy lesions. Modlin, R. L., *et al.* ....(A) 191
[Determination of Langerhans' cells in the skin lesions of leprosy cases with immunohistochemical technique using wheat-germ agglutinin.] Liang, Z., *et al.* ....(A) 749
[Difficulties to detect Hansen's bacilli in lesions; a study of one case.] Valayer, P. and Strobel, M. ....(A) 603
Hansen's disease: computed tomography findings in peripheral nerve lesions. Barbancon, O., *et al.* ....(A) 741
Identification of interferon-gamma mRNA and human serine esterase mRNA in spontaneously occurring DTH reactions in leprosy skin lesions by *in situ* hybridization. Rea, T. H., *et al.* ....(A) 196

Immunogold labeling method for *M. leprae*-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and araldite-embedded leprosy lesions. Boddingius, J. and Dijkman, H. P. ..... (A) 415
In situ characterization of cellular infiltrates in lupus vulgaris indicates lesional T-cell activation. Ramesh, V., *et al.* ..... (A) 635
Leprosy and human immunodeficiency virus infection; a closer look at the lesions. Kennedy, C., *et al.* ..... (A) 744
Lymphocytes bearing antigen-specific gamma/delta T-cell receptors accumulate in human infectious disease lesions. Modlin, R. L., *et al.* ..... (A) 165
Mast cells in histoid lepromatous lesions. Kumar, R. ..... (A) 163
Mast cells in leprosy skin lesions. Cree, I. A., *et al.* ..... (A) 747
[Pathology of the peripheral nerve lesions in infected armadillo with *M. leprae*—a light- and electron-microscopic study.] Liu, Z., *et al.* ..... (A) 422
Penile and scrotal lesions in leprosy: case reports. Parikh, D. A., *et al.* ..... (A) 412
Single lesion subpolar lepromatous leprosy and its possible mode of origin. Sehgal, V. N. and Bhattacharya, S. N. ..... (C) 116
Studies of human leprosy lesions *in situ* using suction-induced blisters. 2. Cell changes and soluble interleukin 2 receptor (Tac peptide) in reversal reactions. Scollard, D. M., *et al.* ..... (O) 469
[Surgical treatment for neurotrophic lesions of leprosy. Application to other types of neuropathy.] Bourrel, P. ..... (A) 174
[Survey of the first skin lesions in 343 cases of leprosy.] Lin, D., *et al.* ..... (A) 411
T-lymphocytes in leprosy lesions. Mehra, V. and Modlin, R. L. ..... (A) 749
[The histopathological observation on erector pili muscle in skin lesions of leprosy; prevention and treatment for skin disease control.] Gao, X.-L., *et al.* ..... (A) 748
Triethanolamine-induced allergic contact dermatitis over a tuberculoid leprosy lesion. Srinivas, C. R., *et al.* ..... (C) 382

Leukocyte(s),
The leukocyte inhibitory factor and circulating immune complex in leprosy patients. Kim, S. J., *et al.* ..... (A) 162

Lipid(s),
A comparison of monocyte oxidative responses in leprosy patients and healthy subjects as influenced by mycobacterial lipid pretreatment. Vachula, M., *et al.* ..... (O) 534
Two-dimensional gas chromatography with electron capture detection for the sensitive determination of specific mycobacterial lipid constituents. Larsson, L., *et al.* ..... (A) 430

Lipoarabinomannan (LAM),
Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *M. leprae*. Gormus, B. J., *et al.* ..... (O) 65
Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. Meeker, H. C., *et al.* ..... (O) 503

Liposome,
Clofazimine and liposomes enhance the susceptibility of intracellular *M. avium* toward rifabutin. Jansons, V. K. and Soggiu, A. ..... (A) 738
Immunogenicity of ribonucleic acid-protein fraction of *M. tuberculosis* encapsulated in liposomes. Pancholi, P., *et al.* ..... (A) 444
Liposome-encapsulated-amikacin therapy of *M. avium* complex infection in beige mice. Cynamon, M. H., *et al.* ..... (A) 440

Lupus,
Cross-reactive idiotypes in sera from patients with leprosy, lupus and Lyme disease and from healthy individuals. Mackworth-Young, C. G. ..... (A) 609
In situ characterization of cellular infiltrates in lupus vulgaris indicates lesional T-cell activation. Ramesh, V., *et al.* ..... (A) 635
[Treatment of discoid lupus erythematosus by thalidomide.] Proença, N. G. and Bernardes, M. F. ..... (A) 178

Lymph node(s),
M. avium-M. intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Barbaro, D. J., *et al.* ..... (A) 438

Lymphocyte(s),

Antigen-reactive TCR γδ lymphocytes in leprosy lesions. Modlin, R. L., *et al.* .....(A) 191

Characterization of antigens associated with the cell walls of *M. leprae* and *M. tuberculosis* using T-lymphocyte clones. Mehra, V., *et al.* .....(A) 200

Detection of interleukin-2 receptor (IL-2r) by indirect immunofluorescence with anti-Tac monoclonal antibody on the surface of T lymphocytes from patients with lepromatous leprosy. Fafutis-Morris, M., *et al.* .....(C) 126

Differential sensitivity of peripheral blood lymphocytes of untreated leprosy patients to mitomycin C. D'Souza, D., *et al.* .....(A) 742

Diversity in migration of CD4 and CD8 lymphocytes in different microanatomical compartments of the skin in the tuberculin reaction in man. Beck, J. S., *et al.* .....(A) 176

Effects of lepromatous leprosy (LL) serum factor(s) on normal blood lymphocytes. D'Souza, D., *et al.* .....(O) 666

[Electron microscopic observation on spleen T lymphocyte in animal model of lepromatous leprosy.] Wang, B., *et al.* .....(A) 179

Generation of antigen-specific, MHC-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement by cutaneous administration of IL-2. Hancock, G. E., *et al.* .....(A) 195

Immunologic defects in leprosy patients. 1. Evidence of immune aberration of suppressor-T lymphocytes in lepromatous leprosy. Makonkawkeyoon, S., *et al.* .....(O) 302

Limited receptor repertoire in a mycobacteria-reactive subset of gamma-delta T lymphocytes. Happ, M. P., *et al.* .....(A) 607

Lymphocytes bearing antigen-specific gamma/delta T-cell receptors accumulate in human infectious disease lesions. Modlin, R. L., *et al.* .....(A) 165

Peripheral blood T lymphocyte subpopulations in patients with tuberculosis and the effect of chemotherapy. Singhal, M., *et al.* .....(A) 447

[Procoagulant activity of the lymphocytes in the peripheral blood of leprosy patients.] Li, M., *et al.* .....(A) 421

Serum lymphocytotoxic activity in leprosy. Rasheed, R. N., *et al.* .....(A) 167

[Study of T lymphocyte subpopulations in patients with leprosy, using incubation with theophylline.] Bottasso, O., *et al.* .....(A) 157

T lymphocyte subsets in leprosy; a study of 24 Egyptian patients. Ashmalla, L., *et al.* .....(A) 410

T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein. Munk, M. E., *et al.* .....(A) 635

T-lymphocytes in leprosy lesions. Mehra, V. and Medlin, R. L. .....(A) 749

The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement of the cutaneous administration of interleukin 2. Hancock, G. E., *et al.* .....(A) 160

Macrophage(s),

1, 25 Dihydroxyvitamin D3-dependent inhibition of growth or killing of *M. avium* complex in human macrophages is mediated by TNF and GM-CSF. Bermudez, L. E. M., *et al.* .....(A) 761

Antigenic protein from *M. leprae* released in macrophages *in vitro* as indicator of viability of bacteria. Nair, I. and Mahadevan, P. R. .....(O) 540

[Assessment of leprous macrophages function.] Maslov, A. K. and Yushchenko, A. A. (A) 164

Enhancement of growth of *M. lepraemurium* in macrophages by gamma interferon. Mor, N., *et al.* .....(A) 165

Ia antigen expression in macrophages after phagocytosis of mycobacteria *in vitro*. Fukutomi, Y., *et al.* .....(A) 196

Induction of non-specific immunosuppression in mice by mycobacterial infections and its relationship to macrophage activation. Appelberg, R., *et al.* .....(A) 627

Killing by antimycobacterial agents of AIDS-derived strains of *M. avium* complex inside cells of the mouse macrophage cell line. Yajko, D. M., *et al.* .....(A) 638

Killing of *M. smegmatis* by macrophages from genetically susceptible and resistant mice. Denis, M., *et al.* .....(A) 417

Macrophage microbicidal mechanism. Swamy, R. .....(C) 389

Primary dapsone resistance as assessed by uptake of labelled thymidine by the macrophage resident *M. leprae*. Thakur, M., *et al.* .....(A) 599

Properties of suppressor macrophages induced with *M. leprae* vaccine. Tomioka, H. and Saito, H. .....(A) 199

Radiolabelling of *M. avium* oligosaccharide determinant and use in macrophage studies. Woodbury, J. L. and Barrow, W. W. ..... (A) 449
Study of the turnover, traffic and function of bone-marrow-derived macrophages in the granulomas of experimental lepromatous leprosy. Krahenbuhl, J. L. and Chae, G.-T. ..... (A) 186
T cells against a bacterial heat shock protein recognize stressed macrophages. Koga, T., *et al.* ..... (A) 421
The role of T cell-macrophage interactions in tuberculosis. Kaufmann, S. H. E. and Flesch, I. E. A. ..... (A) 161
Uptake of purine and pyrimidine nucleosides by macrophage-resident *M. leprae*. ^{3}H-Adenosine as an indicator of viability and antimicrobial activity. Harshan, K. V., *et al.* ..... (O) 526
Viability of *M. leprae* inside macrophages from different strains of mice and possible genetic control. Nair, I., *et al.* ..... (O) 548

Malawi,
Karonga research progress. ..... (N) 584

Mali,
VIIè Congrès International des Léproloques de Langue Française. ..... (N) 399

Malaysia,
An immunohistochemical and morphological study of amyloidosis complicating leprosy in Malaysian patients. Looi, L. M., *et al.* ..... (A) 152
The status of leprosy control in Malaysia. Sukumaran, K. D. ..... (A) 145

Metabolism,
Aspartate metabolism in *M. avium* grown in host tissue and axenically and in *M. leprae*. Sritharan, V., *et al.* ..... (A) 616
Assessment of the respiratory metabolism in the skin from transcutaneous measurements of pO_2 and pCO_2: potential for non-invasive monitoring of response to tuberculin skin testing. Abbot, N. C., *et al.* ..... (A) 627
Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Coleman, M. D., *et al.* ..... (A) 406
Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Jenner, P. J. and Ellard, G. A. ..... (A) 177
Metabolism of fossil fuels by chemoautotrophic nocardioform bacteria from infectious leprosy tissues and its implications. Chakrabarty, A. N., *et al.* ..... (A) 168
Stimulation of K-Cl cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone. Haas, M. and Harrison, J. H., Jr. ..... (A) 407

Mice, murine,
Activity of rifabutin alone and in combination with clofazimine, kanamycin, and ethambutol against *M. intracellulare* infections in mice. Saito, H. and Sato, K. ..... (A) 446
Antagonism between dapsone and rifampicin in experimental *M. leprae* infections in mice. Millan, J. P. and Moulia-Pelat, J. P. ..... (A) 147
Antibody response to phenolic glycolipid I and *Mycobacterium w* antigens and its relation to bacterial load in *M. leprae*-infected mice and leprosy patients. Moudgil, K. D., *et al.* ..... (A) 423
Cloned antigenic determinants of *M. leprae* that react with leprosy patients' sera: their characterization and ability to elicit delayed-type hypersensitivity responses in mice following immunization. Sathish, M., *et al.* ..... (A) 189
Comparative effect of the naphthalenic ansamycins, rifamycin SV, rifampin and cyclopentylrifampicin on murine neutrophil function. Kenny, M. T., *et al.* ..... (A) 597
[Detection of specific circulating immune complexes in leprosy patients by mouse monoclonal antibody against phenolic glycolipid-I.] Wu, Q.-X., *et al.* ..... (A) 754
Effective vaccination of mice against leprosy bacilli with subunits of *M. leprae*. Gelber, R. H., *et al.* ..... (A) 606
Genetic aspects of innate resistance and acquired immunity to mycobacteria in inbred mice. Buschman, E., *et al.* ..... (A) 176

In vivo activities of new quinolones against *M. leprae* infection induced in mice. Saito, H. and Tomioka, H. ..... (A) 188
Induction of non-specific immunosuppression in mice by mycobacterial infections and its relationship to macrophage activation. Appelberg, R., *et al.* ..... (A) 627
Killing by antimycobacterial agents of AIDS-derived strains of *M. avium* complex inside cells of the mouse macrophage cell line. Yajko, D. M., *et al.* ..... (A) 638
Killing of *M. smegmatis* by macrophages from genetically susceptible and resistant mice. Denis, M., *et al.* ..... (A) 417
Liposome-encapsulated-amikacin therapy of *M. avium* complex infection in beige mice. Cynamon, M. H., *et al.* ..... (A) 440
Partial characterization of suppressor factors in spleen cell culture supernatants of *M. lepraemurium*-infected mice. Richard, L., *et al.* ..... (A) 425
Patterns of IL-2 production and utilization in mice heavily infected with *M. bovis* BCG reflect the phase of protective immunity being expressed. Miller, E. S. and Orme, I. M. ..... (A) 443
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Lecoeur, H. F., *et al.* ..... (A) 421
The activity of a beta-lactamase inhibitor, Augmentin®, against *M. leprae* in mice: a novel and promising target for drug development. Gelber, R. H. ..... (A) 187
The mapping of epitopes of the 18-kDa protein of *M. leprae* recognized by murine T cells in a proliferation assay. Harris, D. P., *et al.* ..... (A) 419
The MRL/lpr mouse as an experimental leprosy model (continued). Nakamura, K. and Yogi, Y. ..... (A) 193
Treatment of experimental disseminated *M. avium* complex infection in mice with recombinant IL-2 and tumor necrosis factor. Bermudez, L. E. M., *et al.* ..... (A) 628
Unresponsiveness to ConA in spleen cell cultures of *M. lepraemurium*-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production. Turcotte, R. and Lemieux, S. ..... (A) 167
Viability of *M. leprae* inside macrophages from different strains of mice and possible genetic control. Nair, I., *et al.* ..... (O) 548

Mice, nude,
Effect of lyophilization on viability of *M. leprae* grown in nude mice. Kohsaka, K., *et al.* ..... (A) 192
Effect of simultaneous administration of interferon-γ and chemotherapy against *M. leprae* in experimental infection in nude mice. Banerjee, D. K. and McDermott-Lancaster, R. D. ..... (O) 690
New findings on the mode of entry of *M. leprae* in nude mice. Job, C. K., *et al.* ..... (C) 726
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ..... (A) 756

Microbiology,
European Congress of Clinical Microbiology and Infectious Diseases. ..... (N) 732
Radiometric studies on the use of selective inhibitors in the identification of *Mycobacterium* spp. Collins, T. and Levett, P. N. ..... (A) 630

Microscopy,
Extraction and localization by electron microscopy of an immunosuppressor fraction from *M. bovis* bacillus Calmette-Guérin (BCG). Hiu, I.-J. ..... (A) 765

Monkey(s),
Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *M. leprae*. Gormus, B. J., *et al.* ..... (O) 65
Interactions between simian immunodeficiency virus and *M. leprae* in experimentally inoculated rhesus monkeys. Gormus, B. J., *et al.* ..... (A) 431
Leprosy studies in Philippine cynomolgus monkeys (*Macaca fasicularis*): preliminary results. Walsh, G. P., *et al.* ..... (A) 193
M. kansasii in a rhesus monkey. Jackson, R. K., *et al.* ..... (A) 441
Pathology of dual *M. leprae* and simian immunodeficiency virus infection in rhesus monkeys. Baskin, G. B., *et al.* ..... (O) 358

Monocyte(s),
A comparison of monocyte oxidative responses in leprosy patients and healthy subjects as influenced by mycobacterial lipid pretreatment. Vachula, M., *et al.* .....(O) 534
Accessory cell heterogeneity in lepromatous leprosy; dendritic cells and not monocytes support T cell responses. Mittal, A., *et al.* .....(A) 164
Effect of *M. leprae*'s phenolic glycolipid-I on interferon-gamma augmentation of monocyte oxidative responses. Vachula, M., *et al.* .....(O) 342
Natural killer cell-mediated lysis of *M. avium* complex-infected monocytes. Katz, P., *et al.* .....(A) 766
Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. Schlesinger, L. S. and Horwitz, M. A. .....(A) 751

Multidrug therapy (MDT),
A second report on multidrug therapy for leprosy in Trinidad and Tobago. Suite, M. and Edinborough, N. B. .....(A) 409
A study of relapse in paucibacillary leprosy in a multidrug therapy project, Baroda District, India. Chopra, N. K., *et al.* .....(A) 736
[Application of WHO multidrug therapy in San Pablo (Peru).] Orts Poveda, M. del C. and Bandrés Sánchez, M. P. .....(A) 598
Changes in epidemiological indices following the introduction of WHO MDT into the Guyana leprosy control programme. Rose, P. .....(A) 173
Clinical assessment of paucibacillary leprosy under multidrug therapy—three years followup study. Revankar, C. R., *et al.* .....(A) 148
Clinico-histopathological study of multidrug therapy in indeterminate leprosy. Kar, P. K., *et al.* .....(A) 739
Delivery of MDT through blister calendar packs in leprosy eradication programmes—a multicentre field study (phase I). Revankar, C. R., *et al.* .....(A) 148
[Effect of MDT in 52 cases of MB leprosy for one and a half years.] Zeng, X.-L., *et al.* .....(A) 599
[Examination of viability of *M. leprae* with FDA/EB staining in MDT.] Meng, M.-B., *et al.* .....(A) 598
Eye in multidrug therapy. Rajan, M. A. .....(A) 74
Global Evaluation of the Introduction of Multidrug Therapy. Leprosy Epidemiological Bulletin 4 (1990). .....(B) 734
[Implementation of MDT for leprosy in Guizhou Province.] Lin, G. .....(A) 433
Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Richardson, J. H. and Smith, T. C. .....(A) 409
MDT program to be expanded (Nigeria). .....(N) 585
Mexican MDT program. .....(N) 585
Multiple cold abscesses in a borderline lepromatous patient in multidrug therapy. Kulkarni, V., *et al.* .....(A) 601
New forms of multidrug therapy for the treatment of leprosy. First report on the practice of rifampicin + sulfamethoxazole-thrimethoprim + prothionamide and rifampicin + sulfamethoxazole-trimethoprim + isoniazid. Freerksen, E., *et al.* .....(A) 147
Preliminary assessment of multidrug therapy in leprosy patients in Western Samoa. Paksoy, N. and Levy, V. .....(A) 408
Relapses in paucibacillary leprosy after MDT—a clinical study. Grugni, A., *et al.* .....(O) 19
Selection of MDT strategies through epidemiometric modeling. Lechat, M. F., *et al.* ..(O) 296
Study of multidrug therapy in paucibacillary leprosy. Kar, P. K. and Sohi, A. S. .....(A) 597
Technical problems related to multidrug therapy in leprosy control. Sansarricq, H. ....(A) 598
[The color in the urine of leprosy patients taking MDT and their compliance.] Zhou, Y. .....(A) 599

Muscle(s),
[Correction of lagophthalmos in leprosy by transferring of temporalis muscle bundle and fascial sling—report of 26 cases.] Zhang, G.-C. and Zheng, T.-S. .....(A) 627
[Ischemic contracture of intrinsic muscles of the hand in leprosy.] Carayon, A. .....(A) 436
Phagocytosis of *M. leprae* by cardiac muscle cells—a preliminary report. Job, C. K., *et al.* .....(A) 748
[The histopathological observation on erector pili muscle in skin lesions of leprosy; prevention and treatment for skin disease control.] Gao, X.-L., *et al.* .....(A) 748

Mycobacteria (see also individual species),
A comparative study on the effects of rIL-4, rIL-2, rIFN-γ, and rTNF-α on specific T-cell non-responsiveness to mycobacterial antigens in lepromatous leprosy patients *in vitro*. Ottenhoff, T. H. M., *et al.* ..... (A) 750
A comparison of monocyte oxidative responses in leprosy patients and healthy subjects as influenced by mycobacterial lipid pretreatment. Vachula, M., *et al.* ..... (O) 534
A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. Billingham, M. E. J., *et al.* ..... (A) 604
A study of autoantibodies in chronic mycobacterial infections. Rapoport, B. L., *et al.* . (O) 518
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Wallace, R. J., Jr., *et al.* ..... (A) 449
An ordinary mortal's guide to the molecular biology of mycobacteria. Bloom, B. R. ... (E) 365
Antibodies to mycobacteria in healthy and tuberculous badgers from two English counties. Stainsby, K., *et al.* ..... (A) 447
[Assay of antibodies in blood serum of patients with pulmonary tuberculosis by using mycobacterial antigen isolated by affinity.] Gilburd, B. S., *et al.* ..... (A) 441
Biosynthesis and scavenging of pyrimidines by pathogenic mycobacteria. Wheeler, P. R. ..... (A) 616
Cell subset analysis of cutaneous infiltrate in atypic mycobacteria ulcerations. Esterre, V. P., *et al.* ..... (C) 387
Cell-mediated immunity to mycobacteria: a double-sided sword? Kaufmann, S. H. E., *et al.* ..... (A) 608
Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Prantera, C., *et al.* ..... (A) 445
[Culture of mycobacteria in human plasma.] Miranda, R. N., *et al.* ..... (A) 615
Current status review: role of immunity to mycobacterial stress proteins in rheumatoid arthritis. McLean, L., *et al.* ..... (A) 768
Detection and identification of mycobacteria by amplification of mycobacterial DNAs. Hance, A. J., *et al.* ..... (A) 429
Differential pattern of T cell recognition of the 65-kDa mycobacterial antigen following immunization with the whole protein or peptides. Brett, S. J., *et al.* ..... (A) 416
DR3-restricted T cells from different HLA-DR3-positive individuals recognize the same peptide (amino acids 2-12) of the mycobacterial 65-kDa heat-shock protein. van Schooten, W. C. A., *et al.* ..... (A) 612
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Tsoulfa, G., *et al.* ..... (A) 448
Enzyme-linked immunosorbent assay with BCG sonicate antigen for diagnostic potential of mycobacterial infection in Taiwan. Wang, C.-R., *et al.* ..... (A) 753
Enzymes for biosynthesis *de novo* and elongation of fatty acids in mycobacteria grown in host cells: is *M. leprae* competent in fatty acid biosynthesis? Wheeler, P. R., *et al.* ..... (A) 617
Epitopes of the mycobacterial heat shock protein 65 for human T cells comprise different structures. Munk, M. E., *et al.* ..... (A) 768
Establishment of a host-vector system in mycobacteria. Mizuguchi, Y., *et al.* ..... (A) 198
Faecal mycobacteria and their relationship to HIV-related enteritis in Lusaka, Zambia. Coulon, C. P., *et al.* ..... (A) 630
Genetic aspects of innate resistance and acquired immunity to mycobacteria in inbred mice. Buschman, E., *et al.* ..... (A) 176
Human leukocyte antigen (HLA) and mycobacterial disease. de Vries, R. R. P., *et al.* .. (A) 158
Human phagocyte oxidative burst activation by BCG, *M. leprae*, and atypical mycobacteria: defective activation by *M. leprae* is not reversed by interferon-γ. Launois, P., *et al.* ..... (A) 609
Ia antigen expression in macrophages after phagocytosis of mycobacteria *in vitro*. Fukutomi, Y., *et al.* ..... (A) 196
Immunohistologic analysis of mycobacterial antigens by monoclonal antibodies in tuberculosis and mycobacteriosis. Barbolini, G., *et al.* ..... (A) 438
Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen. Dudani, A. K. and Gupta, R. S. ..... (A) 418

Immunological detection of mycobacterial antigens in infected fluids, cells and tissues by latex agglutination; animal model and clinical application. Cambiaso, C. L., *et al.* ..... (A) 762
Immunological study of the defined constituents of mycobacteria. Ivanyi, J., *et al.* ..... (A) 420
Immunosuppression and mycobacteria other than *M. tuberculosis*: results from patients with and without HIV infection. Peters, M., *et al.* ..... (A) 444
In vitro responses to a 65-kilodalton mycobacterial protein by synovial T cells from inflammatory arthritis patients. Gaston, J. S. H., *et al.* ..... (A) 606
Induction of non-specific immunosuppression in mice by mycobacterial infections and its relationship to macrophage activation. Appelberg, R., *et al.* ..... (A) 627
Inhibition of human lymphoproliferative responses by mycobacterial phenolic glycolipids. Fournie, J.-J., *et al.* ..... (A) 605
Limited receptor repertoire in a mycobacteria-reactive subset of gamma-delta T lymphocytes. Happ, M. P., *et al.* ..... (A) 607
Limiting dilution analysis of T cell unresponsiveness to mycobacteria in advanced disseminated tuberculosis. Gilardini Montani, M. S., *et al.* ..... (A) 440
Modern vaccines; mycobacterial diseases. Fine, P. E. M. and Rodrigues, L. C. ..... (A) 757
Mycobacteria and rheumatoid arthritis. Rook, G., *et al.* ..... (A) 755
Mycobacteria in biofilms. Schulze-Robbecke, R. and Fischeder, R. ..... (A) 446
Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Collins, F. M. ..... (A) 439
Mycobacterial infection in patients infected with the human immunodeficiency virus. Helbert, M., *et al.* ..... (A) 765
Mycobacterial Skin Diseases. Mawali Harahap, ed. Hastings, R. C. ..... (B) 590
Particular matrix for fast atom bombardment mass spectrometric analysis of phenolic glycolipid antigens isolated from pathogen mycobacteria. Riviere, M., *et al.* ..... (A) 170
Pathogenesis of route-related variation in T-suppressor response on immunization with mycobacteria. Shroff, K. E., *et al.* ..... (O) 50
Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Brisson-Noel, A., *et al.* ..... (A) 630
Rapid, sensitive, and specific detection of mycobacteria using gene amplification techniques. Plikaytes, B. B. and Shinnick, T. H. ..... (A) 197
Report of the Indo-European Community Joint Symposium "Leprosy and Other Mycobacterial Diseases," Lonavla, India, 6–9 November 1989. Kaufmann, S. H. E. and Deo, M. G. ..... (E) 566
Results of blood cultures for detection of mycobacteria in AIDS patients. Truffot-Pernot, C., *et al.* ..... (A) 448
Route-related variation in immunogenicity of mycobacteria. Shroff, K. E., *et al.* ..... (O) 44
Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. Meeker, H. C., *et al.* ..... (O) 503
[Specific category of mycobacteria isolated from cattle and environmental objects.] Ovdiyenko, N. P., *et al.* ..... (A) 769
T cell reactivity to the purified mycobacterial antigens p65 and p70 in leprosy patients and their household contacts. Adams, E., *et al.* ..... (A) 747
T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein. Munk, M. E., *et al.* ..... (A) 635
The Biology of the Mycobacteria, Volume 3. C. Ratledge, J. Stanford and J. Grange, eds. Hastings, R. C. ..... (B) 403
The mycobacterial 65 kD heat-shock protein and autoimmune arthritis. van Eden, W., *et al.* ..... (A) 637
The use of fluorescein-conjugated lectins for visualizing atypical mycobacteria. Jackson, M., *et al.* ..... (A) 615
Treatment of adjuvant arthritis in rats: vaccination potential of a synthetic nonapeptide from the 65-kDa heat shock protein of mycobacteria. Yang, X.-D., *et al.* ..... (A) 771
Two-dimensional gas chromatography with electron capture detection for the sensitive determination of specific mycobacterial lipid constituents. Larsson, L., *et al.* ..... (A) 430
Variation in immunogenicity of mycobacteria: role of antigen-presenting cells. Shroff, K. E., *et al.* ..... (O) 58

Mycobacteriosis,
Immunohistologic analysis of mycobacterial antigens by monoclonal antibodies in tuberculosis and mycobacteriosis. Barbolini, G., *et al.* ..... (A) 438
Spindle cell reaction to nontuberculous mycobacteriosis in AIDS mimicking a spindle cell neoplasm; evidence for dual histiocytic and fibroblast-like characteristics of spindle cells. Brandwein, *et al.* ..... (A) 761

Mycobacterium aurum,
Mycolic acid synthesis by *M. aurum* cell-free extracts. Lacave, C., *et al.* ..... (A) 767

***Mycobacterium avium, M. avium* complex,**
1,25 Dihydroxyvitamin D3-dependent inhibition of growth in killing of *M. avium* complex in human macrophages is mediated by TNF and GM-CSF. Bermudez, L. E. M., *et al.* ..... (A) 761
A very long-chain fatty acid elongation system in *M. avium* and a possible mode of action of isoniazid on the system. Kikuchi, S., *et al.* ..... (A) 429
Aspartate metabolism in *M. avium* grown in host tissue and axenically and in *M. leprae.* Sritharan, V., *et al.* ..... (A) 616
Bactericidal activity *in vitro* of various rifamycins against *M. avium* and *M. tuberculosis.* Heifets, L. B., *et al.* ..... (A) 764
Bacteriostatic and bactericidal *in vitro* activity of meropenem against clinical isolates, including *M. avium* complex. Inderlied, C. B., *et al.* ..... (A) 633
Clofazimine and liposomes enhance the susceptibility of intracellular *M. avium* toward rifabutin. Jansons, V. K. and Soggiu, A. ..... (A) 738
Comparative *in vitro* activity of twenty antimicrobial agents against clinical isolates of *M. avium* complex. Khardori, N., *et al.* ..... (A) 634
Different correlations of drug susceptibilities to colonial morphology in *M. avium* complex strains. Tsukamura, M., *et al.* ..... (A) 637
Direct identification of *M. tuberculosis, M. avium,* and *M. intracellulare* from amplified primary cultures in BACTEC media using DNA probes. Peterson, E. M., *et al.* ..... (A) 444
Enhancement of drug susceptibility of *M. avium* by inhibitors of cell envelope synthesis. Rastogi, N., *et al.* ..... (A) 769
Generation of monoclonal antibodies to the specific sugar epitopes of *M. avium* complex serovars. Rivoire, B., *et al.* ..... (A) 636
Geographic distribution, frequency, and specimen source of *M. avium* complex serotypes isolated from patients with acquired immunodeficiency syndrome. Yakrus, M. A. and Good, R. C. ..... (A) 771
In vitro synergistic activity between ethambutol and fluorinated quinolones against *M. avium* complex. Hoffner, S. E., *et al.* ..... (A) 633
In-vitro activity of dapsone and two potentiators against *M. avium* complex. Gonzalez, A. H., *et al.* ..... (A) 177
Killing by antimycobacterial agents of AIDS-derived strains of *M. avium* complex inside cells of the mouse macrophage cell line. Yajko, D. M., *et al.* ..... (A) 638
Liposome-encapsulated-amikacin therapy of *M. avium* complex infection in beige mice. Cynamon, M. H., *et al.* ..... (A) 440
M. avium and *M. intracellulare* infections in patients with and without AIDS. Guthertz, L. S., *et al.* ..... (A) 441
M. avium-M. intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Barbaro, D. J., *et al.* ..... (A) 438
MICs and MBCs of Win 57273 against *M. avium* and *M. tuberculosis.* Heifets, L. B. and Lindholm-Levy, P. J. ..... (A) 764
Mycobacteremia caused by simultaneous infection with *M. avium* and *M. intracellulare* detected by analysis of a BACTEC 13A bottle with the Gen-Probe kit. Conville, P. S., *et al.* ..... (A) 439
Natural killer cell-mediated lysis of *M. avium* complex-infected monocytes. Katz, P., *et al.* ..... (A) 766
Oxidative and non-oxidative intracellular killing of *M. avium* complex. Bermudez, L. E. M. and Young, L. S. ..... (A) 629
Plasmid profiles of *M. avium* complex isolated from swine. Masaki, S., *et al.* ..... (A) 442
Production and characterization of monoclonal antibodies against specific serotypes of *M. avium* and the *M. avium-M. intracellulare-M. scrofulaceum* complex. Kolk, A. H. J., *et al.* ..... (A) 178

Radiolabelling of *M. avium* oligosaccharide determinant and use in macrophage studies. Woodbury, J. L. and Barrow, W. W. ..... (A) 449
Rifabutin (ansamycin LM427) for the treatment of pulmonary *M. avium* complex. O'Brien, R. J., *et al.* ..... (A) 768
Serovars of *M. avium* complex isolated from patients in Sweden. Hoffner, S. E., *et al.* .. (A) 766
Susceptibility of *M. avium* and *M. intracellulare* to various antibacterial drugs. Tomioka, H., *et al.* ..... (A) 448
Treatment of experimental disseminated *M. avium* complex infection in mice with recombinant IL-2 and tumor necrosis factor. Bermudez, L. E. M., *et al.* ..... (A) 628
Virulence of *M. avium* complex strains from acquired immune deficiency syndrome patients: relationship with characteristics of the parasite and host. Gangadharam, P. R. J., *et al.* ..... (A) 632

Mycobacterium bovis,
Crystalline cell surface layer of *M. bovis* BCG. Lounatmaa, K. and Brander, E. ..... (A) 635
Dietary protein deficiency and *M. bovis* BCG affect interleukin-2 activity in experimental pulmonary tuberculosis. McMurray, D. N., *et al.* ..... (A) 443
Effect of single exposure to ultraviolet radiation on *M. bovis* bacillus Calmette-Guérin infection in mice. Jeevan, A. and Kripke, M. L. ..... (A) 634
Extraction and localization by electron microscopy of an immunosuppressor fraction from *M. bovis* bacillus Calmette-Guérin (BCG). Hiu, I.-J. ..... (A) 765
Patterns of IL-2 production and utilization in mice heavily infected with *M. bovis* BCG reflect the phase of protective immunity being expressed. Miller, E. S. and Orme, I. M. ..... (A) 443
Serological response of patients with leprosy to a 28- to 30-kilodalton protein doublet from early cultures of *M. bovis*. Pessolani, M. C. V., *et al.* ..... (A) 423

Mycobacterium fortuitum,
Urinary *M. fortuitum* infection. Oren, B., *et al.* ..... (A) 769

Mycobacterium gastri,
Structural and immunological properties of the phenolic glycolipids from *M. gastri* and *M. kansasii*. Gilleron, M., *et al.* ..... (A) 763

Mycobacterium habana,
The specific 18-kilodalton antigen of *M. leprae* is present in *M. habana* and functions as a heat-shock protein. Lamb, F. I., *et al.* ..... (A) 755

Mycobacterium intracellulare,
Activity of rifabutin alone and in combination with clofazimine, kanamycin, and ethambutol against *M. intracellulare* infections in mice. Saito, H. and Sato, K. ..... (A) 446
Direct identification of *M. tuberculosis, M. avium,* and *M. intracellulare* from amplified primary cultures in BACTEC media using DNA probes. Peterson, E. M., *et al.* ..... (A) 444
M. avium and *M. intracellulare* infections in patients with and without AIDS. Guthertz, L. S., *et al.* ..... (A) 441
M. avium-M. intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Barbaro, D. J., *et al.* ..... (A) 438
Mycobacteremia caused by simultaneous infection with *M. avium* and *M. intracellulare* detected by analysis of a BACTEC 13A bottle with the Gen-Probe kit. Conville, P. S., *et al.* ..... (A) 439
Production and characterization of monoclonal antibodies against specific serotypes of *M. avium* and the *M. avium-M. intracellulare-M. scrofulaceum* complex. Kolk, A. H. J., *et al.* ..... (A) 178
Susceptibility of *M. avium* and *M. intracellulare* to various antibacterial drugs. Tomioka, H., *et al.* ..... (A) 448

Mycobacterium kansasii,
Structural and immunological properties of the phenolic glycolipids from *M. gastri* and *M. kansasii*. Gilleron, M., *et al.* ..... (A) 763

Mycobacterium leprae,
A complex component modulating immune-deficient cells in leprosy patients leading to loss of viability of *M. leprae*—a possible vaccine. Marolia, J., *et al.* ..... (A) 610

A component of *M. leprae* as a serodiagnostic tool for leprosy. Ranade, A. and Mahadevan, P. R. ..... (A) 166
A major immunogenic 36,000-molecular-weight antigen from *M. leprae* contains an immunoreactive region of proline-rich repeats. Thole, J. E. R., *et al.* ..... (A) 753
A rapid method for the detection of potentially viable *M. leprae* in human biopsies: a novel application of PCR. Woods, S. A. and Cole, S. T. ..... (A) 617
Acid-fast bacilli found in sphagnum vegetation of coastal Norway containing *M. leprae*-specific phenolic glycolipid-I. Kazda, J., *et al.* ..... (O) 353
An *in vitro* culture method for screening new drugs against *M. leprae*. Dhople, A. M. and Ortega, I. ..... (A) 755
Analysis of human antibody epitopes on the 65-kilodalton protein of *M. leprae* by using synthetic peptides. Meeker, H. C., *et al.* ..... (A) 422
Analysis of variation in batches of armadillo-derived *M. leprae* by immunoblotting. Ibrahim, M. A., *et al.* ..... (O) 73
Antagonism between dapsone and rifampicin in experimental *M. leprae* infections in mice. Millan, J. P. and Moulia-Pelat, J. P. ..... (A) 147
Anti-*M. leprae* monoclonal antibodies cross-react with human skin: an alternative explanation for the immune responses in leprosy. Naafs, B., *et al.* ..... (A) 749
Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *M. leprae*. Gormus, B. J., *et al.* ..... (O) 65
Antibody response to phenolic glycolipid I and *Mycobacterium w* antigens and its relation to bacterial load in *M. leprae*-infected mice and leprosy patients. Moudgil, K. D., *et al.* ..... (A) 423
Antigenic protein from *M. leprae* released in macrophages *in vitro* as indicator of viability of bacteria. Nair, I. and Mahadevan, P. R. ..... (O) 540
Application of ATP assay for *in vitro* drug screening testing against human derived *M. leprae*. Katoch, V. M., *et al.* ..... (A) 169
Application of polymerase chain reaction amplification technology for the detection of *M. leprae*. Williams, D. L., *et al.* ..... (A) 192
Aromatic amino acid decarboxylase of *M. leprae*. Prabhakaran, K. and Harris, E. B. ..(A) 430
Aspartate metabolism in *M. avium* grown in host tissue and axenically and in *M. leprae*. Sritharan, V., *et al.* ..... (A) 616
Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of *M. leprae* infection in populations of the South Pacific islands. Cartel, J.-L., *et al.* ..... (O) 512
Cellular immune responses of leprosy contacts to fractionated *M. leprae* antigens. Lee, S. P., *et al.* ..... (A) 163
Characterization of antigens associated with the cell walls of *M. leprae* and *M. tuberculosis* using T-lymphocyte clones. Mehra, V., *et al.* ..... (A) 200
[Circulating immune complexes in multibacillary leprosy patients and their relationship with anti-*M. leprae* antibodies and the major immunoglobulin classes.] Suarez Moreno, D., *et al.* ..... (A) 612
Cloned antigenic determinants of *M. leprae* that react with leprosy patients' sera: their characterization and ability to elicit delayed-type hypersensitivity responses in mice following immunization. Sathish, M., *et al.* ..... (A) 189
Comparative *in vitro* activities of 20 fluoroquinolones against *M. leprae*. Franzblau, S. G. and White, K. E. ..... (A) 596
Comparative *in vitro* activity of fluoroquinolones against *M. leprae*. Franzblau, S. G. and White, K. E. ..... (A) 187
Complement receptors and complement component C3 mediate phagocytosis of *M. tuberculosis* and *M. leprae*. Schlesinger, L. S. and Horwitz, M. A. ..... (A) 200
Confirmation of a false-positive result associated with a competition inhibition assay used for detecting antibodies to a protein epitope of *M. leprae*. Vadiee, A. R., *et al.* ..... (A) 753
Conservation of genomic sequences among isolates of *M. leprae*. Clark-Curtiss, J. E. and Walsh, G. P. ..... (A) 429
Correlation of bacterial viability with uptake of [^{14}C]acetate into phenolic glycolipid-1 of *M. leprae* within Schwannoma cells. Mistry, Y., *et al.* ..... (A) 170
Crossreactivity of *M. leprae* and *M. tuberculosis* and the implications for assessment of *in vitro* T cell function in leprosy patients. Rawlinson, W. D. and Basten, A. ..... (A) 424
Cultivation of a nocardioform acid-fast chemoautotrophic bacterium from armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ..... (A) 754

Cultivation of *M. leprae* in artificial culture medium. Biswas, S. K. ..... (A) 754
Diglycosyl phenol phthiocerol diester of *M. leprae*. Daffé, M. and Lanéelle, M.-A. ..... (A) 169
Direct evidence for the oxidation of palmitic acid by host-grown *M. leprae*. Ishaque, M. ..... (A) 152
Drug susceptibility testing of *M. leprae* in the BACTEC 460 system. Franzblau, S. G. ..... (A) 738
Effect of brodimoprim on *M. leprae in vitro* and in mouse foot pads. Dhople, A. M., *et al.* ..... (A) 737
Effect of diet on growth of *M. leprae* in mouse footpads. Foster, R. L., *et al.* ..... (A) 171
Effect of lyophilization on viability of *M. leprae* grown in nude mice. Kohsaka, K., *et al.* ..... (A) 192
Effect of *M. leprae*'s phenolic glycolipid-I on interferon-gamma augmentation of monocyte oxidative responses. Vachula, M., *et al.* ..... (O) 342
Effect of multiple interferon-γ in injections on the disposal of *M. leprae*. Kaplan, G., *et al.* ..... (A) 420
Effect of presensitization with BCG and *M. leprae* on granuloma formation to *M. leprae*. Vijayalakshmi, K., *et al.* ..... (O) 674
Effect of simultaneous administration of interferon-γ and chemotherapy against *M. leprae* in experimental infection in nude mice. Banerjee, D. K. and McDermott-Lancaster, R. D. ..... (O) 690
Effect of temperature, cholesterol and nerve tissue on multiplication of armadillo *M. leprae*. Bhatia, V. N. ..... (A) 614
[Effect of the suppression of the popliteal ganglion in the reproduction of *M. leprae* in the foot pad of mice. Preliminary report.] Suarez Moreno, O. and Rodriguez Silveira, J. ..... (A) 431
Effective vaccination of mice against leprosy bacilli with subunits of *M. leprae*. Gelber, R. H., *et al.* ..... (A) 606
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro*. Choudhury, A., *et al.* ..... (A) 169
Effects of dietary composition on growth of *M. leprae* in mouse footpads. Sanchez, A. and Foster, R. L. ..... (A) 618
Enzymes for biosynthesis *de novo* and elongation of fatty acids in mycobacteria grown in host cells: is *M. leprae* competent in fatty acid biosynthesis? Wheeler, P. R., *et al.* ..... (A) 617
Evaluation of *M. leprae* antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Klatser, P. R., *et al.* ..... (A) 420
[Examination of viability of *M. leprae* with FDA/EB staining in MDT.] Meng, M.-B., *et al.* ..... (A) 598
Experiences with *M. leprae*-soluble antigens in a leprosy-endemic population. Gupta, M. D., *et al.* ..... (A) 758
Failure of *M. leprae* soluble antigens to suppress delayed-type hypersensitivity reaction to tuberculin. Fine, P. E. M., *et al.* ..... (A) 419
Further evidence for the exclusiveness of the *M. leprae*-specific DNA probe. Pitulle, C., *et al.* ..... (C) 130
Generation and characterization of a human monoclonal antibody against phenolic glycolipid-I of *M. leprae*. Moudgil, K. D., *et al.* ..... (A) 611
Growth of *M. leprae* in a redox system: III. Evidence of growth at low temperature (psychrophilia) and further refinement of growth medium. Chatterjee, B. R. and Roy, R. D. ..... (A) 615
Heterogeneity among human T cell clones recognizing an HLA-DR4,Dw4-restricted epitope from the 28-kDa antigen of *M. leprae* defined by synthetic peptides. Oftung, F., *et al.* ..... (A) 750
Human phagocyte oxidative burst activation by BCG, *M. leprae*, and atypical mycobacteria: defective activation by *M. leprae* is not reversed by interferon-γ. Launois, P., *et al.* ..... (A) 609
Identification and characterization of antigenic determinants of *M. leprae* that react with antibodies in sera of leprosy patients. Sathish, M., *et al.* ..... (A) 751
Identification of an immunostimulating protein from *M. leprae*. Mohagheghpour, N., *et al.* ..... (A) 610

IgA antibodies against phenolic glycolipid I from *M. leprae* in serum of leprosy patients and contacts: subclass distribution and relation to disease activity. Schwerer, B., *et al.* ..... (A) 426

Immunogold labeling method for *M. leprae*-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and araldite-embedded leprosy lesions. Boddingius, J. and Dijkman, H. P. ..... (A) 415

In situ locations of *M. leprae*-specific antigen; immuno-electronoptical studies. Boddingius, J. and Dijkman, H. ..... (A) 415

In vitro and *in vivo* experiments with the new inhibitor of *M. leprae* brodimoprim alone and in combination with dapsone. Seydel, J. K., *et al.* ..... (A) 740

In vitro suppression of interleukin 2 production by *M. leprae* antigen. Makonkawkeyoon, S. and Kasinrerk, W. ..... (A) 163

In vivo activities of new quinolones against *M. leprae* infection induced in mice. Saito, H. and Tomioka, H. ..... (A) 188

Induction of antigen-specific immunity and tolerance to *M. leprae* in Lewis rats. Winters, M. A. and Humphres, R. C. ..... (A) 619

Influence of *M. leprae* and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Kaplan, G., *et al.* ..... (A) 161

Interactions between simian immunodeficiency virus and *M. leprae* in experimentally inoculated rhesus monkeys. Gormus, B. J., *et al.* ..... (A) 431

Isolation and characterization of the putative promoter of the *M. leprae* ribosomal RNA operon. Sela, S. and Clark-Curtiss, J. E. ..... (A) 190

Leukopenia secondary to *M. leprae*. Brooks, B. J., Jr., *et al.* ..... (A) 742

M. leprae reactive T cell clones from lepromatous leprosy patients after prolonged dapsone chemotherapy. Gill, H. K., *et al.* ..... (A) 606

New findings on the mode of entry of *M. leprae* in nude mice. Job, C. K., *et al.* ..... (C) 726

Nucleotide and deduced amino acid sequence of *M. leprae* manganese superoxide dismutase. Thangaraj, H. S., *et al.* ..... (A) 431

Pathology of dual *M. leprae* and simian immunodeficiency virus infection in rhesus monkeys. Baskin, G. B., *et al.* ..... (O) 358

[Pathology of the peripheral nerve lesions in infected armadillo with *M. leprae*—a light- and electron-microscopic study.] Liu, Z., *et al.* ..... (A) 422

Phagocytosis of *M. leprae* by cardiac muscle cells—a preliminary report. Job, C. K., *et al.* ..... (A) 748

Phenotypic and functional characterization of human suppressor T-cell clones: II. Activation of *M. leprae* presented by HLA-Dr molecules to $\alpha\beta$ T-cell receptors. Li, S. G., *et al.* ..... (A) 748

Polymerase chain reaction for the detection of *M. leprae*. Hartskeerl, R. A., *et al.* ..... (A) 429

Primary dapsone resistance as assessed by uptake of labelled thymidine by the macrophage resident *M. leprae*. Thakur, M., *et al.* ..... (A) 599

Process of disintegration and degradation of *M. leprae*: study of tissue imprints and tissues. Cologlu, A. S. ..... (A) 605

Properties of suppressor macrophages induced with *M. leprae* vaccine. Tomioka, H. and Saito, H. ..... (A) 199

Quantitation of IgM antibodies to the *M. leprae* synthetic dissacharide can predict early bacterial multiplication in leprosy. Hussain, R., *et al.* ..... (A) 491

Screening of anti-*M. leprae* antibodies in the blood samples eluted from filter paper blood blots. Patil, S. A., *et al.* ..... (C) 123

[Serologic demonstration of the activity of a *M. leprae* antigen stained by chemical synthesis.] Gonzalez-Abreu Castells, E., *et al.* ..... (A) 607

Structure-activity relationships of tetramethylpiperidine-substituted phenazines against *M. leprae in vitro*. Franzblau, S. G., *et al.* ..... (A) 406

[Study on inoculation of *M. leprae* to the tree shrew.] Wang, H.-Y., *et al.* ..... (A) 618

[Study on monoclonal antibody in leprosy. I. Production of monoclonal antibody against antigenic epitope of PGL-I specific to *M. leprae*. Wu, Q.-X., *et al.* ..... (A) 613

Suppression of T-cell proliferation by *M. leprae* and its products: the role of lipopolysaccharide. Molloy, A., *et al.* ..... (A) 610

T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous non-responder defect can be overcome *in vitro* by stimulation with fractionated *M. leprae* components. Ottenhoff, T. H. M., *et al.* ..... (A) 166

T-cell recognition of the 18-kilodalton antigen of *M. leprae*. Dockrell, H. M., *et al.* ...(A) 159
The activity of a beta-lactamase inhibitor, Augmentin®, against *M. leprae* in mice: a novel and promising target for drug development. Gelber, R. H. ...(A) 187
The cellular exudate-*M. leprae* relationship and the critical reading of skin smears. Ridley, M. J. ...(A) 412
The efficacy of a cell-mediated reaction in the disposal of *M. leprae* in human skin. Kaplan, G. ...(A) 152
The mapping of epitopes of the 18-kDa protein of *M. leprae* recognized by murine T cells in a proliferation assay. Harris, D. P., *et al.* ...(A) 419
The native proteins of *M. leprae*: preliminary results on subcellular location, isolation and chemical and immunological characterization. Hunter, S. W. and Brennan, P. J. ...(A) 190
The pathology of the eye in armadillos experimentally infected with *M. leprae*. Brandt, F., *et al.* ...(A) 756
The specific 18-kilodalton antigen of *M. leprae* is present in *M. habana* and functions as a heat-shock protein. Lamb, F. I., *et al.* ...(A) 755
The use of antigen-bearing nitrocellulose particles derived from Western blots to study proliferative responses to 27 antigenic fractions from *M. leprae* in patients and controls. Filley, E., *et al.* ...(A) 159
Time-related decrease of substance P and CGRP in central and peripheral projections of sensory neurones in *M. leprae* infected nude mice: a model for lepromatous leprosy in man. Karanth, S. S., *et al.* ...(A) 756
Uptake of purine and pyrimidine nucleosides by macrophage-resident *M. leprae*. ^{3}H-Adenosine as an indicator of viability and antimicrobial activity. Harshan, K. V., *et al.* ...(O) 526
Viability of *M. leprae* inside macrophages from different strains of mice and possible genetic control. Nair, I., *et al.* ...(O) 548

Mycobacterium lepraemurium,
Doubling time of *M. lepraemurium* in mouse foot pads. Silbaq, F., *et al.* ...(A) 446
Enhancement of growth of *M. lepraemurium* in macrophages by gamma interferon. Mor, N., *et al.* ...(A) 165
Local reactivity, local resistance and systemic dissemination in *M. lepraemurium* (MLM) infection. Lovik, M. and Closs, O. ...(A) 163
Partial characterization of suppressor factors in spleen cell culture supernatants of *M. lepraemurium*-infected mice. Richard, L., *et al.* ...(A) 425
[Preliminary report on culture of *M. lepraemurium in vitro*.] Lu, X.-H., *et al.* ...(A) 635
The disease of CBA and BALB/c mice that follows inoculation of a small number of *M. lepraemurium* into the hind foot pad. Silbaq, F., *et al.* ...(O) 681
Unresponsiveness to ConA in spleen cell cultures of *M. lepraemurium*-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production. Turcotte, R. and Lemieux, S. ...(A) 167

Mycobacterium malmoense,
Enhancement of growth of *M. malmoense* by acidic pH and pyruvate. Katila, M.-L., *et al.* ...(A) 442

Mycobacterium marinum,
Characterization of phenolic glycolipids from *M. marinum*. Dobson, G., *et al.* ...(A) 762

Mycobacterium neoaurum,
Co-ordinated expression of the components of iron transport (mycobactin, exochelin and envelope proteins) in *M. neoaurum*. Sritharan, M. and Ratledge, C. ...(A) 447

Mycobacterium paratuberculosis,
Identification of a repetitive DNA sequence specific to *M. paratuberculosis*. Collins, D. M., *et al.* ...(A) 438

Mycobacterium scrofulaceum,
On the soluble fraction of *M. scrofulaceum* HI-75, originally separated from human leproma, which combines with beta-glucuronidase. Matsuo, E., *et al.* ...(A) 194
Production and characterization of monoclonal antibodies against specific serotypes of *M. avium* and the *M. avium-M. intracellulare-M. scrofulaceum* complex. Kolk, A. H. J., *et al.* ...(A) 178

Mycobacterium smegmatis,
Killing of *M. smegmatis* by macrophages from genetically susceptible and resistant mice. Denis, M., *et al.* ....(A) 417

Mycobacterium thermoresistibile,
Cutaneous *M. thermoresistibile* infection in a heart transplant patient. Neeley, S. P. and Denning, D. W. ....(A) 444

Mycobacterium tuberculosis,
A 38-kD *M. tuberculosis* antigen associated with infection; its isolation and serologic evaluation. Espita, C., *et al.* ....(A) 631
Antigenicity and specificity of selected glycolipid fractions from *M. tuberculosis.* Papa, F., *et al.* ....(A) 615
Bactericidal activity *in vitro* of various rifamycins against *M. avium* and *M. tuberculosis.* Heifets, L. B., *et al.* ....(A) 764
Characterization of antigens associated with the cell walls of *M. leprae* and *M. tuberculosis* using T-lymphocyte clones. Mehra, V., *et al.* ....(A) 200
Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of *M. tuberculosis.* Barnes, P. F., *et al.* ....(A) 628
Cloning and expression of *M. tuberculosis* strain Aoyama B in *Escherichia coli*—a gene encoding 15-kDa and 60-kDa antigens. Tanaka, T., *et al.* ....(A) 197
Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of *M. tuberculosis.* Borremans, M., *et al.* ....(A) 629
[Comparative study of delayed hypersensitivity induced by *M. tuberculosis* and by protein fractions isolated by them.] Badukshanova, N. M., *et al.* ....(A) 438
Comparison of the immunological activity of five defined antigens from *M. tuberculosis* in seven inbred guinea pig strains. The 38-kDa antigen is immunodominant. Haslov, K., *et al.* ....(A) 763
Complement receptors and complement component C3 mediate phagocytosis of *M. tuberculosis* and *M. leprae.* Schlesinger, L. S. and Horwitz, M. A. ....(A) 200
Cord formation in BACTEC 7H12 medium for rapid, presumptive identification of *M. tuberculosis* complex. Yagupsky, P. V., *et al.* ....(A) 770
Crossreactivity of *M. leprae* and *M. tuberculosis* and the implications for assessment of *in vitro* T cell function in leprosy patients. Rawlinson, W. D. and Basten, A. ....(A) 424
Direct identification of *M. tuberculosis, M. avium,* and *M. intracellulare* from amplified primary cultures in BACTEC media using DNA probes. Peterson, E. M., *et al.* ....(A) 444
Enzyme-linked immunosorbent assay for distinguishing serological responses to the 29/33-kilodalton doublet and 64-kilodalton antigens of *M. tuberculosis.* Das, P. K., *et al.* ....(A) 417
Identification of *M. tuberculosis* by polymerase chain reaction. Shankar, P., *et al.* ....(A) 770
Identification, isolation and partial characterization of *M. tuberculosis* glycoprotein antigens. Espita, C. and Mancilla, R. ....(A) 631
Immunogenicity of ribonucleic acid-protein fraction of *M. tuberculosis* encapsulated in liposomes. Pancholi, P., *et al.* ....(A) 444
Immunosuppression and mycobacteria other than *M. tuberculosis*: results from patients with and without HIV infection. Peters, M., *et al.* ....(A) 444
Is pyrazinamide bactericidal against *M. tuberculosis*? Heifets, L. B. and Lindholm-Levy, P. J. ....(A) 633
Killing of *M. tuberculosis* in tissue by microwaves with simultaneous tissue fixation. Douglas-Jones, A. G., *et al.* ....(A) 631
MICs and MBCs of Win 57273 against *M. avium* and *M. tuberculosis.* Heifets, L. B. and Lindholm-Levy, P. J. ....(A) 764
Mycobacterium tuberculosis: Interactions with the Immune System. Bendinelli, M. and Friedman, H., eds. Hastings, R. C. ....(B) 143
Rapid identification of cultured *M. tuberculosis* with a panel of monoclonal antibodies in Western blot and immunofluorescence. Verstijnen, C. P. H. J., *et al.* ....(A) 637
Rapid radiometric method for pyrazinamide susceptibility testing of *M. tuberculosis.* Salfinger, M., *et al.* ....(A) 446
Recognition of novel glycolipid antigens from smooth variants of *M. tuberculosis.* Minnikin, D. E., *et al.* ....(A) 768
Specific detection of *M. tuberculosis* complex strains by polymerase chain reaction. Hermans, P. W. M., *et al.* ....(A) 765

Streptococcal cell wall arthritis; passive transfer of disease with a T cell line and cross-reactivity of streptococcal cell wall antigens with *M. tuberculosis.* DeJoy, S. Q., *et al.* ....(A) 631
Structure and mapping of antigenic domains of protein antigen b, a 30,000-molecular-weight protein of *M. tuberculosis.* Andersen, A. B. and Hansen, E. B. ....(A) 175
The pathogenicity of *M. tuberculosis* during chemotherapy. Clancy, L. J., *et al.* ....(A) 762
The potential use of DNA probes to identify and type strains within the *M. tuberculosis* complex. Cooper, G. L., *et al.* ....(A) 177

Mycobacterium ulcerans,
Characteristic new members of the phthiocerol and phenolphthiocerol families from *M. ulcerans.* Besra, G. S., *et al.* ....(A) 614

Mycobacterium w,
Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, *Mycobacterium w,* in multibacillary leprosy patients. Talwar, G. P., *et al.* ....(A) 752

Mycobacterium xenopi,
Drug action against intracellularly growing *M. xenopi.* Rastogi, N., *et al.* ....(A) 445

Mycobactin,
Co-ordinated expression of the components of iron transport (mycobactin, exochelin and envelope proteins) in *M. neoaurum.* Sritharan, M. and Ratledge, C. ....(A) 447

Nepal,
Leprosy Control Project Annual Report. ....(N) 138

Nerve(s),
An attempt to demonstrate antinerve antibodies in leprosy sera using rabbit nerve as antigen. Parkash, O., *et al.* ....(C) 129
Arthropathy of the wrist in leprosy—what changes are caused by long-standing peripheral nerve palsy? Nagano, J., *et al.* ....(A) 625
[Clofazimine poisoning of the eighth cranial nerves in eight cases of leprosy.] Lin, C. ..(A) 408
Comparison of the characteristics of infiltrates in skin and nerve granulomas of leprosy. Kumar, V., *et al.* ....(A) 609
Effect of temperature, cholesterol and nerve tissue on multiplication of armadillo *M. leprae.* Bhatia, V. N. ....(A) 614
Hansen's disease: computed tomography findings in peripheral nerve lesions. Barbancon, O., *et al.* ....(A) 741
Interosseous transfer of tibialia posterior for common peroneal nerve palsy. Richard, B. M. ....(A) 760
Isolation and characterization of cells in granulomas of nerves of leprosy patients. Kehrer, D., *et al.* ....(A) 608
[Leprous peripheral neuropathy: clinical observation in 11 cases and ultrastructural study of nerve in 2 cases.] Guo, Y.-P., *et al.* ....(A) 744
Major histocompatibility complex class II antigen expression in nerves in leprosy; an immunoelectronmicroscopical study. Cowley, S. A., *et al.* ....(O) 560
Multiple cutaneous nerve abscesses on a healed tuberculoid patch. Saxena, U., *et al.* ..(A) 745
Nerve abscess simulated by a lipoma in a leprosy patient. Malaviya, G. N., *et al.* ....(A) 153
[Pathology of the peripheral nerve lesions in infected armadillo with *M. leprae*—a light- and electron-microscopic study.] Liu, Z., *et al.* ....(A) 422
[Preliminary study on anti-nerve antibody in the sera of leprosy patients.] Huang, L., *et al.* ....(A) 411
Promoted healing of leprous ulcers by transcutaneous nerve stimulation. Kaada, B. and Emru, M. ....(A) 175
Remarks on criterion of nerve function alteration as a sign of relapse in leprosy patients during surveillance or postsurveillance periods. Negesse, Y. and Miko, T. L. ....(C) 722
Sensory recovery in the plantar aspect of the foot after surgical decompression of posterior tibial nerve. Possible role of steroids along with decompression. Rao, K. S. and Siddalinga Swamy, M. K. ....(A) 436
The management of nerve damage in the leprosy control services. Becx-Bleumink, M., *et al.* ....(A) 624
Tuberculous basal meningitis with multiple cranial nerve palsies and leprosy. Mahakul, K. C., *et al.* ....(A) 153

Neuropathy,
[Leprous peripheral neuropathy: clinical observation in 11 cases and ultrastructural study of nerve in 2 cases.] Guo, Y.-P., *et al.* ..... (A) 744
[Surgical treatment for neurotrophic lesions of leprosy. Application to other types of neuropathy.] Bourrel, P. ..... (A) 174

Neutrophil(s),
Comparative effect of the naphthalenic ansamycins rifamycin Sv, rifampin and cyclopentylrifampicin on murine neutrophil function. Kenny, M. T., *et al.* ..... (A) 597

Nigeria,
Leprosy deformities: experience in Molai Leprosy Hospital, Maiduguri, Nigeria. Iyere, B. B. ..... (A) 760
MDT program to be expanded. ..... (N) 585

Norway,
Acid-fast bacilli found in sphagnum vegetation of coastal Norway containing *M. leprae*-specific phenolic glycolipid-I. Kazda, J., *et al.* ..... (O) 353
European Congress of Clinical Microbiology and Infectious Diseases. ..... (N) 732

Nutrition,
Undernutrition to lepromatous leprosy: nutritional deficit in lepromatous patients co-infected with pulmonary tuberculosis. Saha, K. and Rao, K. N. ..... (A) 154

Obituaries,
Binford, Chapman H. by Meyers, W. M. ..... (Ob) 575
Hanks, John H. by Rose, N. R. ..... (Ob) 730
Latapí, Fernando by Saúl, A. ..... (Ob) 396
Rabello, Francisco Eduardo by Azulay, R. D. ..... (Ob) 134
Rollier, René by Basset, A. ..... (Ob) 394

Ofloxacin,
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Wallace, R. J., Jr., *et al.* ..... (A) 449
Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Grosset, J. H., *et al.* ..... (O) 281
Effects of ofloxacin on cell-mediated immune response and lymphokine production. Biglino, A., *et al.* ..... (A) 73
The effect of ofloxacin on the immune system of elderly patients. Munno, I., *et al.* ..... (A) 739

Pakistan,
Culture and "compliance" among leprosy patients in Pakistan. Mull, J. D., *et al.* ..... (A) 595
Dr. Ruth Pfau honored by Pakistan. ..... (N) 397

Papua New Guinea,
BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bagshawe, A., *et al.* ..... (A) 414

Paraguay,
Isoprodian and rifampicin in the treatment of leprosy: a descriptive evaluation of therapy durations in 475 Paraguayan leprosy patients. Pritze, S., *et al.* ..... (A) 408

Pathology,
[Immunopathology of leprosy.] Bottasso, O. A. and Morini, J. C. ..... (A) 416
Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Chan, J., *et al.* ..... (A) 168
Pathology of dual *M. leprae* and simian immunodeficiency virus infection in rhesus monkeys. Baskin, G. B., *et al.* ..... (O) 358
[Pathology of the peripheral nerve lesions in infected armadillo with *M. leprae*—a light- and electron-microscopic study.] Liu, Z., *et al.* ..... (A) 422
The pathology of the eye in armadillos experimentally infected with *M. leprae.* Brandt, F., *et al.* ..... (A) 756

Pefloxacin,
Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Grosset, J. H., *et al.* ..... (O) 281
Effectiveness of pefloxacin in the treatment of lepromatous leprosy. N'Deli, L., *et al.* .. (O) 12

Peru,
[Application of WHO multidrug therapy in San Pablo (Peru).] Orts Poveda, M. del C. and Bandrés Sánchez, M. P. ..... (A) 598

Phagocyte(s),
Apparent involvement of phospholipase A2, but not protein kinase C, in the pro-oxidative interactions of clofazimine with human phagocytes. Anderson, R., *et al.* .. (A) 146
Human phagocyte oxidative burst activation by BCG, *M. leprae,* and atypical mycobacteria: defective activation by *M. leprae* is not reversed by interferon-γ. Launois, P., *et al.* ..... (A) 609

Pharmacokinetic(s),
Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Venkatesan, K. ..... (A) 148

Phenolic glycolipid(s),
A longitudinal study of the incidence of leprosy in a hyperendemic area in Zaire, with special reference to PGL-antibody results. Groenen, G., *et al.* ..... (O) 641
Acid-fast bacilli found in sphagnum vegetation of coastal Norway containing *M. leprae*-specific phenolic glycolipid-I. Kazda, J., *et al.* ..... (O) 353
Antibodies to the phenolic glycolipid-1 antigen for epidemiologic investigations of enzootic leprosy in armadillos (*Dasypus novemcinctus*). Truman, R. W., *et al.* ..... (A) 618
Antibody response to phenolic glycolipid I and *Mycobacterium w* antigens and its relation to bacterial load in *M. leprae*-infected mice and leprosy patients. Moudgil, K. D., *et al.* ..... (A) 423
Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of *M. leprae* infection in populations of the South Pacific islands. Cartel, J.-L., *et al.* ..... (O) 512
Characterization of phenolic glycolipids from *M. marinum.* Dobson, G., *et al.* ..... (A) 762
Comparative evaluation of enzyme immunoassays based on synthetic glycoconjugates and phenolic glycolipid-I for immunodiagnosis of leprosy. Moudgil, K. D., *et al.* ... (A) 749
Correlation of bacterial viability with uptake of [^{14}C]acetate into phenolic glycolipid-1 of *M. leprae* within Schwannoma cells. Mistry, Y., *et al.* ..... (A) 170
[Detection of specific circulating immune complexes in leprosy patients by mouse monoclonal antibody against phenolic glycolipid-I.] Wu, Q.-X., *et al.* ..... (A) 754
Effect of *M. leprae*'s phenolic glycolipid-I on interferon-gamma augmentation of monocyte oxidative responses. Vachula, M., *et al.* ..... (O) 342
Evaluation of fluorescent leprosy antibody absorption test versus enzyme-linked immunosorbent assay with phenolic glycolipid I and their use in immuno-epidemiological studies on leprosy. Wu, Q.-X., *et al.* ..... (A) 428
[FLA-ABS T/PGL-ELISA and their uses in immuno-epidemiological studies for leprosy. Wu, Q., *et al.* ..... (A) 427
Generation and characterization of a human monoclonal antibody against phenolic glycolipid-I of *M. leprae.* Moudgil, K. D., *et al.* ..... (A) 611
IgA antibodies against phenolic glycolipid I from *M. leprae* in serum of leprosy patients and contacts: subclass distribution and relation to disease activity. Schwerer, B., *et al.* ..... (A) 426
IgM serum antibodies to phenolic glycolipid-I and clinical leprosy: two years' observation in a community with hyperendemic leprosy. Bagshawe, A. F., *et al.* ..... (O) 25
Inhibition of human lymphoproliferative responses by mycobacterial phenolic glycolipids. Fournie, J.-J., *et al.* ..... (A) 605
Particular matrix for fast atom bombardment mass spectrometric analysis of phenolic glycolipid antigens isolated from pathogen mycobacteria. Riviere, M., *et al.* ..... (A) 170
Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. Meeker, H. C., *et al.* ..... (O) 503
Structural and immunological properties of the phenolic glycolipids from *M. gastri* and *M. kansasii.* Gilleron, M., *et al.* ..... (A) 763

[Study on monoclonal antibody in leprosy. I. Production of monoclonal antibody against antigenic epitope of PGL-I specific to *M. leprae*.] Wu, Q.-X., *et al.* ..... (A) 613

Phenotype(s),
Generation of antigen-specific, MHC-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement by cutaneous administration of IL-2. Hancock, G. E., *et al.* ..... (A) 195
The effect of intracellular parasitism on cell phenotype. Poulter, L. W. and Condez, A. (A) 423
The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype; enhancement of the cutaneous administration of interleukin 2. Hancock, G. E., *et al.* ..... (A) 160

Philippines, The,
Evaluation of *M. leprae* antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Klatser, P. R., *et al.* ..... (A) 420
Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines, and Korea. Cellona, R. V., *et al.* ..... (O) 1

Phospholipid(s),
Apparent involvement of phospholipase A2, but not protein kinase C, in the prooxidative interactions of clofazimine with human phagocytes. Anderson, R., *et al.* ..... (A) 146

Phthiocerol,
Characteristic new members of the phthiocerol and phenolphthiocerol families from *M. ulcerans*. Besra, G. S., *et al.* ..... (A) 614
Diglycosyl phenol phthiocerol diester of *M. leprae*. Daffé, M. and Lanéelle, M.-A. ..... (A) 169

Polynesia,
The epidemiological transition in an overseas territory: disease mapping in French Polynesia. Vigneron, E. ..... (A) 623

Portugal,
Leprosy in Portugal 1946–80: epidemiologic patterns observed during declining incidence rates. Irgens, L. M., *et al.* ..... (A) 621

Pregnancy,
Thalidomide, pregnancy and renal failure. Brown, M. A., *et al.* ..... (A) 761

Prostaglandin,
Prostaglandin $F_{2\alpha}$ in leprosy—a preliminary study. Dhawan, V., *et al.* ..... (A) 742

Protein(s),
A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. Billingham, M. E. J., *et al.* ..... (A) 604
Analysis of human antibody epitopes on the 65-kilodalton protein of *M. leprae* by using synthetic peptides. Meeker, H. C., *et al.* ..... (A) 422
Antigenic protein from *M. leprae* released in macrophages *in vitro* as indicator of viability of bacteria. Nair, I. and Mahadevan, P. R. ..... (O) 540
Apparent involvement of phospholipase A2, but not protein kinase C, in the prooxidative interactions of clofazimine with human phagocytes. Anderson, R., *et al.* ..... (A) 146
Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of *M. tuberculosis*. Barnes, P. F., *et al.* ..... (A) 628
Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of *M. tuberculosis*. Borremans, M. *et al.* ..... (A) 629
Co-ordinated expression of the components of iron transport (mycobactin, exochelin and envelope proteins) in *M. neoaurum*. Sritharan, M. and Ratledge, C. ..... (A) 447
[Comparative study of delayed hypersensitivity induced by *M. tuberculosis* and by protein fractions isolated by them.] Badukshanova, N. M., *et al.* ..... (A) 438
Confirmation of a false-positive result associated with a competition inhibition assay used for detecting antibodies to a protein epitope of *M. leprae*. Vadiee, A. R., *et al.* ..... (A) 753
Current status review: role of immunity to mycobacterial stress proteins in rheumatoid arthritis. McLean, L., *et al.* ..... (A) 768

Dietary protein deficiency and *M. bovis* BCG affect interleukin-2 activity in experimental pulmonary tuberculosis. McMurray, D. N., *et al.* ..... (A) 443
Differential pattern of T cell recognition of the 65-kDa mycobacterial antigen following immunization with the whole protein or peptides. Brett, S. J., *et al.* ..... (A) 416
DR3-restricted T cells from different HLA-DR3-positive individuals recognize the same peptide (amino acids 2–12) of the mycobacterial 65-kDa heat-shock protein. van Schooten, W. C. A., *et al.* ..... (A) 612
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Tsoulfa, G., *et al.* ..... (A) 448
Epitopes of the mycobacterial heat shock protein 65 for human T cells comprise different structures. Munk, M. E., *et al.* ..... (A) 768
Heterogeneity of serological responses in paucibacillary leprosy—differential responses to protein and carbohydrate antigens and correlation with clinical parameters. Roche, P. W., *et al.* ..... (O) 319
Identification of an immunostimulating protein from *M. leprae.* Mohagheghpour, N., *et al.* ..... (A) 610
Immunogenicity of ribonucleic acid-protein fraction of *M. tuberculosis* encapsulated in liposomes. Pancholi, P., *et al.* ..... (A) 444
In vitro responses to a 65-kilodalton mycobacterial protein by synovial T cells from inflammatory arthritis patients. Gaston, J. S. H., *et al.* ..... (A) 606
In vitro studies on dermal leprosy granulomas: assessment of division and protein synthesis of cells. Narayanan, R. B. and Girdhar, B. K. ..... (A) 611
Protein G-based enzyme-linked immunosorbent assay for anti-MPB70 antibodies in bovine tuberculosis. Harboe, M., *et al.* ..... (A) 763
Role of S-100 protein as a marker for Schwann cells in the diagnosis of tuberculoid leprosy. Job, C. K., *et al.* ..... (C) 392
Serological response of patients with leprosy to a 28- to 30-kilodalton protein doublet from early cultures of *M. bovis.* Pessolani, M. C. V., *et al.* ..... (A) 423
Structure and mapping of antigenic domains of protein antigen b, a 30,000-molecular-weight protein of *M. tuberculosis.* Andersen, A. B. and Hansen, E. B. ..... (A) 175
T cells against a bacterial heat shock protein recognize stressed macrophages. Koga, T., *et al.* ..... (A) 421
T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein. Munk, M. E., *et al.* ..... (A) 635
The mapping of epitopes of the 18-kDa protein of *M. leprae* recognized by murine T cells in a proliferation assay. Harris, D. P., *et al.* ..... (A) 419
The mycobacterial 65 kD heat-shock protein and autoimmune arthritis. van Eden, W., *et al.* ..... (A) 637
The native proteins of *M. leprae*: preliminary results on subcellular location, isolation and chemical and immunological characterization. Hunter, S. W. and Brennan, P. J. ..... (A) 190
The specific 18-kilodalton antigen of *M. leprae* is present in *M. habana* and functions as a heat-shock protein. Lamb, F. I., *et al.* ..... (A) 755
Treatment of adjuvant arthritis in rats: vaccination potential of a synthetic nonapeptide from the 65-kDa heat shock protein of mycobacteria. Yang, X.-D., *et al.* ..... (A) 771

Prothionamide,
New forms of multidrug therapy for the treatment of leprosy. First report on the practice of rifampicin + sulfamethoxazole-thrimethoprim + prothionamide and rifampicin + sulfamethoxazole-trimethoprim + isoniazid. Freerksen, E., *et al.* ..... (A) 147

Psoriasis,
[Evaluation of circulating immune complexes in psoriasis, lichen planus, atopic eczema, leprosy, leukocytoclastic vasculitis, and pyoderma gangrenosum (review of the literature). Fernandez Bussy, R., *et al.* ..... (A) 418

Psychosocial,
[Contribution of the psychological characterization of leprosy patients.] de Rojas, V. and Lastra, R. A. ..... (A) 742
Educational material for the patient with leprosy. McDougall, A. C. and Georgiev, G. D. ..... (A) 411

[Human resources in hanseniasis.] Goncalves, N. N. S. ..... (A) 172
Influence of social perceptions of leprosy and leprosy patients on public health programs. Fassin, D. ..... (E) 111
Studies on social medicine and leprosy in east China. Ma, H., *et al.* ..... (A) 594
[Various social characteristics of leprosy patients in the city of Havana.] de Rojas, V. ..... (A) 757

Purified protein derivative (PPD),
Evaluation of enzyme immunoassays using purified protein derivative (PPD) and its pool fractions 3 and 4 for diagnosis of pulmonary tuberculosis. Kapur, J., *et al.* ..... (A) 608
Purified protein derivative (PPD). Lachmann, P. J. ..... (A) 442

Purine(s),
Uptake of purine and pyrimidine nucleosides by macrophage-resident *M. leprae*. ^{3}H-Adenosine as an indicator of viability and antimicrobial activity. Harshan, K. V., *et al.* ..... (O) 526

Rat(s),
Inhibition of dapsone-induced methaemoglobinaemia in the rat. Coleman, M. D., *et al.* (A) 737
Sex-dependent sensitivity to dapsone-induced methaemoglobinaemia in the rat. Coleman, M. D., *et al.* ..... (A) 737
Stimulation of K-Cl cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone. Haas, M. and Harrison, J. H., Jr. ..... (A) 407

Reaction, leprosy,
Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by *in situ* hybridization. Cooper, C. L., *et al.* ..... (A) 157
Dr. Pannikar replies (relapse or late reversal reaction). Pannikar, V. K. ..... (C) 120
Identification of interferon-gamma mRNA and human serine esterase mRNA in spontaneously occurring DTH reactions in leprosy skin lesions by *in situ* hybridization. Rea, T. H., *et al.* ..... (A) 196
[Levels of circulating immune complexes in a patient with lepromatous leprosy during a type 2 reaction.] Suarez Moreno, O., *et al.* ..... (A) 746
Ocular changes in reactions in leprosy. Shorey, P., *et al.* ..... (A) 155
Pterygium unguis in a patient with recurrent type 2 lepra reaction. Patki, A. H. and Mehta, J. M. ..... (A) 602
Reactions in leprosy—a prospective study of clinical, bacteriological, immunological and histopathological parameters in 35 Indians. Sehgal, V. N. and Sharma, V. ..... (A) 154
Relapse or late reversal reaction? Sehgal, V. N., *et al.* ..... (C) 118
Studies of human leprosy lesions *in situ* using suction-induced blisters. 2. Cell changes and soluble interleukin 2 receptor (Tac peptide) in reversal reactions. Scollard, D. M., *et al.* ..... (O) 469
The efficacy of a cell-mediated reaction in the disposal of *M. leprae* in human skin. Kaplan, G. ..... (A) 152

Rehabilitation,
Pattern of leprosy disabilities in Gorakhpur (Uttar Pradesh). Girdhar, M., *et al.* ..... (A) 625
[Physical disabilities in hanseniasis at the time of diagnosis. I. Evaluation of the disabilities.] Trindade, M. A. B., *et al.* ..... (A) 626
[Physical disabilities in hanseniasis at the time of diagnosis. II. An index of the evaluation of the hanseniasis control program.] Trindade, M. A. B., *et al.* ..... (A) 626
Report and evaluation of Brazilian experience in the rehabilitation of patients with leprosy. Virmond, M., *et al.* ..... (A) 437

Relapse(s),
A study of relapse in paucibacillary leprosy in a multidrug therapy project, Baroda District, India. Chopra, N. K., *et al.* ..... (A) 736
Dr. Kurz replies. Kurz, X. M. ..... (C) 380
Dr. Pannikar replies (relapse or late reversal reaction). Pannikar, V. K. ..... (C) 120
Relapse or late reversal reaction? Sehgal, V. N., *et al.* ..... (C) 118
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Lecoeur, H. F., *et al.* ..... (A) 421
Relapses in multibacillary leprosy. Reddy, R. N. ..... (C) 379
Relapses in paucibacillary leprosy after MDT—a clinical study. Grugni, A., *et al.* ..... (O) 19

Remarks on criterion of nerve function alteration as a sign of relapse in leprosy patients during surveillance or postsurveillance periods. Negesse, Y. and Miko, T. L. .....(C) 722
[The effect of relapse on the basic elimination of leprosy.] Yang, X., *et al.* .....(A) 435

Rifampin,
Antagonism between dapsone and rifampicin in experimental *M. leprae* infections in mice. Millan, J. P. and Moulia-Pelat, J. P. .....(A) 147
[Cell-mediated immunity in patients with leprosy treated with rifampin.] Valdes-Portela, A. and de la Cruz, F. .....(A) 427
Combined regimens of one-year duration in the treatment of multibacillary leprosy—I. Combined regimens with rifampicin administered during one year. Pattyn, S. R., *et al.* .....(A) 147
Combined regimens of one-year duration in the treatment of multibacillary leprosy—II. Combined regimens with rifampicin administered during 6 months. Pattyn, S. R., *et al.* .....(A) 148
Comparative effect of the naphthalenic ansamycins rifamycin Sv, rifampin and cyclopentylrifampicin on murine neutrophil function. Kenny, M. T., *et al.* .....(A) 597
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL South Indian patients: a five-year report. Thomas, A., *et al.* ....(O) 273
Cutaneous vasculitis associated with rifampin therapy. Iredale, J. P., *et al.* .....(A) 407
Evaluation of five treatment regimens, using either dapsone monotherapy or several doses of rifampicin in the treatment of paucibacillary leprosy. Pattyn, S. R., *et al.* ...(A) 739
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Lecoeur, H. F., *et al.* .....(A) 634
"Flu" syndrome on once monthly rifampicin: a case report. Vaz, M., *et al.* .....(A) 409
Interaction of rifampin and glyburide. Self, T. H., *et al.* .....(A) 409
Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Jenner, P. J. and Ellard, G. A. .....(A) 177
Isoprodian and rifampicin in the treatment of leprosy: a descriptive evaluation of therapy durations in 475 Paraguayan leprosy patients. Pritze, S., *et al.* .....(A) 408
New forms of multidrug therapy for the treatment of leprosy. First report on the practice of rifampicin + sulfamethoxazole-thrimethoprim + prothionamide and rifampicin + sulfamethoxazole-trimethoprim + isoniazid. Freerksen, E., *et al.* .....(A) 147
Resistance of *Escherichia coli* to rifampicin and sorangicin A—a comparison. Rommele, G., *et al.* .....(A) 770
Rifampicin-induced pure red cell aplasia. Mariette, X., *et al.* .....(A) 597
Rifampin therapy in rheumatoid arthritis. Gabriel, S. E., *et al.* .....(A) 762
Rifampin-induced immune thrombocytopenia; a case report. Kakaiya, R. M., *et al.* ...(A) 738
Venous thrombosis and rifampicin. White, N. W. .....(A) 410

Rifamycin,
Bactericidal activity *in vitro* of various rifamycins against *M. avium* and *M. tuberculosis.* Heifets, L. B., *et al.* .....(A) 764
Comparative effect of the naphthalenic ansamycins rifamycin Sv, rifampin and cyclopentylrifampicin on murine neutrophil function. Kenny, M. T., *et al.* .....(A) 597
[Study on short-term clinical trial of R-77-3 [3-(4-cyclopentyl-1-piperazinyl) imino methyl rifamycin SV] by mouse foot-pad technique.] Wang, H.-Y., *et al.* .....(A) 599

Sarcoidosis,
Sarcoidosis and leprosy—an epidemiological, clinical, pathological and immunological comparison. Zumla, A. and James, G. D. .....(A) 771
[The interpretation of the Mitsuda and Kveim tests in the differential diagnosis between tuberculoid leprosy and cutaneous sarcoidosis.] Guimarães Proença, N. .....(A) 601

Saudi Arabia,
Leprosy in the Eastern Province of Saudi Arabia. Al Sogair, S. M., *et al.* .....(A) 432

Screening,
An *in vitro* culture method for screening new drugs against *M. leprae.* Dhople, A. M. and Ortega, I. .....(A) 755
Application of ATP assay for *in vitro* drug screening testing against human derived *M. leprae.* Katoch, V. M., *et al.* .....(A) 169
[Evaluation of Ms-ELISA as a screening test for leprosy.] Weng, X.-M., *et al.* .....(A) 613

Screening of anti-*M. leprae* antibodies in the blood samples eluted from filter paper blood blots. Patil, S. A., *et al.* ..... (C) 123

Senegal,
Hepatitis B virus infection in lepromatous and tuberculoid patients from Senegal. Yvonnet, B., *et al.* ..... (A) 603

Sensation(s),
"Pocket filaments" and specifications for the Semmes-Weinstein monofilaments. Bell-Krotoski, J. ..... (A) 625
Thermal sensibility tester now available (Denmark). ..... (N) 731

Serodiagnosis,
Novel gelatin particle agglutination test for serodiagnosis of leprosy in the field. Izumi, S., *et al.* ..... (A) 607
Rapid serodiagnosis of leprosy—a preliminary study on latex agglutination test. Wu, Q.-X., *et al.* ..... (O) 328
Sensitivity, specificity, reliability of positive and negative indirect ELISA and gelatin particle agglutination test for serodiagnosis of leprosy. Izumi, S., *et al.* ..... (A) 191
Serodiagnosis of leprosy in patients' contacts by enzyme-linked immunosorbent assay. Gonzalez-Abeu, E., *et al.* ..... (A) 748
Use of eluates of filter paper blood spots in ELISA for the serodiagnosis of leprosy. Dhandayuthapani, S., *et al.* ..... (A) 158

Serum,
An attempt to demonstrate antinerve antibodies in leprosy sera using rabbit nerve as an antigen. Parkash, O., *et al.* ..... (C) 129
[Assay of antibodies in blood serum of patients with pulmonary tuberculosis by using mycobacterial antigen isolated by affinity.] Gilburd, B. S., *et al.* ..... (A) 441
Cloned antigenic determinants of *M. leprae* that react with leprosy patients' sera: their characterization and ability to elicit delayed-type hypersensitivity responses in mice following immunization. Sathish, M., *et al.* ..... (A) 189
Cross-reactive idiotypes in sera from patients with leprosy, lupus and Lyme disease and from healthy individuals. Mackworth-Young, C. G. ..... (A) 609
Effects of lepromatous leprosy (LL) serum factor(s) on normal blood lymphocytes. D'Souza, D., *et al.* ..... (O) 666
Identification and characterization of antigenic determinants of *M. leprae* that react with antibodies in sera of leprosy patients. Sathish, M., *et al.* ..... (A) 751
IgA antibodies against phenolic glycolipid I from *M. leprae* in serum of leprosy patients and contracts: subclass distribution and relation to disease activity. Schwerer, B., *et al.* ..... (A) 426
IgM serum antibodies to phenolic glycolipiid-I and clinical leprosy: two years' observation in a community with hyperendemic leprosy. Bagshawe, A. F., *et al.* ..... (O) 25
Isolation and identification of a substance from serum of leprosy patients. Garcia Lima, E. and Laura, C. J. ..... (C) 726
Lack of serum antibodies to native type II collagen in leprosy. Clague, R. B., *et al.* ..... (A) 600
[Ms-ELISA for detection of serum antibody level in leprosy patient—establishment of Ms-ELISA.] Wu, Q.-X., *et al.* ..... (A) 613
Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. Schlesinger, L. S. and Horwitz, M. A. ..... (A) 751
[Preliminary study on anti-nerve antibody in the sera of leprosy patients.] Huang, L., *et al.* ..... (A) 411
Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. Meeker, H. C., *et al.* ..... (O) 503
Serum beta-glucuronidase in subtypes of leprosy. George, J., *et al.* ..... (A) 743
Serum glycoproteins in pulmonary tuberculosis. Singh, U., *et al.* ..... (A) 447
Serum lymphocytotoxic activity in leprosy. Rasheed, R. N., *et al.* ..... (A) 167
Serum tumor necrosis factor levels and leishmaniasis. Pisa, P., *et al.* ..... (A) 750
Study of serum calcium and magnesium in leprosy. Saxena, N., *et al.* ..... (A) 412
Suppression of the increase in free cytosolic calcium during the inhibition of T-cell activation by an autoantibody present in the serum of leprosy patients. Poulton, T. A., *et al.* ..... (A) 424

Total and antimycobacterial IgE levels in serum from patients with tuberculosis and leprosy. Yong, A. J., *et al.* ....(A) 428

Skin,
Anti-*M. leprae* monoclonal antibodies cross-react with human skin: an alternative explanation for the immune responses in leprosy. Naafs, B., *et al.* ....(A) 749
CD1-positive epidermal Langerhans cells in skin reactions to autologous peripheral-blood-derived mononuclear cells in leprosy patients. Narayanan, R. B., *et al.* ....(A) 165
Comparison of the characteristics of infiltrates in skin and nerve granulomas of leprosy. Kumar, V., *et al.* ....(A) 609
[Deposition of immunoglobulin and complement in the skin of leprosy patients.] Zhang, X.-Q., *et al.* ....(A) 614
[Determination of Langerhans' cells in the skin lesions of leprosy cases with immunohistochemical technique using wheat-germ agglutinin.] Liang, Z., *et al.* ....(A) 749
Diversity in migration of CD4 and CD8 lymphocytes in different microanatomical compartments of the skin in the tuberculin reaction in man. Beck, J. S., *et al.* ....(A) 176
[Histological chemistry study and quantitative measurement on skin pigmentation of B663 in leprosy.] Gu, C., *et al.* ....(A) 407
Identification of interferon-gamma mRNA and human serine esterase mRNA in spontaneously occurring DTH reactions in leprosy skin lesions by *in situ* hybridization. Rea, T. H., *et al.* ....(A) 196
M. avium-M. intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Barbaro, D. J., *et al.* ....(A) 438
Mast cells in leprosy skin lesions. Cree, I. A., *et al.* ....(A) 747
Mycobacterial Skin Diseases. Mawali Harahap, ed. Hastings, R. C. ....(B) 590
[Observation of the free zone in the skin section of leprosy patients with light- and electronmicroscopy.] Zhu, W., et al. ....(A) 428
Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvements with dapsone treatment. Roger, H., *et al.* ....(A) 770
[Survey of the first skin lesions in 343 cases of leprosy.] Lin, D., *et al.* ....(A) 411
The efficacy of a cell-mediated reaction in the disposal of *M. leprae* in human skin. Kaplan, G. ....(A) 152
[The histopathological observation on erector pili muscle in skin lesions of leprosy; prevention and treatment for skin disease control.] Gao, X.-L., *et al.* ....(A) 748

Skin smear(s),
Reliability of skin smear results: experiences with quality control of skin smears in different routine services in leprosy control programmes. Vettom, L. and Pritze, S. ..(A) 414
The cellular exudate-*M. leprae* relationship and the critical reading of skin smears. Ridley, M. J. ....(A) 412

Skin test(s),
Assessment of the respiratory metabolism in the skin from transcutaneous measurements of pO_2 and pCO_2: potential for non-invasive monitoring of response to tuberculin skin testing. Abbot, N. C., *et al.* ....(A) 627
HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Bahr, G. M., *et al.* ....(A) 156
[The interpretation of the Mitsuda and Kveim tests in the differential diagnosis between tuberculoid leprosy and cutaneous sarcoidosis.] Guimarães Proença, N. ....(A) 601
The post-lepromin scar and its significance in the control of HD. Walter, J. ....(A) 174

Spain,
3rd Congress on Hansenology of Endemic Countries. ....(N) 141
[Epidemiological aspects of leprosy in the province of Jaén, Spain.] Delgado Rodríguez, M., *et al.* ....(A) 621
Fontilles International Course 1990. ....(N) 399
Government leprosy hospital at Trillo to close. ....(N) 585
Second National Meeting of the Spanish Group on Mycobacteriology. ....(N) 139

Spleen,
[Electron microscopic observation on spleen T lymphocyte in animal models of lepromatous leprosy.] Wang, B., *et al.* ....(A) 179

Partial characterization of suppressor factors in spleen cell culture supernatants of *M. lepraemurium*-infected mice. Richard, L., *et al.* ....(A) 425
Unresponsiveness to ConA in spleen cell cultures of *M. lepraemurium*-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production. Turcotte, R. and Lemieux, S. ....(A) 167

Stain(s),
A comparison of the Ziehl-Neelsen and Kinyoun methods in staining smears from leprosy patients. Fandinho, F. C. O., *et al.* ....(C) 389
[Examination of viability of *M. leprae* with FDA/EB staining in MDT.] Meng, M.-B., *et al.* ....(A) 598
Improved staining of leprosy bacilli in tissues. Harada, K. and Suzuki, K. ....(A) 160
[Serologic demonstration of the activity of a *M. leprae* antigen stained by chemical synthesis.] González-Abreu Castells, E., *et al.* ....(A) 607
[Stable solution of fuchsin—new method of preparation for Ziehl-Neelsen staining.] Siqueira, L. F. G., *et al.* ....(A) 170

Steroid(s),
Sensory recovery in the plantar aspect of the foot after surgical decompression of posterior tibial nerve. Possible role of steroids along with decompression. Rao, K. S. and Siddalinga Swamy, M. K. ....(A) 436

Subclinical,
Detection of subclinical infection in leprosy: an 8 years follow-up study. Bharadwaj, V. P. and Katoch, K. ....(A) 604

Sulfone(s),
[Secondary sulfone resistance related to a case of hanseniasis in Rio de Janeiro, Brazil.] Gallo, M. E. N., *et al.* ....(A) 596
Sulfapyride and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum. Stone, O. J. ....(A) 740
[Sulfone—pharmacological aspects, new indications besides hanseniasis, drug resistance.] da Costa Rocha, A. L., *et al.* ....(A) 406

Superoxide,
Nucleotide and deduced amino acid sequence of *M. leprae* manganese superoxide dismutase. Thangaraj, H. S., *et al.* ....(A) 431

Suppression,
A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. Billingham, M. E. J., *et al.* ....(A) 604
[Effect of the suppression of the popliteal ganglion in the reproduction of *M. leprae* in the foot pad of mice. Preliminary report.] Suarez Moreno, O. and Rodriguez Silveira, J. ....(A) 431
In vitro suppression of interleukin 2 production by *M. leprae* antigen. Makonkawkeyoon, S. and Kasinrerk, W. ....(A) 163
On the mechanism of T-cell suppression in leprosy. Salgame, P., *et al.* ....(A) 186
Suppression of T-cell proliferation by *M. leprae* and its products: the role of lipopolysaccharide. Molloy, A., *et al.* ....(A) 610
Suppression of the increase in free cytosolic calcium during the inhibition of T-cell activation by an autoantibody present in the serum of leprosy patients. Poulton, T. A., *et al.* ....(A) 424

Surgery,
Correction of 'Z' pinch in ulnar paralysis of leprosy by transfer of flexor pollicis longus to extensor pollicis longus. Malaviya, G. N., *et al.* ....(A) 436

Sweden,
Serovars of *M. avium* complex isolated from patients in Sweden. Hoffner, S. E., *et al.* ....(A) 766

Switzerland,
FIELDLINCS coordination and technical support grants. ....(N) 585
Leprosy Scientific Working Group September 1989 meeting reviews research needs, new tools and methodologies. ....(N) 399
Multicenter field trial call for participants. ....(N) 586

Reagents available for leprosy research. ....(N) 401
TDR/WHO offers project development grants to LDC scientists. ....(N) 586
THELEP and IMMLEP 1990 meeting schedule. ....(N) 401
WHO forms new Division of Tropical Disease Control (CTD). ....(N) 732
WHO Report on the Consultation on Leprosy Control Within Urban Primary Health Care. ....(N) 139

Taiwan,
Enzyme-linked immunosorbent assay with BCG sonicate antigen for diagnostic potential of mycobacterial infection in Taiwan. Wang, C.-R., *et al.* ....(A) 753
Evaluation of humoral immunity on leprosy patients in Taiwan: a preliminary report. Wang, C.-R., *et al.* ....(A) 613

Testing,
Application of ATP assay for *in vitro* drug screening testing against human derived *M. leprae.* Katoch, V. M., *et al.* ....(A) 169
Assessment of the respiratory metabolism in the skin from transcutaneous measurements of pO_2 and pCO_2: potential for non-invasive monitoring of response to tuberculin skin testing. Abbot, N. C., *et al.* ....(A) 627
Drug susceptibility testing of *M. leprae* in the BACTEC 460 system. Franzblau, S. G. ....(A) 738
"Pocket filaments" and specifications for the Semmes-Weinstein monofilaments. Bell-Krotoski, J. ....(A) 625
Rapid radiometric method for pyrazinamide susceptibility testing of *M. tuberculosis.* Salfinger, M., *et al.* ....(A) 446
Thermal sensibility tester now available (Denmark). ....(N) 731
Value of thermal sensibility testing in the field—field trial of a pocket device. Srinivasan, H. and Stumpe, B. ....(A) 413

Tetanus,
The effect of tetanus toxoid in leprosy patients. Shwe, T., *et al.* ....(A) 746

Texas,
Hansen's disease in south Texas. Guinn, B. ....(A) 759

Thailand,
30 years of the Hartdegen Fund for Thailand's leprosy sufferers. ....(N) 397
Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines, and Korea. Cellona, R. V., *et al.* ....(O) 1
Leprosy situation in Thailand. Montreewasuwat, N. and Peerapakorn, S. ....(A) 172

Thalidomide,
Thalidomide, pregnancy and renal failure. Brown, M. A., *et al.* ....(A) 761
Thalidomide—a therapy for the immunological consequences of HIV infection? Gunzler, V. ....(A) 441
[Thalidomide: an eclectic medication in dermatology.] Proença, N. G. ....(A) 740
The effect of thalidomide on experimental autoimmune myasthenia gravis. Crain, E., *et al.* ....(A) 440
[Treatment of discoid lupus erythematosus by thalidomide.] Proença, N. G. and Bernardes, M. F. ....(A) 178

The Leprosy Mission (TLM),
Dr. Grace Warren retires from TLM. ....(N) 586
Rev. Silvano Perotti retires from TLM. ....(N) 587

THELEP (WHO Chemotherapy of Leprosy Scientific Working Group),
THELEP and IMMLEP 1990 meeting schedule. ....(N) 401

Therapy (see also Chemotherapy, Multidrug therapy),
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Wallace, R. J., Jr., *et al.* ....(A) 449
Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Prantera, C., *et al.* ....(A) 445
Cutaneous vasculitis associated with rifampin therapy. Iredale, J. P., *et al.* ....(A) 407

[Diuciphone and dimociphone in combined therapy of lepra (*sic*) (a 14-year follow-up study).] Goloshchapov, N. M., *et al.* ..... (A) 147
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Lecoeur, H. F., *et al.* ..... (A) 634
[Immunomodulating therapy of multibacillary leprosy using extracts of bacterial ribosomes.] Saint-André, P., *et al.* ..... (A) 611
Isoprodian and rifampicin in the treatment of leprosy: a descriptive evaluation of therapy durations in 475 Paraguayan leprosy patients. Pritze, S., *et al.* ..... (A) 408
Liposome-encapsulated-amikacin therapy of *M. avium* complex infection in beige mice. Cynamon, M. H., *et al.* ..... (A) 440
Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper (*sic*). Font, R. L., *et al.* ..... (A) 151
Rifampin therapy in rheumatoid arthritis. Gabriel, S. E., *et al.* ..... (A) 762
Thalidomide—a therapy for the immunological consequences of HIV infection? Gunzler, V. ..... (A) 441

Thiacetazone,
Is thiacetazone necessary or useful in the intensive phase of anti-tuberculous chemotherapy? McLeod, D. T., *et al.* ..... (A) 178

Thymidine,
Primary dapsone resistance as assessed by uptake of labelled thymidine by the macrophage resident *M. leprae*. Thakur, M., *et al.* ..... (A) 599

Tissue(s),
Aspartate metabolism in *M. avium* grown in host tissue and axenically and in *M. leprae*. Sritharan, V., *et al.* ..... (A) 616
Cultivation of a nocardioform acid-fast chemoautotrophic bacterium from armadillo tissues infected with *M. leprae*. Dastidar, S. G. and Chakrabarty, A. N. ..... (A) 754
Effect of temperature, cholesterol and nerve tissue on multiplication of armadillo *M. leprae*. Bhatia, V. N. ..... (A) 614
Immunological detection of mycobacterial antigens in infected fluids, cells and tissues by latex agglutination; animal model and clinical application. Cambiaso, C. L., *et al.* ..... (A) 762
Improved staining of leprosy bacilli in tissues. Harada, K. and Suzuki, K. ..... (A) 160
Killing of *M. tuberculosis* in tissue by microwaves with simultaneous tissue fixation. Douglas-Jones, A. G., *et al.* ..... (A) 631
Metabolism of fossil fuels by chemoautotrophic nocardioform bacteria from infectious leprosy tissues and its implications. Chakrabarty, A. N., *et al.* ..... (A) 168
Process of disintegration and degradation of *M. leprae*: study of tissue imprints and tissues. Cologlu, A. S. ..... (A) 605
Silicon (Si) utilisation by chemoautotrophic nocardioform bacteria isolated from human and animal tissues infected with leprosy bacillus. Chakrabarty, A. N., *et al.* ..... (A) 168

Tobago,
A second report on multidrug therapy for leprosy in Trinidad and Tobago, Suite. M. and Edinborough, N. B. ..... (A) 409

Trial(s),
BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bagshawe, A., *et al.* ..... (A) 414
Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Grosset, J. H., *et al.* ..... (O) 281
Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL South Indian patients: a five-year report. Thomas, A., *et al.* ..... (O) 273
Controlled clinical trials. Chatterjee, B. R. ..... (C) 376
Do we need trials of agents alleged to improve healing of plantar ulcers? Srinivasan, H. ..... (A) 413
Drs. Grosset and Ji's response to Dr. Chatterjee's comments. Grosset, J. H. and Ji, B.-H. ..... (C) 378
Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines, and Korea. Cellona, R. V., *et al.* ..... (O) 1
Leprosy vaccine trials (India). Jayaraman, K. S. ..... (N) 137

Multicenter field trial call for participants. ....(N) 586
[Study on short-term clinical trial of R-77-3 [3-(4-cyclopentyl-1-piperazinyl) imino methyl rifamycin SV] by mouse foot-pad technique.] Wang, H.-Y., *et al.* ....(A) 599
The sociocultural dimension in leprosy vaccine trials. Kartikeyan, S., *et al.* ....(A) 621
[Trial forecast of incidence of grey calculation in leprosy.] Cen, Y.-H., *et al.* ....(A) 757
Value of thermal sensibility testing in the field—field trial of a pocket device. Srinivasan, H. and Stumpe, B. ....(A) 413

Trinidad,
A second report on multidrug therapy for leprosy in Trinidad and Tobago. Suite, M. and Edinborough, N. B. ....(A) 409

Tuberculin,
Assessment of the respiratory metabolism in the skin from transcutaneous measurements of pO_2 and pCO_2: potential for non-invasive monitoring of response to tuberculin skin testing. Abbot, N. C., *et al.* ....(A) 627
Diversity in migration of CD4 and CD8 lymphocytes in different microanatomical compartments of the skin in the tuberculin reaction in man. Beck, J. S., *et al.* ....(A) 176
Failure of *M. leprae* soluble antigens to suppress delayed-type hypersensitivity reaction to tuberculin. Fine, P. E. M., *et al.* ....(A) 419
HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Bahr, G. M., *et al.* ....(A) 156

Tuberculoid leprosy,
A case of borderline tuberculoid leprosy presenting with papulonodular lesions. Ramachandran, A. and Laxman, R. ....(C) 571
Primary involvement of scrotum in tuberculoid leprosy; a case report. Dixit, V. B., *et al.* ....(A) 742
Psoralene in repigmentation of tuberculoid leprosy. Jha "Amar," A. K. ....(A) 744
Role of S-100 protein as a marker for Schwann cells in the diagnosis of tuberculoid leprosy. Job, C. K., *et al.* ....(C) 392
[The interpretation of the Mitsuda and Kveim tests in the differential diagnosis between tuberculoid leprosy and cutaneous sarcoidosis.] Guimarães Proença, N. ....(A) 601
Triethanolamine-induced allergic contact dermatitis over a tuberculoid leprosy lesion. Srinivas, C. R., *et al.* ....(C) 382
Tuberculoid (TT) leprosy: localization on a tattoo. Sehgal, V. N. and Joginder. ....(A) 602

Tuberculosis,
[Antituberculous antibodies to antigens of different molecular weights in patients with active tuberculosis of the lungs.] Gilburd, B. S., *et al.* ....(A) 632
[Assay of antibodies in blood serum of patients with pulmonary tuberculosis by using mycobacterial antigen isolated by affinity.] Gilburd, B. S., *et al.* ....(A) 441
[Clinical picture and process of pulmonary tuberculosis in new cases of elderly and senile ages isolating L-forms of tubercle bacilli.] Kochetkova, E. Y. ....(A) 442
[Comparative ecology of tuberculosis and hanseniasis.] Rabello, F. E. and Azulay, R. D. ....(A) 424
Dietary protein deficiency and *M. bovis* BCG affect interleukin-2 activity in experimental pulmonary tuberculosis. McMurray, D. N., *et al.* ....(A) 443
[Epidemiologic risk of tuberculosis-affected cattle for people living in the northern regions of Kazakh, SSR.] Kurmanbayev, K. K., *et al.* ....(A) 767
Evaluation of enzyme immunoassays using purified protein derivative (PPD) and its pool fractions 3 and 4 for diagnosis of pulmonary tuberculosis. Kapur, J., *et al.* ....(A) 608
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Lecoeur, H. F., *et al.* ....(A) 634
HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Bahr, G. M., *et al.* ....(A) 156
Immunohistologic analysis of mycobacterial antigens by monoclonal antibodies in tuberculosis and mycobacteriosis. Barbolini, G., *et al.* ....(A) 438
Immunotherapy for leprosy and tuberculosis. Stanford, J. L. ....(A) 426
Leprosy and tuberculosis vaccine design. Kaufmann, S. H. E. ....(A) 420
Limiting dilution analysis of T cell unresponsiveness to mycobacteria in advanced disseminated tuberculosis. Gilardini Montani, M. S., *et al.* ....(A) 440

[Natural killer cells of blood in patients with limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* ..... (A) 442
New strategies for leprosy and tuberculosis and for development of bacillus Calmette-Guérin into a multivaccine vehicle. Bloom, B. R. and Jacobs, W. R., Jr. ..... (A) 747
Peripheral blood T lymphocyte subpopulations in patients with tuberculosis and the effect of chemotherapy. Singhal, M., *et al.* ..... (A) 447
Protein G-based enzyme-linked immunosorbent assay for anti-MPB70 antibodies in bovine tuberculosis. Harboe, M., *et al.* ..... (A) 763
Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Brisson-Noel, A., *et al.* ..... (A) 630
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Lecoeur, H. F., *et al.* ..... (A) 421
Relationship between radiological classification and the serological and haematological features of untreated pulmonary tuberculosis in Indonesia. Caplin, M., *et al.* ..... (A) 177
Research towards global control and prevention of tuberculosis with an emphasis on vaccine development. Snider, D., Jr., *et al.* ..... (A) 636
Serum glycoproteins in pulmonary tuberculosis. Singh, U., *et al.* ..... (A) 447
The role of cytokines in the immunopathology of tuberculosis and the regulation of agalactosyl IgG. Rook, G. A. W., *et al.* ..... (A) 425
The role of T cell-macrophage interactions in tuberculosis. Kaufmann, S. H. E. and Flesch, I. E. A. ..... (A) 161
Total and antimycobacterial IgE levels in serum from patients with tuberculosis and leprosy. Yong, A. J., *et al.* ..... (A) 428
Undernutrition in lepromatous leprosy: nutritional deficit in lepromatous patients co-infected with pulmonary tuberculosis. Saha, K. and Rao, K. N. ..... (A) 154

U.K.,
1989 Indo-U.K. Workshop on Leprosy Research. ..... (N) 732
Dr. Grace Warren retires from TLM. ..... (N) 586
ILEP former President Farine retires. ..... (N) 586
Leprosy in Childhood (revised edition) published. ..... (N) 587
Leprosy surveillance in England and Wales: 1951–1988. ..... (A) 432
Rev. Silvano Perotti retires from TLM. ..... (N) 587
TAMILEP offers paperback edition of "Leprosy" to Third World countries. ..... (N) 587

Ulcer(s),
Cauliflower growths in ulcers of leprosy—a question of malignancy. Duvanchelle, D. and Goldstein, N. ..... (A) 411
Cell subset analysis of cutaneous infiltrate in atypic mycobacteria ulcerations. Esterre, V. P., *et al.* ..... (C) 387
Corneal ulcer caused by *Bipolaris hawaiiensis.* Anandi, V., *et al.* ..... (A) 150
Do we need trials of agents alleged to improve healing of plantar ulcers? Srinivasan, H. ..... (A) 413
[Neurotrophic plantar ulcers in leprosy patients.] Shats, E. I. and Yushchenko, A. A. ..... (A) 175
Promoted healing of leprous ulcers by transcutaneous nerve stimulation. Kaada, B. and Emru, M. ..... (A) 175
Trophic leprosy ulcers: treatment with topical and systemic phenytoin. Bogaert, H., *et al.* ..... (A) 741

Urine,
[The color in the urine of leprosy patients taking MDT and their compliance.] Zhou, Y. ..... (A) 599

U.S.A.,
A case of leprosy in central Louisiana. Holcombe, D. J. ..... (A) 151
AFIP course on Infectious and Parasitic Diseases in the Tropics and the U.S. ..... (N) 733
Directory of International Grants and Fellowships. ..... (N) 733
Hansen's disease seminars at GWLHDC. ..... (N) 401
Heiser Program for Research in Leprosy 1991. ..... (N) 733
Leprosy in Missouri. Westblum, T. U. and Roller, J. A. ..... (A) 156
New leprosy cases in 1989. ..... (N) 402
Regional Hansen's disease centers. ..... (N) 402

Survey for leprosy in nine-banded armadillos (*Dasypus novemcinctus*) from the southeastern United States. Howerth, E. W., *et al.* ....(A) 758
Twenty-fourth Joint Leprosy Research Conference, San Diego, California, 23 and 25 August 1989. .... (—) 180

U.S.–Japan Cooperative Medical Science Program,
Twenty-fourth Joint Leprosy Research Conference, San Diego, California, 23 and 25 August 1989. .... (—) 180

Vaccination,
BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bagshawe, A., *et al.* ....(A) 414
Effective vaccination of mice against leprosy bacilli with subunits of *M. leprae*. Gelber, R. H., *et al.* ....(A) 606
Further comments on leprosy vaccination. Prabhavalkar, A. B., *et al.* ....(C) 573
Leprosy vaccines. Pfaltzgraff, R. E. ....(C) 573
Treatment of adjuvant arthritis in rats: vaccination potential of a synthetic nonapeptide from the 65-kDa heat shock protein of mycobacteria. Yang, X.-D., *et al.* ....(A) 771
Vaccines for Leprosy—Present Status and Future Prospects by Rama Mukherjee. .... (B) 143

Vanuatu,
[Study of leprosy in Vanuatu.] Montaville, B. and Bouree, P. ....(A) 434

Vasculitis,
[Clinical observation on the treatment of cutaneous vasculitis with clofazimine.] Zhan, T., *et al.* ....(A) 771
Cutaneous vasculitis associated with rifampin therapy. Iredale, J. P., *et al.* ....(A) 407
[Evaluation of circulating immune complexes in psoriasis, lichen planus, atopic eczema, leprosy, leukocytoclastic vasculitis, and pyoderma gangrenosum (review of the literature). Fernandez Bussy, R., *et al.* ....(A) 418

World Health Organization (WHO),
[Application of WHO multidrug therapy in San Pablo (Peru).] Orts Poveda, M. del C. and Bandrés Sánchez, M. P. ....(A) 598
Changes in epidemiological indices following the introduction of WHO MDT into the Guyana leprosy control programme. Rose, P. ....(A) 173
ILEP personality (Dr. Enrico Pupulin) moves to WHO. ....(N) 584
TDR/WHO offers project development grants to LDC scientists. ....(N) 586
The Use of Synthetic Antigens for Diagnosis of Infectious Diseases; Report of a WHO Scientific Group. .... (B) 593
WHO forms new Division of Tropical Disease Control (CTD). ....(N) 732
WHO Report on the Consultation on Leprosy Control Within Urban Primary Health Care. ....(N) 139

Zaire,
A longitudinal study of the incidence of leprosy in a hyperendemic area in Zaire, with special reference to PGL-antibody results. Groenen, G., *et al.* ....(O) 641
Cutaneous delayed-type hypersensitivity in patients with human immunodeficiency virus infection in Zaire. Colebunders, R. L., *et al.* ....(A) 630

Zambia,
Faecal mycobacteria and their relationship to HIV-related enteritis in Lusaka, Zambia. Coulon, C. P., *et al.* ....(A) 630

Zimbabwe,
Leprosy in Zimbabwe ending. ....(N) 588